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Introduction and Objectives 
 
1 Introduction and Objectives 
1.1 Introduction 
Drug delivery to the lung is the most relevant route in the local treatment of respiratory 
diseases like bronchial asthma or chronic obstructive pulmonary disease (COPD) and is in 
the focus of research for local drug administration e.g. in cystic fibrosis [1–3]. Reduction of 
drug related side effects by local treatment and high efficacy compared to other 
administration routes favour inhalation therapy. Drug particles entrained by the airflow during 
inhalation are directed straight to their therapeutic target resulting in a faster clinical response 
and higher drug concentrations in the target tissue than for the oral or intravenous routes 
[4,5]. 
Large lung surface area and adequate membrane permeability accompanied by exclusion of 
the first-pass metabolism, improve therapeutic effects not only locally but facilitate an 
attractive administration route for systemic delivery of drugs [4,5]. Several formulations for 
systemic use were approved by the US Food and Drug Administration (FDA) and the 
European Medicines Agency (EMA) recently. Adasuve® (Loxapine, Alexza Pharmaceuticals 
Inc., California, USA) for the treatment of acute agitation associated with schizophrenia or 
bipolar disorder, Afrezza® (FDA-approved only, MannKind Corp., California, USA), marketed 
as inhalable insulin to treat insulin-dependent diabetes mellitus and Tyvaso® (Treprostinil, 
FDA-approved only, United Therapeutics Corp., Maryland, USA) as used against pulmonary 
arterial hypertension are only forerunners for several inhalable drugs for systemic use that 
are still under investigation. 
Apparently, there is a tremendous potential to develop inhalable pharmaceutics against all 
kinds of local or systemic diseases. Many current investigations focus on the development of 
dry powders for inhalation (DPI) since such formulations provide the highest chemical 
stability over time especially compared to liquid formulations. This makes the inhalation 
therapy even conceivable for peptides or proteins (as applied for inhalable insulin) [6]. 
Marketed DPIs are most often carrier-based systems with a sugar as a coarse carrier for fine 
drug particles as this approach helps to overcome size-dependent cohesion forces of drug-
only formulations. Larger drug agglomerates are divided into smaller agglomerates or single 
particles during blending. The formulation of a new inhalation product is always a complex 
task that covers the consideration of many factors that might affect aerodynamic 
performance during inhalation and with this the effective amount of drug [7]. Diverse particle-
particle interactions between carrier and drug, carrier and carrier as well as drug and drug 
need to be controlled to ensure consistent product quality. Apart from these, it is further 
  
 
important to adapt the dry powder formulation to the dispersing mechanism of the 
necessarily required inhaler device. Particle-wall interactions as well as the design of the 
inhaler itself can crucially impact the aerodynamic performance of products for inhalation [8]. 
The challenges derived from carrier particle engineering via spray drying and the use of 
mannitol that has not yet been used as a carrier in marketed formulations will be targeted 
and discussed in this thesis and further be related to particle-particle interactions that arise 
from different carrier and drug properties to examine their effect on the respirable fraction of 
various drug particles. 
1.2 Objectives 
This thesis focusses on the preparation of dry powder formulations and the investigation of 
the complex mechanisms that affect the dispersion during inhalation. Despite several years 
of research on particle-particle interactions that occur in carrier-based systems, there are still 
essential issues that remain unclear [9,10]. The experimental design was geared to enable 
fundamental control over carrier and drug properties during preparation and was paired with 
advanced powder characterisations to improve the mechanistic understanding of drug 
detachment and dispersion during impaction analysis. 
This project was admitted to the priority program “Process Spray” (SPP-1423) funded by the 
German Research Foundation (DFG), which was mainly dealing with the atomisation of 
sprays and its applications.  Spray drying was chosen as technique of choice with respect to 
the magnificent control over product properties by adaption of the spraying parameters 
[11,12]. Collaboration with the Technical University in Dortmund, Germany facilitated the 
carrier preparation with a self-constructed spray tower that was equipped with a special 
laminar rotary atomiser targeting the production of particularly narrow particle size 
distributions as this reduced particle size variability within single batches [13–15]. A design of 
experiments was implemented to gain profound knowledge about the drying history of solute-
water droplets since particle properties can be derived from the drying process and in the 
best case be correlated to particle-particle interactions between drug and carrier. Mannitol 
served as a carrier contrary to marketed products that mostly contain lactose monohydrate 
as this contributes to the storage stability due to the crystalline appearance of mannitol upon 
spray drying [16,17]. 
Drug particles were generated with a wide range of different properties since those 
properties are known to crucially affect the respirable fraction [18]. Spray drying was applied 
as a reliable technique to prepare a set of four drugs (salbutamol sulphate, tiotropium 
bromide, budesonide, formoterol fumarate) that appeared similar in particle size and shape 
but different in hydrophilicity as this enabled to investigate the influence of van der Waals 
forces or hydrogen bonds on the particle-particle interactions between drug and drug or 
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carrier and drug. Further, drug particles were spray dried with different sizes and particle 
shapes as controlled by the drying parameters to examine its effects on the aerodynamic 
performance [19,20]. Spray dried drugs were supplemented by jet-milled qualities to 
compare spherical drug particles with needle-like or unevenly shaped ones as well as 
amorphous state with mostly crystalline structures. 
Dry powder analytics were applied for carrier and drug particles but also for interactive 
powder blends of both to understand the drying process of mannitol-water droplets [21–23] 
but also to generate profound knowledge about particle-particle interactions as these are 
based on respective powder characteristics [10,24–26]. Some supplementary experiments 
were introduced to compare the influences of different inhaler devices (Novolizer® and 
Easyhaler®), but also to investigate the impact of fines on the dispersion of powder blends 
with spray dried mannitol as carrier [27,28]. 
The overall experimental setup covers all steps from accurate carrier and drug preparation, 
over the blending procedure to the required powder analytics to enable considerable control 
over particle and blend characteristics but also to gain insight into the complex mechanisms 
that affect the aerodynamic performance of interactive powder blends during inhalation.  
 
 
  
  
 
 
 
Theoretical Background 
 
2 Theoretical Background 
2.1 Inhalation Therapy 
2.1.1 Human respiratory tract 
The human respiratory tract can anatomically be divided into three different parts. The upper 
airways include the nasal passages, throat and pharynx. The lower respiratory tract is 
subdivided into passage zone, transition zone and respiratory zone with respect to the 
functional background (Figure 2.1) [29].  
 
Figure 2.1 – Division of the lower respiratory tract, adapted from [30] with z = number of 
branches 
The passage zone consisting of larynx, trachea, bronchi and bronchioles conducts air to 
transition and respiratory zone that include respiratory bronchioles, alveolar ducts and 
alveolar sacs. The trachea splits up into two bronchi that enter the right and left lung before 
they branch up into bronchioles and later alveolar ducts to finally terminate in the alveolar 
sacs [31]. Gas exchange between air and lung as the primary function of the lungs occurs in 
blood vessel-covered respiratory bronchioles, alveolar ducts, but mainly in alveolar sacs 
which likewise cover the main part of the total surface area of the lungs (total area of 80 – 
90 m²) [29,31]. 
  
 
Based on the branched lung structure, inhaled particles are deposited at different places 
depending on particle size and density. Higher flow velocities in the bronchi and for the first 
branches of bronchioles trigger inertial impaction of inhaled material, whereas reduction of 
flow resistance by vastly increased total diameter of the airways reduced the flow velocities 
to finally reason sedimentation of smaller particles and diffusion of smallest particles with 
respect to the aerodynamic diameter (dadyn) of those particles (Figure 2.2) [4,31]. 
 
Figure 2.2 – Influence of the aerodynamic diameter (dadyn) on the lung deposition of inhaled 
material (reprinted from Labiris and Dolovich [4]) 
This is of special interest for the inhalation of an aerosol consisting of droplets or particles 
dispersed in a gas phase. Particles with a dadyn above 5 µm will preferably deposit in trachea 
or bronchi since high air flow velocity in connection to appropriate particle mass results in 
inertial impaction (Figure 2.3 – A). Materials stick to mucus-covered walls and are mainly 
removed by ciliary clearance to subsequently be swallowed and digested [4,9].  
Smaller particles with a dadyn ranging from 0.5 – 5 µm deposit by sedimentation in the 
respiratory zone with its alveolar ducts and sacs (Figure 2.3 – B) [32]. This fraction of 
particles, so called Fine Particle Fraction (FPF), is likewise the fraction of interest for all 
drugs administered to the lungs [33]. 
Lung deposition of the finest particles (dadyn < 0.5 µm) is mainly affected by Brownian motion 
and, therefore, by diffusion (Figure 2.3 – C). However, only small amounts will get attached 
to the lung tissue, while most particles will be exhaled. 
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Figure 2.3 – Mechanism of lung deposition in relation to aerodynamic diameter (reprinted from 
Frömming et. al [34]) 
2.1.2 Targets of Inhalation Therapy 
Inhalation of drugs has successfully been established to locally treat lung diseases. Several 
marketed products contain a wide range of different drugs for the treatment of asthma or 
COPD as the lung diseases with the highest prevalence [35,36]. Current research is further 
focussing on the therapy of cystic fibrosis and lung cancer or the vaccination via the lungs 
since the lung provides the bronchus associated lymphoid tissue (BALT) that enables 
mucosal vaccinations [2,37,38]. 
Systemically, inhalation therapy is of great interest as active pharmaceutical ingredients 
(APIs) or proteins delivered to the lungs avoid the hepatic first-pass effect and degradation in 
the gastro intestinal tract. Some marketed products proved this concept and raised hope for 
the development of pharmaceutics objected to all kinds of diseases [6,39,40]. 
Different drugs used in this project are all known from asthma or COPD therapy guidelines. 
The Global Initiative for Asthma (GINA) and the Global Initiative for Chronic Obstructive Lung 
Disease (GOLD) release guidelines based on the latest state of the art and suggest the drug 
therapy with respect to disease severity [41–44]. 
The lung is mainly targeted by inhalation as local therapy was found to be the most effective 
route of drug delivery for those diseases. Drug classes for inhalation cover short or long 
acting ß2-agonists (SABA / LABA), inhaled corticosteroids (ICS), anticholinergics, leukotriene 
receptor antagonists (LTRA, inhalation under investigation, marketed as oral formulation) as 
well as oral theophylline [29,41]. 
  
 
ß2 receptor agonists are used to mainly trigger bronchodilation. SABA like SBS are used as 
reliever in case of an exacerbation, while LABA like FOR are used as controller of the 
asthmatic symptoms. Muscarinic M3 receptors are further targeted to also result in 
bronchodilation. This drug class is represented by TIO in this project. BUD that belongs to 
the ICS is regularly applied to control inflammation associated with asthma or COPD. A 
combination of BUD and FOR can also serve as a reliever due to the fast onset of the 
ß2 receptor agonist, when applied in asthma therapy of higher severity [29,41,42,44]. 
2.1.3 Formulation Strategies 
All formulations for inhalation require dry or liquid particles (or agglomerates) of dadyn < 5 µm 
to penetrate the deeper airways as described earlier (Section 2.1.1). Currently, four different 
device classes that are all based on different formulations are described by the European 
Pharmacopeia (Ph. Eur) [45].  
2.1.3.1 Nebulisers 
Nebulisers provide drug delivery to the lungs by conversion of drug solutions or suspensions 
into an aerosol. The devices use vibrating meshes, ultrasonic transducer or simply 
pressurised air for atomisation (air jet nebuliser) to generate droplets of appropriate size 
[46,47]. The emerging aerosol is then inhaled over a mouthpiece or a facemask. Virtually any 
soluble drug or mixture of different drugs and in any dose can be administered by 
nebulisation, which favours them for infant therapy [1]. Nebulisers can further be used for 
ventilated patients or those suffering from diseases like dementia or Alzheimer since no 
specific coordination or device actuation is needed. 
At the same time, those device systems are quite cost-intensive, bulky and require a 
consistent power supply, which limits the use in everyday life [46]. Single dose delivery 
covers prolonged treatment times compared to pMDIs or DPIs and is reported to shift in 
droplet size over time [48,49]. Hence, other devices are preferred for standard therapy of 
asthma or COPD. 
2.1.3.2 Pressurised Metered-Dose Inhalers (pMDI) 
Pressurised metered-dose inhalers (pMDIs) are portable devices that provide the 
aerosolisation of drug solutions or suspensions upon actuation by the patient. The drugs are 
therefore either dispersed in the propellant to form a suspension or dissolved in the 
propellant to build a drug solution [50]. MDIs have been invented in the 1950s [46] based on 
chlorofluorocarbon propellants (CFCs) that have mostly been replaced by environmentally 
less harmful hydrofluoroalkanes (HFAs) at current stage [51]. The formulation, often 
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supplemented by stabilising or performance modifying excipients, is added to a can with 
metering valve to ensure adequate dosing. 
A single dose is released from the inhaler device upon actuation forcing the drug solution or 
suspension through a spray orifice to generate an aerosol. The propellant evaporates rapidly 
to leave solid particles of adequate size (0.5 – 5 µm) that are subsequently inhaled by the 
patient [46]. 
For pMDIs, very short treatment times, low production costs and fine particles of the 
emerging aerosol contrast to stability concerns of the dissolved or suspended drug and high 
aerosol cloud velocities that result in remarkable particle depositions in the oropharynx when 
misapplied by the patient [52,53]. However, pMDIs are typically known to enable high FPFs, 
while reduced lung deposition is further supplemented by issues with the coordination of 
pMDI actuation and simultaneous inspiration, which results in dose variability and low lung 
doses as reported in several studies [54]. Spacers that reduce inhalation variability based on 
easier coordination during inhalation are rather applied for infants or elder people and help to 
overcome coordination and oropharynx deposition issues. However, they are not routinely 
used with respect to higher costs. 
Breath-actuated devices like the Autohaler® have been invented to overcome coordination 
issues as the aerosol cloud is released upon inhalation. Accordingly, patient-to-patient 
variability is decreased for those devices. 
2.1.3.3 Non-Pressurised Metered Dose Inhalers 
Non-pressurised metered-dose inhalers or so-called soft mist inhalers (SMIs) as invented 
with Boehringer Ingelheim´s Respimat® generate a low velocity spray from aqueous or 
ethanolic drug solutions that are forced through a nozzle system. Administration of the drug 
dose is actuated by the patient and independent from the inspiratory effort. Coordination 
between inhalation and actuation is simplified due to prolonged treatment times based on 
lower spray velocities, which in turn results in higher respirable fractions and lower dose 
variability due to less deposition in the oropharynx compared to pMDIs [46,55,56]. 
Nevertheless, the use of the Respimat® is restricted as only aqueous or ethanolic drug 
solutions but no suspensions can be delivered, which might change for future devices with 
adapted dispersion mechanism. Currently, SMIs are designed as a non-reusable devices 
resulting in remarkably higher costs compared to simple pMDIs [46]. 
Excellent inhalation performance contrasts to stability concerns and the low number of drugs 
that can be used for SMIs, which favours dry powder formulations for adequate drug delivery 
to the lungs as will be discussed in the following sections. 
  
 
2.1.3.4 Dry Powder Inhalers (DPIs) 
Dry powder formulations were initially invented in the 1970s, where the first capsule-based 
inhaler device (Spinhaler®), containing sodium cromoglycate as a drug, was marketed [57]. 
Portable DPI devices combine several advantages such as prolonged long-term stability of 
drugs, higher drug contents per dose or increased respirable drug fractions compared to 
pMDIs [46]. Marketed inhaler devices work breath-actuated and use the inspiratory forces of 
the patient for particle dispersion, which results in reduced aerosol velocities and lower 
oropharyngeal drug depositions that in turn induce higher respirable fractions than gained for 
pMDIs [58]. DPIs are further beneficial to nebulisers or pMDIs as no propellants or external 
power sources are demanded to disperse the drug particles [46]. 
Formulations are packed in capsules, reservoir containers or blister stripes, which further 
protect them from moisture uptake. Dose adaptations can easily be implemented by 
replacing capsule sizes and capsule cavity, blister cavity volume or the dosing cavity of a 
container-based multi dose inhaler by another one [32]. 
Nevertheless, it needs to be mentioned that despite better results in the overall inhalative 
dispersing mechanism differences from patient to patient can be observed with respect to the 
applied inspiratory airflow. Especially, elder people or those suffering from severe asthma or 
COPD are known to not sufficiently inhale drugs with a DPI, which is reflected in the 
respirable fraction of drug [59]. 
The aerodynamic performance of any dry powder for inhalation is a combination of powder 
properties, inhaler device and the patient habits [59]. 
2.1.4 Market Review 
Despite their advantages or disadvantages, all mentioned devices are currently marketed all 
over the earth. Lavorini et al. examined the overall retail sales between 2002 and 2008 
retrospectively for sixteen European countries to discover the dispensing habits regarding 
nebulisers, pMDIs and DPIs [60]. They found that more than 75 % of the respiratory drugs 
prescribed in the UK were applied with pMDIs, while at the same time more than 80 % of the 
patients in Sweden used DPIs for their inhalation therapy. Germany ranged in the midfield 
with < 40 % pMDIs and > 45 % DPIs in respiratory use [60]. 
The large number of sold pMDIs, especially for the use of SABA and ICS containing inhalers 
[60], can be attributed to low costs for the healthcare system, but also to SABA containing 
formulations that are commonly used as favourable rescue medication. Figure 2.4 illustrates 
those discrepancies as the sales volume of DPIs covers less than 25 % of the totally sold 
respiratory formulations but demands almost half of the costs of all formulations, while pMDIs 
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as the cheapest marketed devices make up over 60 % of the total sales volume, but only 
20 % of the associated costs [61]. 
 
Figure 2.4 – Market review of medicine sold in asthma therapy A: sales values by device / 
formulation in % (US-$) for the six major markets (US, France, Germany, Italy, Spain and the 
UK) and B: sales volumes by device / formulation in standard units for the same markets in 
2009 [61] 
Nevertheless, it is beneficial to support inhalation therapy based on DPIs with respect to 
adequate and reliable lung depositions due to convenient handling even though single unit 
costs exceed pMDI expenses. 
Future trends in respiratory drug therapy predict increasing sales values for the following 
decade. Current sales values of 14,740m US-$ (2013) in asthma therapy are awaited to 
reach 17,689m US-$ in 2021, while COPD therapy is predicted to increase from 8,395m US-
$ (2013) to 9,464m US-$ in 2021. Most recent launches, such as Spiolto® (olodaterol and 
tiotropium bromide) or Striverdi® (olodaterol), were applying the Respimat® for administration, 
while others such as Breo® or Relvar® (both fluticasone furoate and vilanterol trifenatate) 
using an Ellipta® DPI device or Eklira® (aclidinium bromide) administered with a Genuair® 
inhaler device were based on dry powder formulations. Accordingly, market growth will most 
likely be accompanied by further shift towards modern inhaler devices with respective 
dispersion mechanisms. 
2.2 Dry Powder Formulations 
The development of new formulations for DPI use requires the consideration of a large 
number of factors that might influence the overall aerodynamic performance of the new 
product. Not only particle properties of all components including the drug itself, particle-
particle interactions between all components or particle-wall interactions between formulation 
and inhaler device, but also the choice for the best inhaler device with its associated 
dispersing mechanism is of importance.  
  
 
2.2.1 Challenges in the Development of Dry Powder Formulations 
Based on the lung anatomy, drug particle size is known as the critical factor for the lung 
deposition of inhaled formulations (see Section 2.1.1). Aerodynamic particles sizes of dadyn = 
0.5 – 5 µm are required for adequate deposition in transition or respiratory zone of the lungs 
[32]. In these days, drug particles are mainly prepared by micronisation [62], whereas other 
techniques like spray drying [16,63–65], freeze drying or the micronisation from super critical 
fluids [66] have also shown to be applicable for these size ranges [32,62]. However, drug 
particle engineering demands the control of physicochemical characteristics as properties 
might shift over storage time as will be discussed later [67]. 
Cohesiveness of drug particles is by far the main challenge in dry powder formulations. A 
pronounced tendency to build drug agglomerates can be attributed to the sum of adhesion 
forces (e.g. van der Waals forces, capillary forces or dielectric forces) as associated to 
increased specific surface area that dominates gravitational forces due to low mass of single 
drug particles. Drug bulk flowability is massively decreased for those small particles, which 
renders adequate dosing impossible for pre-metered capsules or blister stripes but also for 
container based devices. 
Different engineering techniques have been applied to overcome those issues. Some 
formulations target the preparation of size-controlled agglomerates (soft pellets) that size-
dependently provide adequate flow characteristics and, thus, appropriate dosing quality. 
Those agglomerates require dispersion by inspiratory shear forces to enable penetration of 
the lungs [68]. Another concept has been implemented with the PulmoSphere® technique 
which is based on the preparation of low density spheres by a spray drying approach. The 
spheres are larger than commonly applied drug particles which triggers adequate powder 
flow and impact in the respiratory zone of the lung due to low density and, hence, reduced 
inertial forces [69,70]. 
Most launched products apply larger carrier particles to improve powder flow and dosing 
accuracy. Those binary so-called interactive powder blends usually consist of coarse 
carbohydrate particles and small drug particles, but can be supplemented by fine sugar 
particles (so-called fines) to receive ternary interactive powder blends [27,32]. Figure 2.5 
illustrates the preparation and inhalation of binary interactive powder blends. Carrier 
particles, mostly consisting of lactose monohydrate with sizes ranging from 50 – 200 µm are 
blended with drug particles in micrometre range (0.5 – 5 µm) to evenly distribute the drug on 
the carrier surface. The improved powder flow enables accurate dosing for all kinds of inhaler 
devices and inspiratory shear forces ensure the detachment of single drug particles or small 
drug agglomerates from the carrier surface to get entrained by the airflow to penetrate the 
lungs [46]. 
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Figure 2.5 – Blending of binary powder blends and dispersion during inhalation 
Further, several marketed dry powder formulations and studies published in literature involve 
fines (further component smaller in size than the carrier) added to the formulation to gain 
ternary powder blends [7,27]. Lactose fines with a size slightly larger than the drug were 
described to be beneficial for the respirable drug fraction. Grasmeijer et al. mentioned 
different theories with positive effect on the inhalative performance such as the buffer theory 
for which slightly larger mannitol fines protect drug particles from press-on forces [24,27], the 
agglomeration theory that suggests small agglomerates of drug and fines for easier 
detachment [7,71] or the active-sites theory which describes that fines preferably bind to 
highly active sites on the carrier to result in simplified release of drug particles [28,71,72]. 
Profound knowledge about particle-particle interactions that occur during all stages from 
preparation of single excipients, over blending and storage to the inhalative usage becomes 
evident for all kinds of dry powder formulation concepts, but requires supplementary 
information about the impact of the inhaler device as this is necessarily used to administer 
those formulations. 
2.2.2 Devices for Dry Powder Inhalation 
The de-agglomeration of interactive powder blends requires energy provided by inhalation 
with an inhaler device to overcome interparticulate forces and to result in adequate lung 
deposition as mainly assured by detachment and dispersion of drug agglomerates. The 
aerodynamic performance of the powder formulation is therefore strongly depending on the 
dose metering system and the mechanism to disperse the powder [46,73]. 
The first modern DPI device invented by Fisons Laboratories was marketed in 1969 with the 
sodium cromoglycate containing Spinhaler® as a passively-used capsule-based unit dose 
inhaler [57]. Several innovative inhaler devices were designed during the following decades 
to result in quite different device classes. 
Most of the devices marketed for inhalation therapy are passive DPIs that deliver drug 
particles breath-actuated by inspiratory forces of the patient [46]. Some recent products, 
especially for systemic therapies, use an active dispersing system to de-agglomerate the dry 
  
 
powder formulation (Afreeza®). Active DPIs are rather developed for APIs with low 
therapeutic index (such as insulin in Afreeza®) due to dosing variability that is present in 
passive devices based on differences in the inspiratory flow rate by the patient [74]. Active 
DPIs ensure accurate drug dispersion by the device itself and limit patient to patient 
variabilities. Further, they can be applied to boost the dispersion of those powders that are 
difficult to disperse. 
Passive DPIs as implemented for inhalation therapy against pulmonary diseases comprise a 
broad range of different inhaler classes. Capsule-based unit dose inhaler such as 
Cyclohaler® or Handihaler® or multiple unit dose devices based on blister stripes (Diskus®) 
are designed as pre-metered dose inhalers that attain the lowest dosing variability of all 
devices. Devices applied in this thesis belong to the group of reservoir-based multi-dose 
DPIs that administer the drug upon a volume-based on-site metering of each dose with a 
respective dosing cavity. Adequate flowability is essential for formulations dispersed with a 
reservoir-based inhaler system to ensure suitably low dosing variability. 
Reservoir-based multi-dose inhaler systems, first invented with the Turbohaler® in 1988, 
consist of powder reservoir, a dosing cavity adaptable in volume and different kinds of 
dispersing approaches [68]. Experiments performed in the framework of this project were 
mainly based on the Novolizer® (Figure 2.6). The device was designed and experimentally 
investigated by de Boer et al. [75]. Here, the fluidised powder dose was stressed by cyclone 
and impaction walls to disintegrate the interactive powder blends. 
 
Figure 2.6 – Scheme of the Novolizer
®
; A: 3D scheme of the Novolizer
®
 with mouthpiece lid, 
powder reservoir and dose actuator; B: 2D scheme of the Novolizer
®
 with powder reservoir, 
dosing pocket and cyclone; C: 3D scheme of the dosing slide with dosing pocket and 
impaction walls [75] 
Inhalation procedure starts with an initial dosing step performed by the patient via the dose 
actuator. Dispersion of the powder happens upon patient inhalation through the device and is 
supported by increased shear forces gained from the cyclone. This device was mainly 
designed for large solid carrier particles of higher true density as this results in inertial 
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impaction to impaction walls rather than for small or hollow particles. Inertial forces cause 
collisions of carriers to the impaction walls to enforce further drug detachment from the 
carrier surface [76]. 
This device was explicitly convenient for purposes in this project as it provides high 
detachment rates based on its dispersing mechanism, which allow easier detection of slight 
differences in the aerodynamic performances of different powder blends. Nevertheless, spray 
dried carrier particles used here comprise quite low bulk densities compared to milled or 
sieved qualities, which might reduce the impaction forces during inhalation. 
The Easyhaler® (Figure 2.7) is another container-based multi-dose device that was tested to 
examine the applicability of results gained with the Novolizer® for other inhaler systems [77]. 
Here, inhaler design is kept very simple as only dose actuator with a spring, powder reservoir 
and dosing wheel were introduced without having an extra effect on the dispersion of the dry 
powder formulation. Respirable fractions were most likely expected to be lower than for the 
Novolizer® as cyclone or impaction walls are missing. 
 
Figure 2.7 – Scheme of the Easyhaler
®
 with dose actuator, powder reservoir and dosing wheel 
2.3 Particle-Particle Interactions 
Efficient drug dispersion during inhalation is governed by several factors that can coherently 
be described as particle-particle interactions. The energy transferred from inspiratory forces 
to the powder blends needs to exceed the energy that arises from particle-particle 
interactions to effectively disperse drug and carrier particles (plus eventually fines). Major 
forces that are described in literature (Figure 2.8) include those being dominated by physical 
forces without material bridges such as mechanical interlocking of particles in surface 
asperities (c), electrostatic charging by acceptor and donor charge transfers or tribo-
electrification due to collision or friction of particles (d) and van der Waals forces that occur 
when dipoles are induced (f) [58]. 
  
 
 
Figure 2.8 – Particle-particle interactions between carrier surface and small particles adhered 
to the surface modified from Hickey et al. [58] 
Even stronger interactions arise from methods or ambient conditions that enforce material 
bridges as observed for liquid films or solid bridges. The presence of moisture at the 
interface of two particles induces capillary forces (e), while sintering of particles as caused by 
higher temperatures (a) or the recrystallisation of amorphous spots on the surface (b) 
triggers solid bridges between particles [58]. 
Further, acid-base interactions or hydrogen bonds (g) are mentioned as chemical properties 
that impact on particle-particle interactions. Particle properties like particle size, morphology 
or the porosity are therefore important as they impact on these interparticulate forces (Figure 
2.9). A lot of work has been done earlier to discover dependencies between particle 
characteristics and performance during inhalation. Impaction analysis as a technique to study 
the detachment and dispersion of drug particles upon device actuation was introduced to 
investigate these dependencies and is required by the Ph. Eur. to assess the fine particle 
dose (FPD) of any formulation applied for inhalation [78]. The following sections will briefly 
summarise the main issues based on carrier and drug properties. 
 
Figure 2.9 – Factors with impact on particle-particle interactions in interactive powder blends 
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2.3.1 Particle Size 
Major impact on particle-particle interactions results from drug or carrier size, but can also be 
attributed to the addition of fines in so-called ternary powder blends as will be described later 
[79]. Adhesion of e.g. drug particles on the surface of a carrier or cohesion between particles 
consisting of the same material correlates to the ratio of interparticulate forces and weight 
forces that in turn depend on particle size and its bulk density (Figure 2.10). Interparticulate 
forces such as mechanical interlocking, capillary forces, electrostatic forces or van der Waals 
forces need to exceed the weight forces to enable attachment of drug particles on the carrier 
surface, but need to be small enough to ensure detachment by inspiratory forces [58]. At the 
same time, carrier particles require particle sizes that prevent agglomeration as carrier flow is 
crucial for adequate powder handling, filling and dosing [79]. 
Carrier sizes of 50 – 200 µm are required to generate adequate powder flow, but smaller 
carriers were found to perform better than larger ones [80,81]. The perfect carrier size is 
determined by low cohesion forces between single particles to prevent agglomerates and 
preferably low particle mass since this impacts press-on forces that press drug particles on 
the carrier surface during blending. The smallest carriers with the lowest mass and the least 
press-on forces that concurrently provide adequate powder flow are preferred for dry powder 
formulations. 
 
Figure 2.10 – Particle-particle interactions between carrier (large light grey particles) and drug 
particles (dark grey particles) modified from Steckel [48] 
  
 
Drug particles are desired to penetrate the deeper airways of the lungs, which limits their 
suitable particle size. The inspiratory airflow detaches larger particles more easily than small 
ones with respect to a lower adhesion forces to mass ratio. However, improved drug 
dispersion contrasts to the targeted drug size that enables impaction in the deeper airways of 
the lung. Drug particles of perfect size are large enough to enable easy detachment, but 
small enough to penetrate the lungs to reach the respiratory zone (0.5 – 5 µm). Dispersion of 
interactive powder blends is further governed by the tendency to build agglomerates that 
consist of fine drug particles attached to each other by cohesion forces. However, 
agglomerates are not necessarily disadvantageous since dispersion enforces the generation 
of smaller agglomerates or single drug particles depending on agglomerate strength and 
inspiratory forces. High agglomerate strength or large single drug particles cause reduced 
respirable fractions. 
A variety of different engineering approaches is conceivable for particle preparation of 
virtually any size required for inhalation purposes as introduced in Section 2.4, but demands 
the consideration of particle morphology as different particle shapes or surface structures 
influence particle-particle interactions (Section 2.3.2). 
2.3.2 Particle Morphology 
Particle-particle interactions arising from the particle surface are a measure of contact area 
and mechanical interlocking. The particle morphology of either carrier or drug particles is 
known to affect the dispersion of interactive powder blends. In accordance to marketed 
products, most of the studies published in the scope of interactive powder blends and 
dependencies on particle morphology are based on lactose monohydrate qualities, but have 
been extended to mannitol by Maas et al. [82,83] and Littringer et al. earlier within this project 
[16,20,22,23,64]. 
Former work targeted the optimisation of carrier properties by e.g. the controlled solvation of 
the carriers to generate smoother surfaces [84] or carrier modification upon milling or sieving 
[85]. Littringer et al. were the first focussing on the inhalation of spray dried mannitol carrier 
particles within this project. Mostly spherical particles were investigated and the impaction 
results were evaluated with respect to the particle morphology of the carriers [16,23]. 
In general, adhesion forces that arise from the effective contact area between carrier and 
drug correlate to the respirable fraction. The larger the contact area, the lower appears the 
drug fraction of interest. This correlation is apparently not only a function of carrier 
smoothness but also of drug shape as both interact with each other. Littringer et al. 
mentioned rough carrier surfaces to be beneficial for dispersion of micronised drugs due to 
an increased number of contact points, but a decreased total effective contact area [23]. 
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When investigating the particle morphology it is crucial to differentiate between surface 
asperities that are assigned to surface roughness and those that describe the overall shape 
of the particle. Surface smoothing reduces the surface roughness but might also remove 
indentions that initially provide space for drug particles. Indentions or edges as e.g. gained 
by milling can enable mechanical interlocking and entrapment of particles resulting in 
lowered respirable fractions [86]. Mechanical interlocking can further impact on the flowability 
of a bulk as spherical particles provide the conceivably best flow properties. 
The differentiation between particle shape and surface roughness was implemented for 
spray dried mannitol carriers to distinguish effects on the impaction analysis. Further, drug 
particles of alternating shapes were investigated to not only cover carrier morphology but 
also drug shape. All carriers or drugs used in this thesis were prepared by appropriate 
engineering approaches as introduced in Section 2.4. 
2.3.3 Intrinsic particle properties 
Particle-particle interactions arise not only from individually adjustable particle characteristics 
like size or morphology, but also from intrinsic particle properties that are dedicated to 
chemical structure, the engineering approach or to storage conditions. 
The chemical structure of a material is the basis for other intrinsic particles properties such 
as the hydrophilicity [32]. It enables to determine the octanol-water-coefficient or so-called 
log P value as a measure of hydrophilicity. Low values indicate a material to be hydrophilic, 
while higher values are assigned to lipophilic substances. Long hydrocarbon chains or 
aromatic compounds as contained in substances with high log P values are attributed to the 
ability to build low energy van der Waals bonds, whereas nitrogen or oxygen containing 
functional groups support high energy hydrogen bonds in accordance to lower log P values 
and appropriate solubility in water, but are not the only factors affecting log P values. The 
effect of hydrophilicity on the DPI performance was investigated by implementation of drugs 
with different log P values to discover effects on particle-particle interactions between drug 
and hydrophilic mannitol carrier surface. 
Substances purchased as pure organic material are usually crystalline, indicating that 
molecules are arranged in an ordered repeating pattern that forms the crystal lattice based 
on several non-covalent interactions [58]. Most solids exist in more than one crystal form. 
This so-called polymorphism implies one crystal modification to be the thermodynamically 
most stable one, while others tend to change to the thermodynamically more stable one 
based on the ambient conditions. Depending on the processing method, some substances 
even occur as non-crystalline or amorphous solid without long-range order. Crystal 
modifications are material-specific. Spray dried mannitol normally appears in the most-stable 
ß-modification as proved by Littringer et al. earlier, whereas most drug substances result in 
  
 
unstable amorphous structures upon rapid drying [16,87–89]. Optimally, excipients or drugs 
used for pharmaceutical products are used in the most stable modification to avoid stability 
issues. However, in some cases other modifications or amorphous materials may be 
beneficial in therapeutic use due to improved solubility especially of sparely soluble drugs 
[90] or possibly enhanced dispersion during inhalation as will be examined in this project. 
Handling stability issues was one of the main targets when working with spray dried drugs. 
Polymorphs differ not only in density, melting point or solubility, but also in the ability to 
absorb water. The capacity to absorb moisture in correlation to the ambient relative humidity 
(rH) is correlated to the crystal modification [67]. Amorphous products with high free Gibbs 
energies absorb more moisture than crystalline modifications of lower energy, but tend to 
transition into lower energy states upon moisture uptake or in correlation to the ambient 
temperature [32]. As this might trigger particle growth and, therefore, reduced respirable 
fractions, stability of the product during storage and handling is one of the main tasks.  
Capillary forces are prominent for those particles that have absorbed moisture from the 
ambient air. Hydrogen bonds and capillary forces arising from absorbed moisture evoke quite 
strong particle-particle interactions that might further reduce the FPF during inhalation. 
Controlled moisture contents are required to enable repeatable results especially for 
thermodynamically instable products [32,58].  
However, electrostatic charging of particle surfaces needs to be considered when reducing 
the ambient relative humidity. Some factors such as atmospheric ionisation, contact with 
charged objects, the chemical composition or triboelectric charges that arise from motion or 
wall friction of blend and device, generate electrostatic charges which might influence the 
inhalation performance as published by Karner et al. earlier within this project [91–93]. 
Nevertheless, charging can be reduced by adequate deionisation with respective instruments 
as performed in this thesis, but is not applicable in every-day life. 
Particle properties might influence dry powder inhalation crucially, but can be controlled by 
the right choice of particle engineering, constant ambient conditions or adequate 
deionisation. 
2.4 Particle Engineering 
Current research and development projects in pharmaceutical industry require maximum 
control over the engineering processes of all excipients used for formulations as this 
determines their particle properties. Most components used in dry powder formulations are 
limited in over-all particle properties as most marketed products consist of sieved or milled 
lactose blended with micronised drug particles of undefined shape. This section gives an 
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introduction to different engineering approaches possibly used to prepare carrier or drug 
particles for inhalation. 
2.4.1 Carrier Preparation 
Carbohydrates for dry powder formulations demand the fulfilment of high quality standards 
since small differences in particle properties might vastly influence the aerodynamic 
behaviour. Carrier engineering is therefore targeting narrow particle size distributions (PSDs) 
and reproducible morphologies. 
2.4.1.1 Recrystallisation and Sieving 
Marketed products specialised for inhalation purposes are mainly based on sieved lactose 
monohydrate qualities e.g. InhaLac®. The crystalline raw material has previously been 
recrystallised by cooling the dissolved sugar and separating emerging particles from the 
solvent [94]. Sieving steps are mandatory to receive PSDs of adequate width. Different sieve 
fractions are applicable for inhalation with respect to several factors such as the inhaler 
device, the dry powder formulation or the purpose (carrier or fines). Sugar fines require an 
additional milling step to reach their final particle size. 
Mannitol used here is usually gained by catalytic hydrogenation from mannose and 
recrystallised to end up with a raw product of wide PSD that requires sieving steps to achieve 
carrier qualities of controlled particle sizes. 
For both, sieving of lactose monohydrate or mannitol, the sieving method can serve as a 
critical step during preparation as it might impact on the carrier surface. Especially, lactose 
monohydrate is susceptible to the generation of amorphous spots that might affect the 
inhalation performance. 
Standard sieving methods are restricted by the flow characteristics of the bulk. The 
preparation of smaller particles like fines as added to ternary powder blends requires other 
approaches like milling to further grind the particles (Section 2.4.2.1). 
2.4.1.2 Spray Drying 
Another approach for carrier particle engineering in a size range applicable for inhalation is to 
spray dry dissolved sugar alcohols with a spray drier of appropriate size [11,12,16]. The 
surface expansion during spray generation enables efficient drying of droplets due to the 
large partial pressure gradient of solvents in a heated drying air stream. Nozzles, such as 
twin fluid nozzles or single substance pressure nozzles, or rotary atomisers are most 
commonly applied for atomisation of dissolved substances [95]. Process control is vital for 
droplet generation as every single droplet gives rise to a single product particle. Spray towers 
are restricted to a maximum droplet size or amount of water that can be evaporated with 
  
 
respect to the chosen drying temperature, so that the drying capacity can be derived from 
tower size, drying temperature, air stream volume and droplet size. Parameters like mass 
concentration, drying temperature, rotation speed or volume of the drying gas are 
conceivable to affect the particle properties [16]. 
Rotary atomisers as applied for the preparation of carrier particles in this project accelerate 
the feed by centrifugal forces. The emerging lamella or threads disintegrate to droplets upon 
interaction with the heated drying air. The droplet size can be controlled by the rotation 
speed of the rotary wheel since higher acceleration reduces the filament diameter and thus 
the initial droplet size [96]. 
 
Figure 2.11 – Cross section of the LamRot atomiser with feed inlet, perforated ring and sixty 
bores for generation of laminar threads [97] 
A special self-constructed laminar rotary atomiser (LamRot) was applied for experiments 
described here to particularly target narrow PDSs (Figure 2.11) [15,98]. The feed enters the 
atomiser at the top to experience homogeneous distribution by a perforated ring. A total of 
sixty bores are located at the bottom-side of the atomiser to release the liquid as single 
laminar threads that get further stretched by acceleration to disintegrate following the 
principle of Rayleigh (Figure 2.11) [14,99,100]. The gas distribution system constructed by 
Mescher et al. was implemented to overcome those challenges [15]. Uncontrolled thread 
disruption (green arrows) as suggested for the axial drying air stream (red arrows) – still 
applied as the main drying source – has been reduced by adding a second so-called swirl air 
stream (blue arrows) to the tower (Figure 2.12). 
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Figure 2.12 – Scheme of the gas distribution of the self-constructed spray tower used for spray 
drying of carrier particles 
The velocity of the swirl air stream was adjusted to meet the velocity of the emerging threads 
targeting low relative velocities between air and threads, which results in almost perfect 
Rayleigh break-up [14,99]. The main air stream is hitting the droplets beyond the break-up 
zone and deflects them to prevent wall collisions. Studies performed on the basis of polyvinyl 
pyrolidon (PVP) by Mescher et al. proved this concept as particle span was reduced 
compared to experiments without the swirl air stream [14]. 
It is generally known from literature that spray drying is applicable to control particle 
morphology [11,64,101,102]. Most spray dried substances, such as lactose monohydrate or 
SBS, are gained as almost spherical particles with respect to the shape of the droplet from 
which the particles emerge, while others are reported with wrinkled shape as e.g. observed 
for spray dried trileucine [11,103]. Earlier experiments performed on mannitol in the 
framework of this priority program revealed particle shape to depend on the drying 
temperatures. Mostly spherical particles were gained for lower drying temperatures, while 
increase of drying temperature correlated to the occurrence of indentions [16,64,82]. 
The equipment used for carrier drying experiments was improved by heater batteries for the 
swirl air stream to enable maximum control and the lowest batch-to-batch variation for 
particles dried at the same conditions. 
The drying of particles during spray drying processes can be described by the Peclet number 
(Pe) as a dimensionless value based on the diffusion ability of the solute in the solvent with 
respect to the chosen drying rate [11]. Pe values below 1 indicate rapid diffusion of the 
solute. Evaporation of solvent appears slow enough to avoid the formation of concentration 
gradients within the droplet. Pe values that exceed 1 predict an enrichment of the solute at 
the droplet surface which most likely results in a shell formation and hollow particles [11,104]. 
Pe numbers vary depending on the drying rate, which enables correlations to the particle 
size as will be discussed in this thesis [11]. 
  
 
Marketed spray dried sugar alcohols such as the mannitol equivalents Pearlitol® 200SD 
(Roquette Frères, Lestrem, France) or spray granulated Partec® M200 (Merck, Darmstadt, 
Germany) are commonly used for tabletting processes due to excellent compression abilities. 
The applicability of spray granulated particle engineered mannitol qualities in inhalation 
therapy is currently tested in a project performed by Rhein et al. targeting at the first 
marketed mannitol quality for inhalation purposes [105]. 
2.4.2 Drug Preparation 
The preparation of drug particles meant for inhalation purposes demands particles with a 
dadyn of 0.5 to 5 µm as described earlier. Several approaches have been introduced to target 
this size range, but only a few are currently used for marketed products. Micronisation 
techniques published in literature suggest freeze drying, micronisation from supercritical 
fluids or air jet milling to be applicable for drug preparation since all techniques provide 
particles with respective size and appropriate aerodynamic behaviour. 
This thesis compares spray dried drug particles of four different model drugs with jet-milled 
qualities of a choice of two model drugs. 
2.4.2.1 Air Jet Milling 
Micronisation by air jet milling is the most commonly used method to prepare particles for 
inhalation purposes. The process appears cost-effective and is reliable with regards to batch-
to-batch variations. 
The crystalline raw materials are introduced into a grinding chamber and grinded by high 
pressure nozzles using an inert gas. The resulting particle size is determined by the chosen 
grinding pressure since fine particles are separated based on the inert gas velocity in the 
chamber. It has been reported that micronised materials comprise amorphous spots on the 
surface due to the high energy input during micronisation. Drawbacks are not only related to 
amorphous spots that might recrystallise during storage due to their high free Gibbs energy 
but also to drug particle shape [106]. Most substances appear with unevenly shaped 
particles upon jet milling [18], so that particle adherence to carrier particles cannot be derived 
from distinct controlled product properties. 
Spray drying approaches overcome those challenges as this technique is known for its 
homogeneous overall particle shape. 
2.4.2.2 Spray Drying 
Spray drying of drug particles for inhalation follows the theory described in Section 2.4.1.2 
obenbut is rather based on twin fluid nozzles or even ultrasonic meshes than on rotary 
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atomisers. The maximum rotation speed of the rotary wheel limits the minimum droplet size 
and, therefore, the particle size. 
However, twin fluid nozzles or ultrasonic meshes can easily be applied to control drug 
particles in size based on mass fraction and spraying gas or mesh size, respectively. The 
liquid is therefore disintegrated by spraying gas or vibration induced by a piezo crystal.  
The overall appearance of the particles is homogenous contrary to jet milled qualities as 
described above. Papers published earlier, found SBS, BUD and FOR particles to appear 
mostly spherical in shape, which most likely is beneficial for the development of new 
formulations due to maximum control in drug shape [20,88]. However, the crystal habitus of 
spray dried drugs has been studied likewise indicating all products to be fully amorphous 
when analysed by X-Ray powder diffraction (XRPD). This suggests a crucial lack in storage 
stability since most products tend to recrystallise when exposed to higher ambient relative 
humidity and / or temperatures [88,89]. 
Nevertheless, amorphous contents in drug particles might be beneficial for sparely soluble 
drugs as mentioned earlier. Experiments performed here will focus on the preparation of 
carrier and drug particles with controlled particle properties by appropriate methods and the 
physico-chemical analysis of those as described in the following. 
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3 Materials and Methods 
3.1 Materials 
3.1.1 D-Mannitol 
D-mannitol (C6H14O6) is a white, crystalline powder of 182.2 g ● mol
-1 in molecular mass and 
with the melting point at Tm = 168 °C, which is classified as polyol due to its chemical 
structure (Figure 3.1) and belongs to the sugar alcohols since it is derived from a sugar. Its 
solubility in water is reported to be 216 g ● L-1 [107] and hydrophilicity is claimed with a log P 
of - 3.7 [108]. Mannitol can be gained from mannose by reduction and belongs to the group 
of non-reducing sugar alcohols, which accounts mannitol to be compatible for molecules 
containing amide-bonds e.g. proteins [109] due to low reactivity with other molecules. Three 
different modifications (α, β, γ) are known from literature, where the β-modification is 
mentioned to be the most stable one [87]. Mannitol has been reported to initially recrystallise 
during spray drying due to a very low Tg (Tg ≈ 30 °C), but might be prepared in other 
crystalline states by e.g. freeze drying [110]. 
 
Figure 3.1 – Chemical structure of D-mannitol [111] 
In these experiments mannitol was applied for the spray drying of carrier particles and the 
preparation of mannitol fines for use in ternary powder blends. Pearlitol® 160C, which served 
as raw material for all investigations, was kindly provided by Roquette Fréres (Lestrem, 
France) as a crystalline quality of mannitol. 
3.1.2 Salbutamol Sulphate 
Salbutamol sulphate is typically used for the treatment of asthma or COPD and is listed on 
the World Health Organisation List of Essential Medicines [112]. Drug delivery to the lungs by 
inhalation is the most common application route. SBS serves as a short-acting β2 selective 
adrenergic receptor agonist which causes relaxation of smooth muscles and therefore 
dilation of bronchial passages as well as vasodilation in muscle and liver [113]. 
 
  
 
Table 3.1 – Chemical, physical and pharmacological drug properties [107,114–117] 
Drug SBS TIO BUD FOR 
Molecular weight, g ● mol-1 239.3 472.4 430.5 344.4 
Melting point, °C 157 – 158 217 – 227 226 138 – 140 
Log P 0.64 - 1.80 1.90 2.20 
Solubility in H2O 
Sparingly 
soluble 
Sparingly 
soluble 
Insoluble 
Poorly 
soluble 
Drug class 
Short-acting 
β2 agonist 
M3 receptor 
antagonist 
Gluco-
corticoid 
Long-acting 
β2 agonist 
Standard dose, µg [35] 100 - 200 9 - 18 200 - 400 6 – 12 
 
The drug molecule (C13H21NO3) belongs to the resorcinol derivatives, is used as a racemic 
mixture of R- and S-enantiomer with chemical, physical and pharmacological properties as 
mentioned in Table 3.1.  
 
Figure 3.2 – Chemical structures of the R- and S- enantiomer of salbutamol sulphate [111]  
This project applied SBS as one of the two hydrophilic model drugs (log P = 0.64). The drug 
was initially spray dried in the framework of a design of experiments to discover the effect of 
drying parameters on the particle properties to then use spray dried and jet-milled qualities 
for powder blends with mannitol carrier particles. Raw SBS was purchased from 
Selectchemie AG (Zürich, Switzerland) and modified as described in Section 3.1.2 to 
generate the desired drug particle size and shape.  
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3.1.3 Tiotropium Bromide 
Tiotropium bromide is usually applied for the maintenance treatment of COPD or as add-on 
controller for asthma. The muscarinic receptor antagonist mediates a bronchodilatory effect 
acting on muscarinic acetylcholine receptors (M3) located on smooth muscles or submucosal 
glands [113]. 
Chemically, TIO (C19H22BrNO4S2) belongs to the N-quaternary anticholinergic derivatives 
with an ionic structure, so that it cannot pass the blood brain barrier. The chemical, physical 
and pharmacological properties are summarised in Table 3.1.  
TIO used for this study was gained from Hangzhou Hyper Chemicals Ltd. (Zhejiang, China) 
and was spray dried for further use in binary interactive powder blends with mannitol carrier 
particles. Preparation of particles for inhalation is further described in Section 3.3.5. 
 
Figure 3.3 – Chemical structure of tiotropium bromide [111] 
3.1.4 Budesonide 
Budesonide serves as anti-inflammatory drug in the long term management of asthma and 
COPD when administered to the lung or against allergic rhinitis and nasal polyps when 
deposited in the nose. It belongs to the steroid derivatives and is also listed on the World 
Health Organisation´s List of Essential Medicines [112]. 
Its common use in inhalative therapy of pulmonic diseases is mainly based on high receptor 
affinity, lipophilic character and, therefore, low systemic bioavailability of 10 – 20 % [118]. 
The chemical, physical and pharmacological properties of this racemic mixture are depicted 
in Table 3.1.  
This study applied BUD purchased from Minakem SAS (Dunkerque, France) in micronised 
quality (d50.3 = 1.81 µm) as gained from the vendor and spray dried quality prepared as 
depicted in Section 3.3.3 to investigate the aerodynamic behaviour of binary interactive 
powder blends of BUD and mannitol carrier particles. 
  
 
 
Figure 3.4 – Chemical structure of the R- and S- enantiomer of budesonide [111] 
3.1.5 Formoterol Fumarate 
Similarly to SBS, formoterol fumarate belongs to the group of β2 selective adrenergic 
receptor agonists but is applied in therapy as a long-acting derivate with prolonged duration 
of action. It is commonly used to treat the pulmonic diseases asthma and COPD as it 
provokes bronchodilation by relaxing smooth muscles. 
FOR appears as racemic mixture with the chemical, physical and pharmacological properties 
summarised in Table 3.1.  
The raw material provided from Vamsi Labs Ltd. (Maharashtra, India) was used to prepare 
spray dried drug particles of lipophilic quality and defined shape as further described in 
Section 3.3.4. 
 
Figure 3.5 – Chemical structure of the R- and S- enantiomer of formoterol fumarate [111] 
3.1.6 Further Reagents 
All further reagents as necessary for analytics are further listed in Section 8.2. 
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3.2 Design of Experiments 
A Design of Experiments (DoE) with a defined set of conditions was applied for the spray 
drying of mannitol carrier particles and SBS drug particles to investigate influences of drying 
conditions on the product properties. In general, DoE optimises the number of required 
experiments with respect to the underlying statistics [119–121] and enable predictions for 
follow-up experiments, when significant models are found. 
 
Figure 3.6 – CCF design with three factors (rotary speed, n; axial air stream temperature, Tax; 
swirl air stream temperature, Tswirl) on three levels for spray drying of mannitol in the 
framework of a DoE. The cube shows 15 different experimental setups, for which the center 
point (cp) was repeated five times. 
 
Figure 3.7 – CCF design with two factors (mass fraction, Ym; outlet temperature, Tout) on three 
levels for the spray drying of SBS in the framework of a DoE. The cube shows 9 different 
experimental setups, for which the center point (CP) was repeated five times 
A large number of different designs is available to cover a broad range of purposes. This 
study applied a face-centred central composite (CCF) response surface designs which 
covers a 3D cube for three different factors and a 2D plane for two different factors as 
illustrated in Figure 3.6 and Figure 3.7. The final number of experiments can be calculated 
according to Equation (3.1). 
 
 
  
 
N = 2f + 2f + cp (3.1) 
 
 N Total number of experiments 
 f Number of factors 
 cp Number of centre points 
 
Both DoE varied the factors on three equidistant levels, which allowed the investigation of 
linear and quadratic terms. The centre point of the designs was repeated five times in order 
to gain information about reproducibility and validity of the chosen design and to improve 
prediction abilities. Factors including the levels of interest of both DoE were summarised in 
Section 3.3.1 and Section 3.3.2.1. 
Resulting particle properties were evaluated as responses (y) to the chosen factor levels. 
Every potential term, which might affect the appropriate response, was included for the 
evaluation initially, which results in the following equation representing a design for three 
factors: 
 
y = a0 + a1 f1 + a2 f2 + a3 f3 + a4 f1
2 + a5 f2
2 + a6 f3
2 + a7 f1 f2 + a8 f1 f3 + a9 f2 f3 (3.2) 
 
 y Response to the chosen factors 
 ai Coefficient (displaying the statistical significance of the term) 
 fx Factor level 
 
Based on the design, a model was fitted to every single response by neglecting insignificant 
terms in a backward regression. The resulting equations describe correlations between 
alteration of factors and effects on the response coherently and are depicted in the results 
sections for valid models. Respective coefficients are given as scaled and centred values 
which indicate the physical effect on a response when the appropriate factor is increased by 
one level. 
All models were checked for adequate model quality on the basis of four quality parameters: 
The percent of variation explained by the model (R2) which estimates how well the model fits 
the data; the prediction quality (Q2) which measures the predictive power of the model; the 
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validity of the model (p-value) and the reproducibility (RP) which illustrates the variation of 
experiments that were conducted at the same conditions (centre points). Plausibility of the 
model is related to appropriate limits of these quality parameters. The best model quality is 
generally illustrated by a value of 1. For R2 and Q2 limit of acceptance was set to 0.5 at 
minimum, which represents a well fitted model with good predictive qualities. Model validity 
must exceed 0.25 to indicate that the lack of fit for single measurements occurs smaller than 
the pure error given by RP. This includes that models might show reduced model validities 
due to extraordinarily good RP values which in turn is known as artificial lack of fit due to the 
very small experimental (pure) error. Nevertheless, RP was desired to reach values close to 
1 to display how well experiments can be repeated [122]. 
In general, the DoE was created and evaluated with the DoE software Modde (Version 
10.1.1, Umetrics AB, Umeå, Sweden) by using the Multi Linear Regression (MLR) method. 
  
 
3.3 Preparative Methods 
3.3.1 Preparation of Engineered Carriers 
Mannitol carrier particles were prepared by spray drying a bi-component solution of mannitol 
and water with a self-constructed spray tower located at the Technical University in 
Dortmund, Germany (group of Prof. Walzel).  
 
Figure 3.8 – A: Scheme of the self-constructed spray tower with (I) axial inlet air stream and the 
point of measure for Tax, (II) swirl inlet air stream and point of measure for Tswirl, (III) heated feed 
stock vessel, (IV) LamRot atomiser with rotation speed n, (V) collecting vessel and (VI) cyclone; 
the tower has a height H of 4.7 m and a diameter D of 1.5 m, B: photograph of the conical part 
of the spray tower [123] 
The tower consists of a cylindrical upper part (H = 2.5 m) and a conical lower part (H = 
2.2 m) with a total height of H = 4.7 m and a diameter of D = 1.5 m (Figure 3.8). The mannitol 
solution was fed to the drying chamber with a special laminar rotary atomiser (LamRot, 
Figure 3.9) which was designed to generate products of narrow PSDs. The bi-component 
solution was added to the atomiser centrically to be distributed to the inner wall of the 
LamRot atomiser. Droplets emerged from sixty bores around the rotating LamRot atomiser 
(Figure 3.9) and got redirected towards the tower bottom by an axial air stream that entered 
the tower at the top (Figure 3.8, red arrows). A swirl air stream (Figure 3.8, green arrows) 
was applied to the spray tower to improve controlled droplet break-up and to govern the 
temperature next to the rotary atomiser separated from the axial inlet air stream [14,15]. Both 
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inlet air streams were heated by heater batteries and could be adjusted in volume per time. 
The main collecting vessel was attached at the bottom of the tower. The drying air stream left 
the drying chamber concentrically and was directed to a cyclone, which was applied to 
separate fines. A filter was assembled to clean the exhaust air from finest particles. 
 
Figure 3.9 – A: Scheme of the LamRot atomiser with sixty bores; B: Photograph of mannitol-
water filaments emerging from the atomiser [123] 
Spray drying took place in the framework of a CCF design as described in Section 3.2. Tax, 
Tswirl and n were chosen as factors, which were altered on three levels (-1, 0, +1) to generate 
a broad set of mannitol batches with various particle properties (Table 3.2). 
Rotation speed was chosen with regard to droplet size distribution experiments in an off-site 
setup, where the effect of different LamRot velocities on the droplet size was tested by laser 
diffraction (Malvern Spraytec, Malvern Instruments, Worchestershire, UK). Mannitol with a 
feed concentration of 10 % [w/w] was fed to the atomiser with a feed rate of 10 L ● h-1 to 
mimic the standard spraying conditions in the pilot scale spray tower. Those experiments 
were mainly conducted to estimate resulting particle sizes from the observed droplet sizes to 
finally generate carrier particles between 50 µm and 80 µm. 
Table 3.2 – Displays the three levels of the factors chosen for the CCF design of spray drying 
mannitol; *marks the center point conditions, which were repeated five times 
Factor - 1 0* + 1 
Rotary speed, n, rpm 8,000 11,000 14,000 
Axial air stream 
temperature, Tax, °C 
130 160 190 
Swirl air stream 
temperature, Tswirl, °C 
60 80 100 
 
Drying temperature was chosen to be varied for both inlet air streams in contrast to earlier 
experiments by Littringer et al. [16,23,23]. The temperatures were set with respect to Tout 
since a minimum drying temperature is required to generate dry particles. The axial air 
stream dealt as the main drying air stream with the larger volume per time (Vax = 1000 m³ ● 
  
 
h-1) for these experiments and was varied from Tax = 130 °C to 190 °C. Tswirl of the swirl air 
stream (Vswirl = 400 m³ ● h
-1) was kept between 60 °C and 100 °C due to heat limitations of 
the used equipment. 
Several further parameters were kept at constant levels (Table 3.3). The mannitol was 
dissolved in purified water to reach a feed concentration of 15 % [w/w] and preheated to 
Tfeed = 25 °C in a closed feed stock vessel prior to the experiment. The bi-component solution 
was fed to the LamRot atomiser with a feed rate of Vfeed = 10 L ● h
-1 by the use of a 
peristaltic pump. The swirl air stream volume was kept at Vswirl = 400 m³ ● h
-1, for which the 
gas velocity corresponds to the circumferential velocity of medium rotary speeds. The 
particles collected in the main collecting vessel were dried at 100 °C in a compartment drier 
for at least 1 h to remove residual moisture and to prevent agglomeration. Product caught in 
the cyclone was not employed for further analysis. 
The resulting nineteen batches were analysed by various techniques as described in 
Section 3.4. A selection of these mannitol carriers was used for the preparation of interactive 
powder blends (Section 3.3.7). 
Table 3.3 – Constant parameters during the spray drying process 
Constant Parameter Process Condition 
Vax 1000 m³ ● h
-1 
Vswirl 400 m³ ● h
-1 
Cfeed 15 % [w/w] 
Tfeed 25 °C 
Vfeed 10 L ● h
-1 
 
3.3.2 Salbutamol Sulphate 
The hydrophilic model drug SBS (log P = 0.64) was used in micronised quality with an 
irregular shape and spray dried quality with spherical particles to discover the effect of drug 
shape on the particle-particle interactions.  
3.3.2.1 Spray drying of SBS 
Spray drying of SBS was conducted with a commercially available lab scale spray dryer 
(Büchi Mini Spray Dryer B-290, Büchi Labortechnik AG, Flawil, Switzerland) to generate 
particles of spherical shape.  
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Figure 3.10 –Scheme of the Büchi Mini Spray Dryer B-290 as used for aqueous solutions with 
open cycle [124] 
Figure 3.10 shows a scheme of the dryer. The prepared stock solution of salbutamol 
sulphate in bi-distilled H20 was passed through a peristaltic pump and fed to the main drying 
chamber over a two-fluid nozzle (, , d = 2 mm). The aspirator set to 100 % for all 
experiments was used to suck ambient air into the system (). The air was preheated by a 
heater and introduced to the spray tower at the top, where Tin was measured. Droplets were 
dried in the drying chamber () and particles were collected in the product vessel () after 
separation by the cyclone (). Tout was determined in the bypass between drying chamber 
and cyclone. The air was finally sucked through a filter to be cleared from fine particles (). 
The spray drying of SBS was used to investigate the influence of drying parameters on the 
drug properties. SBS concentration (Ym) in bi-distilled H2O and Tout were chosen as factors to 
be varied on three levels in the framework of a DoE. A total of 13 batches including the 
center point batch, which was repeated five times, were dried with the lab scale spray dryer. 
The feed concentration Ym was set between 2.5 % and 12.5 %, while Tout was varied linearly 
at a range from 90 °C to 150 °C (Table 3.4). The inlet temperature was set to Tin = Tout + 
60 °C. Tout as a function of the inlet temperature and the amount of solution spray dried per 
time was controlled by the chosen feed rate. Further parameters like the aspirator capacity 
(100 %, 38 m³ ● h-1) and the spraying air (40 mm, 666 L ● h-1) [124], which controls the 
droplet and by this the particle size, were kept constant for these experiments. The product 
was collected from the vessel beneath the cyclone and stored in a desiccator upon blue gel 
(Sigma Aldrich Chemie GmbH, Munich, Germany) until further analysis to ensure the stability 
of the product. 
  
 
Table 3.4 – Three levels of the chosen factors for the spray drying of SBS. *marks the 
conditions of the center point experiments 
Factor - 1 0* + 1 
SBS concentration, Ym, 
% [w/w] 
2.5 7.5 12.5 
Outlet temperature, 
Tout, °C 
90 120 150 
 
3.3.2.2 Jet-Milling of SBS 
Micronisation of SBS was performed to generate unevenly shaped drug particles of inhalable 
size. Jet milling was chosen for this task as a reliable technique to generate micronised 
materials with quite narrow particle size distributions. Cracking of particles by particle-particle 
collisions or particle-wall collisions facilitates decrease in size that can be controlled by the 
chosen micronising conditions. An air Jet-O-Nizer Modell 00 (Figure 3.11, Fluid Energy Aljet, 
Plumsteadville, USA) with nitrogen 2.8 (Linde AG, Hamburg, Germany) as inert gas was 
applied to run the process.  
 
Figure 3.11 – Scheme of the jet mill used for grinding of SBS and mannitol (Pearlitol
®
 160C) 
Grinding pressure was set to 6.0 bar while injection pressure was 7.0 bar to ensure the 
feeding of SBS. The raw material was fed at a feed rate of approximately 1 g ● min-1 and 
product was collected in a filter pocket right after leaving the grinding chamber. Jet-milled 
SBS was stored in a desiccator upon blue gel as jet milling may create small amorphous 
regions which might recrystalllise under ambient conditions [67]. 
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3.3.3 Budesonide 
BUD, which served as a lipophilic model drug (log P = 1.9) in this project, was used in spray 
dried and micronised quality. Micronised BUD was supplied by Minakem SAS (Dunkerque, 
France) and was used without further treatment (d50.3 = 1.81 µm). The spray dried quality 
was prepared with the Büchi B-290 Mini Spray Dryer as described earlier (Section 3.3.2.1). 
The inert loop modul Büchi B-295 (Büchi Labortechnik AG, Flawil, Switzerland) was applied 
to overcome explosion hazards of methylene chloride in ambient air. The closed cycle was 
operated with Nitrogen 5.0 as spraying gas to ensure that oxygen is excluded during the 
drying process.  
A feed concentration of 7 % BUD in methylene chloride was chosen to generate particles of 
2.0 – 2.5 µm in size. The spraying gas was adjusted to 35 mm on the Büchi scale, which 
corresponds to 538 L ● h-1, respectively, [124] and drying temperature was set to Tin = 100 °C 
prior to the experiment. Spray drying was started at constant conditions with a feed rate of 
8 %. The product was collected in the small vessel beneath the cyclone and stored upon 
silica gel in a desiccator until further analysis. 
3.3.4 Formoterol Fumarate 
FOR was used as a lipophilic model drug (log P = 2.2) in this project. The spray dried quality 
was prepared with a Büchi B-290 Mini Spray Dryer in connection with the inert loop module 
Büchi B-295 as formoterol was dissolved in methanol prior to drying. The closed loop 
enables the recovery of methanol by condensation and diminishes explosion hazards. 
Spray drying conditions were chosen based on earlier experiments (data not shown) aiming 
at particles of 2.0 – 2.5 µm in size. The feed concentration was set to 4.8 % [w/w] FOR 
dissolved in methanol. The feed vessel was sealed with parafilm to prohibit evaporation of 
solvent. Spraying air was set to 33 mm on the Büchi scale corresponding to ≈ 498 L ● h-1. 
The inlet temperature was kept at 100 °C during the drying process, which resulted in an 
outlet temperature of approximately 60 – 62 °C. Particles collected in the vessel beneath the 
cyclone were stored upon silica gel in a desiccator to guarantee stability of the product. 
3.3.5 Tiotropium Bromide 
Spray dried TIO particles (log P = -1.8) were gained as described for SBS earlier (Section 
3.3.2.1). The Mini Büchi B-290 was set to an inlet temperature of Tin = 150 °C which resulted 
in a temperature of approximately Tout = 81 – 83 °C. 2 % [w/w] TIO were dissolved in bi-
distilled H2O and conveyed with a feed rate of 10 %. A spraying air of 40 mm or 667 L ● h
-1 
was applied in order to generate particles with a size of 2.0 to 2.5 µm. The product was 
stored upon silica gel until further analysis. 
  
 
3.3.6 Mannitol Fines 
Apart from drug particles, mannitol fines were needed for further trials. Jet milling was 
chosen to comminute Pearlitol® 160C as raw material to a desired final particle size of 4 –
 5 µm. Micronisation was performed according to Section 3.3.2.2. With respect to the desired 
final particle size grinding pressure was set to 5.5 bar while the pusher nozzle was run at 
6.5 bar. The final product collected with the filter pockets was stored at ambient conditions as 
mannitol was found to be stable at these conditions (Section 4.1.1). 
3.3.7 Preparation of Powder Blends 
Interactive powder blends of mannitol carrier particles and fine drug particles were prepared 
with a Turbula® blender (Figure 3.12, Typ T2C, Willy A. Bachhofen AG, Basel, Switzerland). 
A total of six mannitol batches was chosen with regard to different particle shapes and sizes 
as generated in the framework of the DoE (Section 4.1, Table 4.1). Blending procedures 
were adapted for different drug particles to overcome stability concerns with regards to 
recrystallisation of amorphous contents or the elimination of drug agglomerates as will be 
described in this section. 
 
Figure 3.12 – Scheme of the Turbula
®
 blender as a free fall blender 
Blending of all powder blends was performed under controlled conditions in a climatic 
chamber (Imtech Deutschland GmbH & Co KG, Hamburg, Germany). Relative humidity was 
kept as low as necessary to ensure stability of amorphous contents and as high as possible 
to prevent electrostatic charging of powder blends during preparation or blending. A stainless 
steel sieve with a mesh size of 355 µm was used for all drugs and mannitol batches to 
remove agglomerates manually prior to blending. Each interactive powder blend consisted of 
14.85 g mannitol (99 % [w/w]) and 0.15 g drug (1 % [w/w]), which resulted in 30 – 40 % filling 
volume of the stainless steel vessel used for blending. With respect to blend homogeneity a 
double sandwich weighing method was applied for mannitol carrier and drug containing 
blends starting with 4.95 g (
1
3
) mannitol plus 0.075 g (
1
2
) of drug followed by another 4.95 g (
1
3
) 
mannitol, 0.075 g (
1
2
) of drug and 4.95 g (
1
3
) of mannitol. The blending vessel was then fixed 
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into the Turbula® blender (Figure 3.12) and blended for appropriate blending times. Sieving 
steps were introduced to eliminate agglomerates. Ten samples were randomly taken from 
different positions of the finished product to check for homogeneity. A drug recovery of 90 – 
110 % and a relative standard deviation below 5 % were set as limits for further analysis. 
Samples were dissolved in appropriate solvents and drug content analysed via reversed 
phase high performance liquid chromatography (RP-HPLC) as described in Section 3.4.6. 
The finished product was stored upon silica gel in a desiccator until further analysis. 
The blending procedures were adapted in terms of climatic conditions or blending steps to 
meet requirements for the blend quality. 
SBS containing blends were prepared at 21 °C and 35 % rH, which prevents the 
recrystallisation of amorphous structures of the drug particles while keeping electrostatic 
charging as low as possible. Blending was performed for 2 x 15 min with one in-between 
sieving step. Rotation speed of the Turbula® blender was kept at 42 rpm. SBS was used in 
spray dried and micronised quality. 
BUD containing blends were produced at the same climatic conditions (21 °C, 35 % rH) but 
demanded another blending step to fulfil the homogeneity requirements. The blending 
procedure was extended to 3 x 15 min including two in-between sieving steps. Rotation 
speed was kept on the same level for both spray dried and micronised BUD qualities. 
FOR handling was performed at 21 °C and 35 % rH to keep amorphous contents stable. 
Carrier and drug were blended for 2 x 15 min, but with increased rotation speed of 90 rpm, 
as higher energy input was necessary to eliminate FOR agglomerates and to accomplish 
homogeneity requirements. FOR was only used in spray dried quality. 
TIO containing powder blends were prepared at lower relative humidity (21 °C, 25 % rH) as 
TIO is known to be hygroscopic (Section 4.2.4). Blending was performed for 3 x 15 min at 
42 rpm including two in-between sieving steps. 
SBS and Fines were blended with conditions according to powder blends only containing 
mannitol carrier and SBS particles. Mannitol fines were added first in different concentrations 
(0 % to 15 %) following the sandwich weighing method mentioned above. The drug particles 
were then added after the first blending step instead of sieving the initial blend of mannitol 
carrier and fines. The drug was therefore separated in several small portions to be added to 
different spots in the mixing vessel. Sieving was conducted between second and third 
blending step. 
  
 
3.4 Analytical Methods 
3.4.1 Particle Size 
Particle size can be described by several different particle diameters with regard to the 
technique chosen and the purpose of the analysis. In general, three dimensions (length, 
width, depth) are mandatory to define a particle by size. Ferret´s or Martin´s diameter are 
exemplary for two-dimensional measurements as performed with a microscope while a broad 
range of different equivalent diameters refer to corresponding spherical particles. Results 
presented here are either corresponding to the volume based equivalent diameter (d50.3) 
which describes the diameter of a sphere with the same volume as the particle or the 
aerodynamic equivalent diameter (dadyn) representing the diameter of a spherical particle with 
the density 1 g ● cm-3 and the same settling velocity as the (irregular) particle of interest 
[125]. 
Various techniques can be used to determine the desired diameters. Laser diffraction as a 
standard method for dry powder analytics was applied to measure the volume based 
diameters (d50.3). Aerodynamic diameters (dadyn) of drug particles for inhalation were gained 
by impaction analysis as described in Section 3.4.1.2. 
3.4.1.1 Laser Diffraction 
Volume based equivalent diameters were determined by laser light scattering. The laser 
diffraction technique relies on the characteristic diffraction pattern of incident laser light by 
the particles of interest. The diffraction angles are inversely proportional to the size. Small 
particles cause large diffraction rings with low intensity, while small diffraction rings of high 
intensity refer to large particles. The according diffraction pattern is evaluated based on the 
Mie theory or the Fraunhofer approximation resulting in the volume based equivalent 
diameter. It needs to be considered that both calculations assume that the particles to 
measure are of spherical shape [125]. 
Prior to final product determinations a Malvern laser diffraction system (STP 5921, Malvern 
Spraytec, Malvern Instruments, Worchesterchire, UK) was applied to measure the initial 
droplet size distributions of the droplets emerging from the LamRot atomizer in an off-site 
setup. The effect of rotation speed (n) on the droplet size was tested by increasing n from 
3,000 rpm to 14,000 rpm. Feed concentration (15 % [w/w]) of mannitol in water and feed rate 
(10 L ● h-1) were selected with respect to the spray drying conditions chosen for the DoE. 
Droplet sizes were used to calculate resulting particle sizes based on a shift factor, which 
was determined according to an approach invented by Maas et al. [82]. Shift factor was set 
to 1.73 with respect to initial density of mannitol in water (15 % [w/w], 1030 kg ● m-3), the 
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bulk density of mannitol (1200 kg ● m-3) and an assumed final porosity of 50 %. The final 
particle size can then be calculated from the measured droplet size as follows: 
 
𝑑50.3(𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒 𝑠𝑖𝑧𝑒) =  
𝑑50.3(𝑑𝑟𝑜𝑝𝑙𝑒𝑡 𝑠𝑖𝑧𝑒) 
1.73
 (3.3) 
 
Laser diffraction was further used for particle size investigations of dry carrier and drug 
particles in this thesis. For both, the HELOS laser diffraction system (Sympatec GmbH, 
Clausthal-Zellerfeld, Germany) equipped with a helium neon laser (λ = 623.8 nm) was used 
in connection with the RODOS dry dispersing unit (Sympatec GmbH, Clausthal-Zellerfeld, 
Germany). Pressurised air was applied to deagglomerate the samples. The dispersing 
pressure was chosen with respect to the breaking strength of the particles [126]. Mannitol 
carrier batches were measured with a dispersing pressure of pabs = 1.2 bar to prevent particle 
break-up. Smaller drug samples were dispersed at pabs = 4.0 bar due to their cohesiveness 
and facilitated by their higher physical stability. All samples were fed to the dispenser 
manually to reach a minimum optical density of 1 %. Samples were measured in triplicate 
and evaluated with the Windox software (Version 5.4.2.0, Sympatec GmbH, Clausthal-
Zellerfeld, Germany). Results were gained as volume based equivalent diameters, for which 
the cumulative distribution and density distribution were plotted. The median (d50.3) as well as 
the 10 % (d10.3) and 90 % (d90.3) quantile were used for further analysis. 
 
𝑠𝑝𝑎𝑛 =  
(𝑑90.3 – 𝑑10.3) 
𝑑50.3
 (3.4) 
 
 span width of PSD 
 d90.3. volume-based 90 % quantile of the PSD 
 d50.3 volume-based 50 % quantile of the PSD 
 d10.3 volume-based 10 % quantile of the PSD 
 
Span values were calculated according to Equation (3.4 to assess the width of the PSDs 
[126]. 
  
 
3.4.1.2 Next Generation Pharmaceutical Impactor (NGI) 
 
Figure 3.13 – Scheme of the opened Next Generation Pharmaceutical Impactor (NGI) with seven 
stages and the Multiple Orifice Collector (MOC) at the bottom and the appropriate nozzles in 
the lid  
  
Figure 3.14 – Scheme of the closed Next Generation Pharmaceutical Impactor (NGI) with a 
throat-like tube connected to the preseparator and the stages and nozzles at the bottom (see 
Figure 3.13) 
Aerodynamic equivalent diameters are commonly evaluated by cascade impaction. This 
covers the impact of particle shape and density as particles with lower densities behave 
aerodynamically as though they are smaller than their physical size and vice versa. 
Impaction analysis enables to assess the fine particle fraction and provides useful 
information about the aerodynamic behaviour of the particles. Cascade impactors are built of 
one or more stages with nozzles of defined diameters and cups beyond the nozzles to collect 
the droplets or particles. The Ph. Eur. lists three different impactors to determine the “Fine 
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Particle Fraction” of dry powders according to “Preparations for inhalation – aerodynamic 
assessment of fine particles” (Apparatus C, D, E, Ph.Eur. 2.9.18) [127]. 
In this thesis the aerodynamic characterisation of interactive powder blends was examined 
with the Next Generation Pharmaceutical Impactor (NGI, Apparatus E, Pharmacopeia 
Europaea, 2.9.18, Copley Scientific, Nottingham, UK) [127]. The impactor was equipped with 
an induction port to attach appropriate mouth pieces for all types of inhalation devices and a 
preseparator for the deposition of larger particles. Seven stages and a multiple orifice 
collector (MOC), which served as filter for the smallest particles, were applied for the 
accurate assessment of fine particles (Figure 3.13, Figure 3.14). 
The Ph. Eur. requires a pressure drop of 4 kPa over the inhaler device and an inhaled 
volume of 4 L which corresponds to the standard lung volume of an adult [127]. The 
appropriate pressure drop was implemented by adjusting the volumetric flow rate (Q) as 
measured with the digital flowmeter (DFM3, Copley Scientific, Nottingham, UK). The opening 
times (Tinh) of the solenoid valves of the critical flowmeter (TPK, Copley Scientific, 
Nottingham, UK) were calculated according to Equation (3.5) to ensure an inhaled volume of 
Vinh = 4 L. 
 
𝑇𝑖𝑛ℎ =  
𝑉𝑖𝑛ℎ
𝑄
 (3.5) 
 
 Tinh Valve opening time, s 
 Vinh Absoulte inhaled volume, 4 L 
 Q Volumetric flow rate, L ● min-1 
 
Table 3.5 shows the respective parameters as used for analysis with two chosen commercial 
inhaler devices, Novolizer® (Meda Pharma, Bad Homburg, Germany) and Easyhaler® (Figure 
2.7). 
 
 
 
 
  
 
Table 3.5 – Device-dependent parameters for impaction analysis with the NGI using the 
Novolizer
®
 and Easyhaler
®
 as devices 
 Novolizer® Easyhaler® 
Volumetric flow rate, Q, L ● min-1 78.2 45.0 
Valve opening time, Tinh, s 3.1 5.3 
The collection cups including preseparator and MOC of the NGI were coated with a special 
stage coating consisting of ethanol, Brij® 35 and glycerol (51:15:34 [w/w]) prior to every 
measurement to minimise bouncing of particles. The container of the appropriate inhaler 
device was filled with 1.0 g of interactive powder blend. An external collection tube with a 
suitable mouthpiece adapter was applied for priming the inhaler device. Initially, twenty 
doses (doses 1 – 20) were discharged into the tube. Inhalation was triggered by opening the 
solenoid valve of the critical flowmeter for the calculated timeframe. The following doses 
were administered with the inhaler device connected to the induction port. 
All experiments performed with the Easyhaler® were conducted with SBS, while the 
Novolizer® was used for impaction analysis with SBS, BUD, TIO and FOR. The number of 
doses discharged to the impactor was varied with respect to the maximum load of the 
collection cups. The Novolizer® was actuated ten times for SBS, TIO and FOR (doses 21-30) 
and five times for BUD (doses 21-25) to generate appropriate drug concentrations for 
quantification. Induction port (including mouthpiece), preseparator, seven stages and the 
MOC were sampled separately. The deposited drug was dissolved with predefined volumes 
of the appropriate solvent and distinct rinsing times to avoid undissolved drug residues.  
The results of the aerodynamic characterisations as gained by drug quantification by 
reversed phase high pressure liquid chromatograpy (RP-HPLC, Section 3.4.6) were 
evaluated with the Copley Inhaler Testing Data Analysis Software (Copley Scientific, 
Nottingham, UK). The total drug content detected in the impactor from mouthpiece to MOC 
was defined as emitted dose (ED) released by the inhaler device. The cut-off diameters of 
the stages which depend on nozzle diameter and the chosen flow rate determine the fraction 
of particles with a median mass aerodynamic diameter (MMAD) of < 5 µm, which represents 
the d50 of the cumulative aerodynamic PSD. The fine particle dose (FPD) is defined as the 
mass of drug particles with a MMAD < 5 µm, while the fine particle fraction (FPF) is 
calculated as the fraction of particles with a MMAD < 5 µm in % referring to the ED (Equation 
(3.6)) [46]. 
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𝐹𝑃𝐹 =  
𝐹𝑃𝐷
𝐸𝐷
 × 100 % (3.6) 
 
 FPF Fine Particle Fraction, % 
 FPD Fine Particle Dose, µg 
 ED Emitted Dose, µg 
 
All adhesive mixtures were measured in triplicate and results were given as mean of three ± 
standard deviation.  
3.4.2 Imaging Techniques 
Imaging techniques, as widely employed in pharmaceutical research and development, 
provide the opportunity to characterise particles with regard to their visual appearance. The 
morphology of particles is of utmost interest to discover the drying kinetics during spray 
drying as well as to understand particle-particle interactions in interactive powder blends. 
Different parameters to describe the morphology can most easily be assessed by different 
imaging techniques [125]. In this thesis, the morphology of carrier particles was divided into 
particle shape and surface roughness as these properties can be controlled separately 
during the spray drying process. Additionally, the drug shape of SBS particles prepared at 
different conditions was evaluated next to carrier shape and roughness to investigate the 
effect of drug morphology on the impaction results. 
Scanning Electron Microscopy (SEM) was chosen to visualise all carrier and drug particles 
as well as powder blends prior to and after the aerodynamic characterisation (Section 
3.4.2.1). Different surveys were applied to evaluate the particle morphology based on 
categorisation of these SEM images (Section 3.4.2.2, Section 3.4.2.5). Further, image 
analysis was performed to discover the sphericity and aspect ratios of the carriers to support 
the survey results in terms of particle shape. 
Surface roughness of the carriers as principally evaluated by categorisation of SEM images 
was supported by 3D laser scanning microscopy (Section 3.4.2.6) which generates a 3D 
surface of the carriers. 
Further, a special confocal Raman spectroscopy approach which combines surface 
topography and the according Raman scattering was applied to overcome concerns of the 
location of drug particles on the carrier surface (Section 3.4.2.7). 
  
 
3.4.2.1 Scanning Electron Microscopy (SEM) 
The SEM technique as the imaging tool with the highest resolution and depth of focus is 
based on the scattering of an electron beam originated from an electron gun [125]. The 
electrons are accelerated in correlation to the chosen working voltage, where high working 
voltages between 10 kV and 15 kV serve the best resolution but cause deeper penetration 
and degradation of the specimen. Lower working voltages of < 5 kV offer perfect conditions 
for surface topography investigations due to the low penetration depth. The electrons of the 
scanning electron beam strike the sample surface which triggers the emission of low energy 
secondary electrons (SEs) or high energy backscattered electrons. An array of specialised 
detectors helps to visualise the signals. To minimise beam scattering by gas molecules, SEM 
analysis is conducted at very high vacuum [125]. 
This project applied a Zeiss Ultra 55 Plus (Carl Zeiss NTS GmbH, Oberkochen, Germany) for 
visualisation. All samples were fixed on carbon stickers (Plano GmbH, Wetzlar, Germany) 
and sputter coated using a Bal-Tec SCP 050 Sputter Coater (Leica Instruments, Wetzlar, 
Germany) as this ensures conductivity for the analysis of electrically nonconductive organic 
substances. Sputtering was conducted in an evacuated chamber for 65 s at 50 mA with 
Argon 5.0 (Linde AG, Hamburg, Germany). Argon ions were accelerated towards a gold 
target to generate a thin conductive gold layer on the specimen surface. The coated samples 
were transferred to the SEM chamber and scanned with a working voltage of 2 kV. Images 
were gained from secondary electrons with the SE-2 detector. All samples were visualised at 
different magnifications from 100-fold to 10,000-fold when reasonable. 
3.4.2.2 Carrier and Drug Shape by Survey 
Analysing the shape of particles is still a challenging task as most techniques require 
appropriate size ranges to provide useful information. A visual evaluation of SEM images by 
twenty volunteers, who were filling in a survey, was chosen as the principal method to 
investigate the particle shape of spray dried mannitol carriers and was supported by image 
analysis (Section 3.4.2.3) and particle cross sections (Section 3.4.2.4). Images of different 
magnifications (100 fold to 1,000 fold) were chosen to be classified into five categories 
regarding its particle shape as listed in Table 3.6. Results were analysed as continuous 
values in the framework of the DoE. 
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Table 3.6 – Five shape categories as used for the evaluation of the carrier shape by a survey 
Category  Description 
1 All particles are completely spherical without any indentations. 
2 Some particles exhibit single small indentations. 
3 Most particles with several small indentations and first single 
deeper indentations. 
4 All particles with at least small indentations, several particles with 
deep indentations. 
5 All particles show many deep indentations. 
 
The shape of spray dried SBS drug particles was examined similarly, as these particles 
appear even smaller, so that drug shape cannot be assessed by image analysis or cross 
sections. Five different categories were defined as mentioned in Table 3.7 to evaluate the 
drug shape in the framework of a survey and based on SEM images of different 
magnifications (1,000 fold to 5,000 fold). Results were again analysed as continuous values 
by the DoE software Modde. 
Table 3.7 – Five categories for the evaluation of SBS drug shape by a survey 
Category  Description 
1 No golf ball structure for drug particles of every size (all particles 
with smooth surface). 
2 Only larger particles with a slight golf ball structure, medium and 
small particles with smooth surface. 
3 Medium and large particles with a slight golf ball structure, small 
particles with smooth surface. 
4 Large particles with prominent golf ball structure, medium and 
small particles with a slight golf ball structure. 
5 Prominent golf ball structure for drug particles of every size (all 
particles with obvious indentations). 
  
 
3.4.2.3 Image Analysis 
Image analysis was implemented targeting the aspect ratio (AR) of particles as a measure to 
describe particle shape. A high speed camera was used with the QICPIC system (Sympatec 
GmbH, Clausthal-Zellerfeld, Germany) that provides a 2D visualisation of dispersed particles 
with a frequency of 450 hz. Appropriate dispersion was ensured by application of the 
RODOS dry dispersing unit with the same conditions mentioned in Section 3.4.1.1. The 
carrier particles of six different mannitol batches as used for the preparation of powder 
blends (Section 4.1.2) were examined to support the data gained by visual categorisation 
(Section 3.4.2.2, Section 3.4.2.5). The Windox software (Version 5.8.0.0, Sympatec GmbH, 
Clausthal-Zellerfeld, Germany) was calculating the aspect ratio as depicted in Equation (3.7). 
 
𝐴𝑅 =  
𝑑𝑚𝑖𝑛
𝑑𝑚𝑎𝑥
 (3.7) 
 
 AR aspect ratio 
 dmin minimal diameter of a particle with defined orientation, m 
 dmax maximum diameter of a particle with defined orientation, m 
 
An AR of 1 describes a perfect sphere, while indentions or other shapes like platelets or 
elongated particles lead to a lowered AR. 
 
Figure 3.15 – Particle gallery of mannitol particles with a size between 25 µm and 125 µm and 
the AR above 0.75 as gained by image analysis 
The particle gallery was used to set requirements for evaluation (Figure 3.15). An aspect 
ratio of AR ≥ 0.70 was demanded to avoid agglomerates and overlaid particles which cause 
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incorrectly lower aspect ratios. Particle size was chosen as another parameter to exclude 
large agglomerates. Only particles with an equivalent circle diameter of 25 – 150 µm were 
taken into account. Smaller particles were excluded since the resolution is not appropriate for 
accurate evaluation. 
3.4.2.4 Particle Cross Sections 
As not only the outer shape is of interest for the examination of drying kinetics, particle cross 
sections were implemented to discover the inner particle structure. Exemplarily, a mostly 
spherical and an indented mannitol batch were embedded in tissue freezing medium (Tissue-
Tek®, Sakura Finetek, California, USA) at – 25 °C. Slices of 5 µm in thickness were cut with a 
cryomicrotome (CryoStar NX 70, Thermo Scientific, Waltham, Massachusetts, USA) and 
placed on the carbon sticker of a SEM sample holder. The cross sections were visualised as 
described in Section 3.4.2.1. 
3.4.2.5 Surface Roughness by Survey 
The determination of surface roughness parameters for mostly spherical particles by an 
analytical method like 3D laser scanning microscopy is challenging due to a number of 
reasons. The calculation of appropriate values is complicated due to spherical character and 
occurrence of indentations as results need to be flattened prior to evaluation. Further, only a 
few single particles can be covered by these approaches. Therefore, visual evaluation of 
SEM images was selected as the principal method to discover the surface roughness for all 
spray dried carrier batches. As for the particle shape, twenty volunteers were asked to 
categorise three SEM images of different magnification into five categories from smooth to 
crystalline structures with granular accumulations (crystallinity was predetermined by XRPD) 
as listed in Table 3.8. The results were evaluated as continuous values in the context of the 
DoE. 3D laser scanning microscopy was performed to support those data (Section 3.4.2.6).  
  
  
 
Table 3.8 - Five roughness categories as used for the evaluation of the carrier surface 
roughness by a survey 
Category  Description 
1 Surface of all particles completely smooth 
2 Some single crystalline structures on the surface 
3 Several crystalline structures on the surface 
4 Several crystalline structures on the surface including some single 
granular accumulations 
5 All particles with crystalline structures and granular accumulations 
on the particle surface 
 
3.4.2.6 3D Laser Scanning Microscopy 
3D laser scanning microscopy (3D Laser Scanning Microscope VKX-200, Keyence 
Deutschland GmbH, Neu-Isenburg, Germany) was applied in order to visualise and quantify 
the roughness of the mannitol carrier surface of six different mannitol carriers (Section 4.1.2). 
A violet laser (λ = 408 nm) served for a maximum resolution of 1 mega pixel (135 µm x 
101 µm) at 100 fold magnification. The particles of interest were placed on a microscope 
slide and fixed by glue prior to measuring. Surface visualisation was performed with a 
working distance of 0.3 mm and analysed with the Keyence MultiFile Analyser (Keyence 
Deutschland GmbH, Neu-Isenburg, Germany). A Gauss filter that describes the maximum 
altitude recognised as surface roughness was set to λc = 0.08 mm in order to distinguish 
between surface roughness and particle shape. The bending of the spherical particle shape 
was further considered for calculation. The surface roughness was calculated as arithmetic 
average of absolute values (Ra) for one-dimensional values (Equation (3.8)) corresponding to 
DIN EN ISO 4287 [128] and as arithmetic average of absolute values for an area (Sa) for two-
dimensional values (Equation (3.9)). 
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𝑅𝑎 =  
1
𝑙
 ∑|𝑧(𝑥)|
𝑙
0
𝑑𝑥 (3.8) 
 
 Ra Arithmetic average of absolute values for a line (1D), µm 
 l Length of the line in x direction with deviations in z direction, µm 
 z(x) (cumulative) deviations in z direction, µm 
 dx length of sector x in x direction, µm 
 
Accordingly, Ra corresponds to the sum of all deviations z(x) from the mean line divided by 
the sampling length l as was further illustrated in Figure 3.16. 
 
Figure 3.16 – Ra determination according to the roughness profile curve over the chosen 
sampling length l 
The calculation of the arithmetic average of all deviations (Sa) from an area (A) follows the 
assumptions illustrated for Ra in Figure 3.16 as described by Equation (3.9). 
 
𝑆𝑎 =  
1
𝐴
 ∑|𝑧(𝑥, 𝑦)|𝑑𝑥𝑑𝑦
𝐴
0
 (3.9) 
 
 Sa arithmetic average of all deviations from an area, µm 
 A area defined in x and y direction with deviations in z direction, µm² 
 z(x,y) cumulative deviations (z direction) of the area (x and y), µm 
 dxdy size of area covered for the measurements (x and y direction), µm² 
 
  
 
3.4.2.7 Confocal Raman Spectroscopy 
A confocal Raman analysis approach was applied to distinguish between drug and carrier 
particles in interactive powder blends as the detection of drug accumulates with regard to the 
carrier particle shape was of special interest. Raman spectroscopy studies the inelastic 
Stokes Raman scattering of monochromatic radiation by a sample. 
Experiments were performed with a WITec alpha 300R+ (WITec Instruments Corp., Ulm, 
Germany), which involved a surface topography module to gain a 3D profile of the particles. 
A green laser light source (λ = 532 nm) was used to excite electrons in mannitol carrier 
particles as well as micronised BUD particles. Compound identification was based on 
characteristic Raman shifts at 1656 cm-1 for BUD and 875 cm-1 for mannitol. The surface 
topography of each particle was determined under white light in order to gain the height of 
the surface, which serves as the focal plane for the Raman spectra acquisition. Integration 
time was set to 0.5 s / line with a step size of 1 µm. The analysis was performed on powder 
blends consisting of micronised BUD and two mannitol qualities, a spherical (M71(L)) and an 
indented one (M97(L)). Five particles were examined per batch. The overlay images were 
applied for qualitative evaluation of drug localisation after blending. 
3.4.3 Flowability 
Bulk flowability as a crucial parameter for carrier based powder blends can be determined 
based on diverse techniques. This project included Carr´s Index (CI) as a measure related to 
analytics described in the Ph. Eur. [129] and the Basic Flowability Energy (BFE) measured 
with a powder rheometer for evaluation of particle-particle interactions in mannitol carrier 
samples. 
3.4.3.1 Carr Index 
CI describes the compressibility of a powder and is often used to classify its overall flow 
properties. Here, a jolting volumeter (Erweka SVM 121/221, Erweka GmbH, Heusenstamm, 
Germany) was applied to investigate bulk and tapped density based on Ph. Eur. 2.9.34 [129]. 
CI was calculated according to the following equation: 
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𝐶𝐼 = (1 −
𝑝𝐵
𝑝𝑇
)𝑥100 (3.10) 
 
 CI Carr Index 
 pB Bulk Density, g ● cm
-3 
 pT Tapped Density, g ● cm
-³ 
 
A small CI (CI < 20) represents free-flowing powders as bulk and tapped density will be close 
in value, while large a CI (CI > 20) indicates that more particle-particle interactions occur, 
which decreases particle flow. 
3.4.3.2 Powder Rheometer 
In general, rheology analytics are applied to record how the flow behaviour of a test material 
changes, when different strain rates are used. It is commonly introduced as a routine 
characterisation technique for liquid and semi-solid systems [130], but has rarely been used 
for solids like powder particles. Nevertheless, powder rheology approaches provide 
promising opportunities in order to analyse powder flow and, therefore, interparticulate 
forces. 
An FT-4 Powder Rheometer® (Freeman Technology, Glouchestershire, UK) was applied to 
examine all mannitol batches for the BFE which was used to describe the flow properties 
within this project. The BFE represents the work which is needed to agitate a twisted blade 
downwards through a cylindrical borosilicate test vessel filled with the powder to test (Figure 
3.17).  
All samples were sieved with a 355 µm sieve prior to analysis to avoid agglomerates and 
discharged with a rod ionisator (S-Line LC, 50 VA, Haug GmbH & Co. KG, Leinfelden-
Echterdingen, Germany) to overcome electrostatic forces. The analysis was started with 
conditioning cycles to induce loosening of the powder by turning the twisted blade clockwise 
(tip speed = 100 mm ● s-1). This aimed at a standardised packing density and improved 
comparability of the results. Reversing the direction of the rotating blade (compared to the 
conditioning cycles) caused compaction of the sample. The force detected versus the 
distance travelled by the blade during the downward traverse gives the work (BFE) needed 
to generate a defined flow pattern within the sample [131]. Each measurement was repeated 
ten times and mean values were evaluated within the scope of the DoE. 
  
 
 
Figure 3.17 – Test vessel of the FT-4 powder rheometer with twisted blade and defined volume 
of powder particles 
In theory, BFE is supposed to be lower for non-cohesive samples with less adhesion forces 
or mechanical interlocking than for powder batches with more interparticulate forces. The 
flow properties of a bulk can further be linked to particle characteristics like particle size or 
morphology as those are known to affect the particle-particle interactions and, therefore, the 
bulk flowability. 
3.4.4 Surface Analytics 
3.4.4.1 Surface area 
Surface area measurements using the adsorption of an inert gas such as nitrogen, helium or 
krypton are based on the assumption that the amount of adsorbed gas is proportional to the 
surface area of the particles to test. Brunauer, Emmet and Teller (BET) introduced the BET 
equation [132] which can be simplified to the following: 
 
𝑆𝑡 =  
𝑉𝑚 𝑁0 𝐴𝑐𝑠
𝑀𝑤
 (3.11) 
 
 St  total surface area, m² g
-1 
 N0 Avogadro´s number 
 Acs cross-sectional area of the adsorbent molecule, m² 
 MW molecular weight of the adsorbent, g ● mol
-1 
 Vm volume of gas adsorbed as a monolayer 
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The specific surface area is then obtained by correlation of St and the mass of powder 
measured. Measurements performed in the framework of this project were performed 
according to the European Pharmacopeia monograph “Specific surface area by gas 
adsorption” [133] to support the results gained for particle size and morphology 
determinations, as the BET surface area is known to be affected by these particle properties 
[134]. Sample preparation was started one day prior to measuring since samples were 
subjected to vacuum for > 12 h as a conditioning step (VacPrep 61, Micromeritics Instrument 
Corporation, Norcross, USA) to avoid unspecific binding of gas molecules on the surface. A 
Gemini 2360 System (Micromeritics Instrument Corporation, Norcross, USA) was applied for 
the BET investigations. The samples to test were compared to a reference sample filled with 
the amount of glass beads, which corresponds to the dead space volume of the sample as 
measured with a helium pycnometer before. Both sample tubes were cooled to 77 °K by 
liquid nitrogen during analysis. The dead space of the sample tube was measured with 
Helium (Quality 5.0, Linde Gas Hamburg, Germany) prior to each measurement. The amount 
of adsorbed Nitrogen (Quality 5.0, Linde Gas Hamburg, Germany) which was applied as test 
gas was defined as the volume difference between sample and reference vessel. Specific 
surface area calculations were based on a multipoint correlation with eleven different relative 
pressures between 0.05 and 0.3 p/p0, which was requiring a correlation coefficient of > 0.999 
to be considered for evaluation. Samples were measured in triplicate and interpreted within 
the scope of the DoE. 
3.4.4.2 Specific Surface Energy 
Surface energy as determined by inverse gas chromatography (iGC) can be used to explain 
powder characteristics, such as crystallinity, morphology or the detachment of drug particles 
from a carrier surface during inhalation. A column packed with the sample to test is 
investigated with gas probes of known properties. Non-polar eluents are used to examine the 
dispersive component of the free surface energy (γs
d), while polar ones are necessary for the 
acid-base interactions (γL
d). The total surface energy (𝛾𝑠) is described by the addition of both, 
dispersive surface energy and polar surface energy [125,135,136]. 
Results described in this thesis are gained by non-polar eluents to examine the dispersive 
surface energy. Dispersive (apolar) interactions, also known as Lifshitz–van der Waals 
interactions, consist of London interactions which originate from electron density changes 
(the force between two instantaneously induced dipoles) but may also include both Keesom 
(the force between two permanent dipoles) and Debye (the force between a permanent 
dipole and a corresponding induced dipole) interactions. Specific (polar) interactions explain 
all other types of interactions, but were not measured in this project. 
  
 
IGC analysis was performed with an SMS iGC (Surface Measurement Systems Ltd., 
Alperton, UK). Special iGC columns (Surface Measurement Systems Ltd., Alperton, UK) of 
3 mm in diameter for drug samples and 4 mm in diameter for mannitol samples were packed 
and tapped with an iGC Column Packer (Surface Measurement Systems Ltd., Alperton, UK) 
for 10 min at level 6 to get comparable packing densities for all samples. The powder was 
fixed in the column by silanised glass wool (Supelco, Bellefonte, USA). Analysis was 
performed with two different methods, where both methods use Helium at 10 ppm as a 
carrier gas. First, samples were measured with a series of alkanes (hexane, heptane, 
octane, nonane, decane) at a vapour concentration of 0.03 p/p0, which corresponds to an 
infinite dilution. This injection concentration can be linearly related to the adsorbed amount 
as Henry´s Law is applicable at this point of the adsorption isotherm [137]. Methane, which 
shows no interference with the surface of the specimen, was used to determine the death 
volume (0.01 p/p0). The eluents were detected with a flame ionisation detector (FID) after 
passing the column. This method was used to calculate the dispersive surface energy (iGC 
Advanced Analysis Macro V1.41 for Microsoft Excel 2013, Surface Measurement Systems 
Ltd., Alperton, UK / Microsoft Corporation, Redmond, USA). 
The same alkanes were used for further investigations at finite concentration to examine the 
dispersive surface energy profiles of the mannitol carrier. In theory, probe molecules adhere 
to high energy spots on the surface prior to low energy ones, when present. Different vapour 
concentrations from p/p0 = 0.03 to p/p0 = 0.95 were screened to generate an isotherm for 
each alkane used. The isotherms display that in this setup the Langmuirian adsorption 
isotherm (Type I) but not Henry´s Law is applicable for evaluation [132,138]. This method 
was used to investigate the heterogeneity of the carrier surfaces, as the surface energy was 
plotted against the surface loading at different concentrations [138]. The surface was 
assumed to be homogenous for Δγs
d < 5 mJ. 
Dispersive surface energy as the free energy of adsorption can be expressed by 
Equation (3.12), so that RT ln VR
0 can be plotted against √γL
d to gain the dispersive surface 
energy from the slope of a linear correlation (2NA√γs
d). 
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𝑅𝑇 𝑙𝑛 𝑉𝑅
0 = 2𝑁𝐴 × 𝑎 × √𝛾𝐿
𝑑 × 𝛾𝑠
𝑑 + 𝐾 (3.12) 
 
 R general gas constant, J ● kg-1 K-1 
 T temperature, °K 
 VR net retention volume, m³ 
 NA Avogadro number, 6.022 x 10
23 mol-1 
 a cross sectional area of the probe molecule, 0.162 nm² for N² 
 γL
d dispersive surface energy of the liquid phase, mJ ● m-2 
 γs
d dispersive surface energy of the solid surface, mJ ● m-2 
 K probe molecule specific constant 
 
3.4.4.3 Dynamic Vapour Sorption 
The ability to adsorb water not only on the surface but also absorb it into the material can 
often be related to amorphous contents, which recrystallise when a distinct content of 
moisture occurs. The mass of adsorbed and absorbed water depends on the crystal habit of 
the sample and the relative humidity (p/p0). 
The behaviour of drug particles at defined ambient moisture contents was investigated with a 
DVS-1 (Surface Measurement Systems Ltd., London, UK) that measures the humidity-
dependent increase in mass gravimetrically. According moisture sorption isotherms were 
recorded for an increase of the p/p0 value from 0.0 p/p0 to 0.9 p/p0 (steps 0.1 p/p0) and the 
decrease to 0.0 p/p0 again. Moisture contents were kept stable for up to 720 min unless 
change in mass was < 0.0005 % ● min-1. The first cycle was repeated once to enable 
statements on water uptake during the first cycle as crystallisation events occur irreversibly 
and do not affect the moisture sorption isotherm of the second cycle.  
Mannitol samples were measured accordingly but with a DVS-HT (Surface Measurement 
Systems Ltd., London, UK) which allowed the determination of up to ten samples 
simultaneously. 
3.4.4.4 Differential Scanning Calorimetry 
Differential Scanning Calorimetry (DSC) was applied as a method to examine thermic events 
that occur during heating a sample. The differential heat flow between sample and reference 
  
 
cell was investigated with a Perkin Elmer PYRIS Diamond DSC (Perkin Elmer, Waltham, 
USA) to relate differences to events like melting, recrystallisation or glass transition.  
Therefore, 4 – 5 mg of sample was accurately weighed into aluminium DSC pans and the 
pans were closed with a pierced lid. A temperature-time-program with a heating rate of 10 °C 
min-1 was applied to sample and reference cell for all samples. The minimum temperature 
was chosen to be 20 °C, while the maximum temperature was adjusted according to the 
melting temperature of each sample gained from literature. Measurements were performed 
at a nitrogen flow of 20 mL ● min-1. Calculation of recrystallisation temperature (Tc) and 
melting temperature (Tm) was performed with PYRIS software 3.8 (Perkin Elmer, Waltham, 
USA). 
3.4.5 Crystal Lattice 
X-Ray powder diffraction (XRPD) is known as a method to analyse crystal lattice structures 
of crystalline samples or to indicate that a product occurs fully amorphous. The according 
XRPD diffractograms display the intensity of X-Rays in correlation to the detected diffraction 
angles by the sample of interest. 
The X-Rays are generated in an evacuated X-Ray tube. High voltage is applied to a wolfram 
cathode which accelerates electrons towards the anode. The kinetic energy is mainly 
converted into thermal energy, but serves to also emit a small amount of X-Rays, which were 
used for analysis. The X-Rays are directed to the sample to be diffracted by the crystal lattice 
(when short- or long order appears). The crystal lattice can be derived from diffraction pattern 
in relation to the respective diffraction angle and peak intensity since different structures and 
polymorphs refract differently. 
Mannitol and drug samples were investigated by XRPD (Stadi P diffractometer, Stoe & Cie 
GmbH, Darmstadt, Germany) using an acceleration voltage of 40 kV and a current strength 
of 30 mA applied to the cupper anode to emit CuKα1 X-Rays for interference with the sample. 
The diffracted beams were measured in the range of θ = 8 – 35° at a step rate of 2 θ = 0.05°. 
For evaluation, diffraction intensity was plotted against bending angle 2 θ. 
Mannitol diffractograms were further compared to data of the three polymorphs alpha, beta 
and delta which are known from literature [87]. 
3.4.6 Drug Quantification 
Drug quantification was performed by reversed phase high performance liquid 
chromatography (RP-HPLC), as this technique is known to generate accurate results for a 
broad range of concentrations and with a very low limit of detection. In total, four different 
drugs were analysed. SBS and BUD were quantified using a Waters HPLC system (Waters 
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Corporation, Milford, USA) and evaluated with Empower® Pro 2 software (Waters 
Corporation, Milford, USA). TIO and FOR samples were investigated with an Agilent HPLC 
system (Agilent Technologies Inc., Santa Clara, USA). The respective methods are 
summarised in Section 8.1. The raw materials of each drug served as external standards for 
a calibration curve that was calculated prior to every test series. 
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4 Results & Discussion 
4.1 Spray Dried Engineered Carriers 
The preparation of mannitol carrier particles was performed with a pilot scale spray dryer as 
used by Littringer et al. and Maas et al. earlier [16,23,82] and described in Section 3.3.1. In 
total, nineteen different batches were spray dried as part of a DoE to further investigate 
mannitol carrier properties in dependence of the chosen drying conditions. 
4.1.1 Carrier Storage Stability 
It is known from literature that mannitol appears in different polymorphs (α, β, δ) depending 
on preparation, treatment or storage of the sugar alcohol. Investigations on spray dried 
mannitol as performed by XRPD revealed that all batches prepared within this project 
consisted of β-mannitol which is likewise the most stable conformation [87]. Figure 4.1 
exemplarily shows one batch of the spray dried sugar alcohol, whose peak pattern agrees 
with the one of β-mannitol as published by Littringer et al. [23] and Fronczek et al. earlier 
[87].  
 
Figure 4.1 – XRPD diffractograms of the three different polymorphs of mannitol (α, β, δ) 
described in literature [87] and exemplarily one batch (M70(S)) of spray dried mannitol as 
gained by spray drying with the pilot scale spray dryer 
XRPD results were gained to generate qualitative information about the crystallinity. Earlier 
investigations by Littringer et al. observed that almost 100 % of the spray dried product 
appears in form of the β-polymorph [23]. 
  
 
Further analysis was performed to test product properties during storage as this might affect 
the product quality. Figure 4.2 shows the change in mass during a DVS analysis, when the 
mannitol surrounding moisture content was increased stepwise from 0 % rH to 90 % rH. 
Differences between first and second cycle, which would indicate recrystallisation by 
moisture uptake during the first cycle, could not be detected. Sample mass was increased by 
~ 1.3 % during both cycles, when moisture was kept at 90 % rH. Data exhibit spray dried 
mannitol batches to be slightly hygroscopic according to the Ph. Eur. as the amount of 
moisture uptake was found to be below 2 %, but above 0.2 % [133]. In general, these data 
support the XRPD results suggesting that the product appeared in the most stable β-
polymorph as no recrystallisation events were detected. Crystalline mannitol was most likely 
observed with respect to the low Tg (≈ 30 °C) that governs instant recrystallisation during the 
spray drying process [110]. 
 
Figure 4.2 – Change in mass plot of the DVS analysis with spray dried mannitol, exemplarily 
displayed for one batch (Run 15). The x-axis shows the time in minutes. The 1
st
 y-axis displays 
the change in mass (Δm) in % (lower plot), while the target moisture (p/p0) in % rH was plotted 
on the 2
nd
 y-axis. 
DSC analysis was performed on spray dried mannitol to finally support the XRPD results 
along with the examination of its purity. Figure 4.3 displays the DSC plot of mannitol, when 
the sample was heated from 50 °C to 200 °C. Only a single event was observed for the heat 
flow which represented the melting point of mannitol at Tm = 166.1 °C (Figure 4.3) matching 
earlier results for the raw material Pearlitol® 160C published by Cares-Pacheco et al. [139]. 
Further events which might indicate recrystallisation of the product were not detected. 
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Figure 4.3 – DSC results of spray dried mannitol (M70(S)) with the heat flow in mW (y-axis) 
plotted against the temperature in °C (x-axis). 
Engineered mannitol carrier particles occurred in the β-modification which is supposed to be 
the most stable one, and were found to sparsely absorb moisture even at high relative 
humidity, which further supports storage stability as moisture uptake promotes 
recrystallisation and by this crystal growth. 
Stability of the product is of great importance for all formulations in pharmaceutical use. 
Spray dried mannitol carrier particles were found to be stable at ambient conditions which 
simplifies the storage over time. All products prepared in the scope of the DoE as described 
in the following section were stored at room temperature and without further moisture control. 
4.1.2 Design of Experiments 
The conditions used for the spray drying of nineteen mannitol carrier batches are displayed 
in Table 4.1 as factors which were altered for three levels (Section 3.3.1). All spray dried 
mannitol carrier batches were analysed for a broad set of different powder characteristics 
and evaluated in the framework of the DoE. Results for analyses, which were performed on 
all mannitol carrier batches generated in this project, are summarised in Table 4.1 as 
responses. Further, these results were supplemented by further analytics which were only 
performed on those six batches chosen for the use in interactive powder blends (Table 4.1). 
The batches were numbered according to the run order given by the DoE. Additional labels 
were allocated to the six batches that were applied for aerodynamic characterisation, 
providing further information regarding particle size and morphology of the carrier. The batch 
labels distinguish between small (S, 45 – 55 µm), medium (M, 55 – 65 µm) and large 
particles (L, 65 – 75 µm) and inform about the chosen outlet temperature as particle 
morphology was found to depend on the drying temperature as will be discussed later. 
  
 
Table 4.1 – Results of powder analytics on nineteen mannitol carrier batches as spray dried in the framework of the DoE.  
 
Run 
Order
Exp. 
Name
n, rpm Tax , °C Tswirl , °C
Particle 
Size, x50.3 , 
µm
Particle 
Shape, 
Cat. 1-5
Surface 
Rough-
ness,       
Cat. 1-5
Basic 
Flow-
ability 
Energy, 
BFE, mJ
BET 
surface 
area, 
m²/g
10 1 M71(L) 8000 130 60 71 68.1 1.4 2.7 91 0.26 0.69 0.8967 0.53 / 0.10 0.49 9.73 47.2 0.62
19 2 8000 190 60 96 73.6 3.6 3.4 144 0.33 0.69 0.53 13.61 0.60
15 3 8000 130 100 75 69.2 2.8 3.0 109 0.44 0.72 0.51 11.11 0.60
11 4 M97(L) 8000 190 100 97 76.8 4.9 4.5 149 0.61 0.71 0.8547 3.02 / 0.37 0.52 9.11 65.2 0.64
9 5 M70(S) 14000 130 60 70 51.1 1.7 2.2 82 0.44 0.83 0.8866 0.89 / 0.08 0.51 11.97 64.8 0.62
8 6 14000 190 60 82 65.3 4.5 4.4 102 0.51 0.87 0.50 12.73 0.61
5 7 14000 130 100 78 57.1 2.9 3.3 94 0.51 0.91 0.54 13.03 0.59
12 8 14000 190 100 93 64.6 4.6 4.0 95 0.65 0.98 0.50 15.93 0.63
14 9 M74(M) 11000 130 80 74 57.5 2.5 2.9 98 0.42 0.76 0.8825 0.70 / 0.12 0.51 11.97 61.4 0.50
7 10 11000 190 80 90 66.3 4.4 4.5 126 0.59 0.83 0.52 15.47 0.61
17 11 11000 160 60 81 60.8 3.3 3.0 125 0.52 0.85 0.54 14.29 0.61
6 12 11000 160 100 86 60.7 3.8 3.4 117 0.55 0.75 0.54 13.98 0.60
18 13 8000 160 80 85 70.7 3.7 3.6 141 0.49 0.79 0.53 11.44 0.59
13 14 M80(S) 14000 160 80 80 53.7 4.3 3.6 111 0.57 0.83 0.8676 3.57 / 0.23 0.54 16.49 65.0 0.60
1 15 11000 160 80 81 62.1 3.8 3.2 123 0.56 0.71 0.54 14.29 0.60
3 16 11000 160 80 81 61.2 3.8 3.8 119 0.56 0.74 0.54 13.03 0.60
4 17 11000 160 80 80 60.5 3.6 3.9 114 0.53 0.87 0.53 12.71 0.59
16 18 11000 160 80 81 60.3 4.4 3.8 133 0.55 0.87 0.54 15.04 0.60
2 19 M80(M) 11000 160 80 80 60.8 3.7 3.9 130 0.55 0.71 0.8661 1.55 / 0.15 0.53 12.71 64.3 0.43
DoE: Naming
Results: 
Extra 
Labelling
Sample Name Spray drying conditions
To ut , °C
DoE: Factors DoE: Responses with significant models
Particle Properties
Span
Aspect 
Ratio
Surface / 
Line Rough-
ness,       
Sa  / Ra , µm
Tapped 
Density,    
g/cm³
Carrs 
Index
Surface 
Energy, 
mJ/m²
Porosity
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All analytical results were considered for DoE evaluation but only significant results are 
shown here. The quality parameters as described in Section 3.2 are displayed in Table 4.2. 
Models for every single response were gained followed by a backward regression of 
insignificant terms which resulted in the best fitting model for the evaluated data. Model 
quality for particle size, particle shape, basic flowability energy and BET surface area was 
found to be excellent, as the models exhibit optimal fittings to the analytical results (R²) and 
allow prediction of particle properties for further experiments (Q²). Medium but adequate 
quality was found for all quality parameters of surface roughness as a response. 
Table 4.2 – Quality parameters for mannitol properties evaluated within the DoE. First column 
gives the evaluated quality parameter including the limits of acceptance. Further columns 
show the responses and the according quality results. *artificial lack of fit due to high 
reproducibility 
quality 
parameter 
particle 
size x50.3, 
µm 
particle 
shape, 
Cat. 1-5 
particle 
roughness, 
Cat. 1-5 
basic 
flowability 
energy 
(BFE), mJ 
BET 
surface 
area,  
m²/g 
R² (> 0.50) 0.94 0.90 0.74 0.91 0.94 
Q² (> 0.50) 0.86 0.83 0.61 0.81 0.82 
P (> 0.25) 0.04* 0.83 0.76 0.94 0.36* 
RP (> 0.50) 0.99 0.89 0.79 0.84 0.97 
 
DoE quality was examined to ensure that fittings enable interpretations in terms of e.g. drying 
kinetics during the spray drying of bi-component mannitol water droplets based on profound 
models. Those results will be discussed in the next sections. 
4.1.3 Particle Size 
The spray drying technique and its various parameters enable the production of particles with 
controlled particle sizes. Several factors have been found to significantly influence the size of 
the finished product. The resulting dimensions are mainly a function of dissolved mass per 
solvent, spray droplet size and drying temperature. Drying of droplets is further limited by 
spray tower size and air stream volume as this determines the resident time in the drying 
chamber and so the maximum droplet size that can be dried adequately. The mass fraction 
of mannitol to dry, which was 15 % [w/w] and was not altered for the drying of mannitol 
carriers in the framework of the DoE, theoretically impacts on the size due to the point when 
saturation occurs on the droplet surface. Saturation solubility is reached earlier when the 
mannitol concentration in the solvent is higher, which leads to an earlier crystallisation and 
  
 
larger particles while the solvent gets evaporated [11,22]. However, this aspect was not 
further covered by this DoE since earlier experiments within the scope of this project were 
dealing with different mass fractions showing the effects mentioned before. 
Three different factors were chosen to be altered on three different levels for this study to 
examine the influence on mannitol carrier properties. The effect of the LamRot atomiser 
rotation speed on the droplet size was initially tested in an off-site setup by laser diffraction to 
calculate the resulting particle sizes, assuming an average porosity of 40 % as mentioned by 
Littringer et al. [22]. The screening of rotation speeds between 3,000 and 14,000 rpm led to 
droplets of d50.3 = 200 µm when low acceleration forces occurred and to d50.3 = 78 µm for the 
highest rotation speed (Table 4.3). Span values revealed droplets generated at medium 
rotation speeds (span = 0.40 – 0.45; 5,000 – 10,000 rpm) to have the narrowest droplet size 
distribution. Calculated particle sizes (Equation (3.3)) suggested particles to have a final 
volumetric diameter of d50.3 = 45 µm to 116 µm assuming that all particles have the shape of 
a perfect sphere. Rotation speed used for the final experiments was varied between 8,000 
and 14,000 rpm with respect to earlier experiments performed by Littringer et al, who 
conducted experiments at 6,300 to 8,100 rpm [16]. Hence, experiments were aiming at 
particles of smaller size than gained by former studies. 
All factors considered here were tested for influences on the final particle size but only 
rotation speed (n) and axial air stream temperature (Tax) were found to have an effect. 
Dependencies for particle size as response (y) of the DoE can be displayed by Equation (4.1: 
 
y = a0 + a1Tax + a3n + a4Tax
2 + a6n
2 (4.1) 
 
which was obtained from Equation (3.2) by neglecting insignificant terms in a backward 
regression as mentioned in Section 3.2. Remaining terms show a linear term of Tax and n as 
well as a quadratic correlation of Tax to have a significant effect on the final carrier size. 
Scaled and centred values for the coefficients given in Table 4.4 assumed that n has the 
main impact on the final particle size. An increase of n by one level or n = 3000 rpm reduces 
the resulting particle size for about 6.66 ± 0.59 µm, while Tax enlarges the carriers by 
4.37 ± 0.59 µm per level (Tax = 30 °C). 
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Table 4.3 – Droplet sizes of an aqueous solution of mannitol after atomisation with the LamRot 
atomiser in an off-site spray experiment 
LamRot rotation 
speed, rpm 
Droplet size, d50.3, µm Span, 
(𝑑90.3−𝑑10.3)
𝑑50.3
 
Calculated particle 
size, d50.3, µm 
3,000 200 0.53 116 
4,000 169 0.48 98 
5,000 152 0.45 87 
6,000 140 0.44 80 
7,000 132 0.41 76 
8,000 116 0.43 67 
9,000 109 0.42 63 
10,000 103 0.43 60 
11,000 97 0.46 56 
12,000 91 0.5 52 
13,000 83 0.55 48 
14,000 78 0.78 45 
 
Table 4.4 – Scaled and centred coefficients (± standard deviation) for carrier particle size as a 
response. Values give the effect on the final particle size in µm, when the factor is changed for 
one level (Tax = 30 °C; n = 3,000 rpm) 
Coefficients 
Particle size d50.3, µm 
scaled & centred 
a0 - 
Tax 4.37 ± 0.59 
n -6.66 ± 0.59 
Tax·Tax 2.29 ± 1.05 
n·n 2.58 ± 1.05 
 
Experiments resulted in final carrier sizes of 51.1 µm to 76.8 µm as summarised in Table 4.1. 
The effect of Tax and n was further visualised in the contour plot shown in Figure 4.4, which 
displays that the smallest particles (d50.3 < 55 µm) were generated at high rotation speeds 
(n = 14,000 rpm) and low axial air stream temperatures (Tax = 130 °C), while the largest 
  
 
particles (d50.3 > 75 µm) occurred for low rotation speeds (n = 8,000 rpm) and high axial air 
stream temperatures (Tax = 190 °C). 
 
Figure 4.4 – Contour plot of the final particle size as a response of the DoE with the factor 
rotation speed (n) on the y-axis and the axial air stream temperature (Tax) on the x-axis 
The effects observed here prove findings discussed in literature earlier. Rotation speed and 
its influence on the droplet size have been shown by Littringer et al. within the same project 
for lower rotation speeds [16,22]. The acceleration of the emerging filaments determines the 
filament diameter and by this the moment of droplet disruption, which in turn defines the 
droplet diameter and by this the resulting particle size [14,98]. 
The way bi-component droplets dry is governed by the interplay of the diffusion of dissolved 
molecules and the evaporation of its solvent. Results presented here revealed the drying 
temperature Tax to affect mannitol carrier particle size. In general for the drying of mannitol, 
evaporation of water molecules exceeds the diffusion of mannitol molecules in an aqueous 
solution, which reasons that mannitol concentrates on the surface of a droplet during drying 
[140]. The shell, which was built when saturation solubility was reached on the droplet 
surface, determined the final particle size. The effect of drying temperature on the shell 
formation – and by this the particle size – is further displayed in Figure 4.5. The temperature 
of the ambient drying air also affected the evaporation of water. Higher temperatures cause 
higher drying rates, which resulted in faster evaporation and surface reduction accompanied 
by saturation of mannitol on the droplet surface. This led to an earlier shell formation and 
larger particles compared to droplets dried at moderate conditions as can be seen in Figure 
4.4 and Figure 4.5. 
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This effect can also be explained by the dimensionless Peclet numbers (Pe) which underline 
the described effect as these numbers depend on the drying velocity. The larger Pe, the 
faster is the evaporation of water from the surface which in turn results in larger particles. 
The Pe calculated for an outlet temperature of Tout = 70.2 °C amounts to Pe = 139.6, while 
the Pe for particles dried at Tout = 97.2 °C amounts to Pe = 200.5, which reflects that higher 
outlet temperatures indicate an earlier shell formation than lower ones as published by 
Gopireddy et al. earlier [141]. Diffusion of mannitol from the droplet surface towards the 
inside proceeds too slow to compensate the diffusion and evaporation of water, which results 
in rising mannitol surface concentrations and higher Pe numbers, which in turn reasons the 
earlier shell formation. 
 
Figure 4.5 – Sketch of the drying of bi-component mannitol-water droplets at different drying 
temperatures (T) 
Further, the mannitol carrier PSD was of interest, as the combination of LamRot atomiser 
and swirl air stream was designed to control the droplet break-up and by this to lower span 
values. In fact, all batches dried within the DoE revealed span values < 1.0 (Table 4.1) with 
the narrowest PSD for some batches dried with a rotation speed of 8000 rpm (Run 1 / 2; 
span = 0.69). Figure 4.6 shows the PSD of DoE Run 2 exemplarily for all other batches, 
illustrating that spray drying of mannitol lead to monomodal and narrow PSDs, when 
compared to Pearlitol 160C, which was used as raw material for these experiments. These 
results can be attributed to the defined diameters of the sixty bores distributed around the 
LamRot atomizer (Figure 3.9), but also to the swirl air stream, which allows unaffected 
droplet break-up by the repression of axial forces by the axial air stream. 
 
  
 
 
Figure 4.6 - PSDs of spray dried mannitol Run 2 and commercially available Pearlitol 160C as a 
sieved mannitol quality 
A medium span value of 0.79 ± 0.08 was measured for the current nineteen experiments, 
whilst experiments conducted by Littringer et al. [16] using the same pilot scale spray dryer 
resulted in an average span of 0.84 ± 0.06 indicating slight improvements, which however 
were not significant as examined with an unpaired t-test. It can be suggested that control of 
the swirl air stream volume (Vswirl) might further improve the span value of spray dried 
mannitol particles. Mescher et al. have proved on the drying of PVP that Vswirl and the 
resulting swirl air stream velocity need to meet the acceleration forces of the LamRot 
atomiser or the droplet velocity, respectively, to generate the best PSD results [15], which 
was not implemented for mannitol drying to stay with a reasonable number of factors. 
With respect to the use in DPIs, particles of 50 – 80 µm as generated by spray drying with 
the pilot scale spray dryer match the desired size range. Literature mentioned particles with a 
size > 50 µm to be suitable for carriers with inhalation purpose [16,46]. 
4.1.4 Particle Morphology 
The morphology of carrier particles used for inhalation purposes has been described to 
impact the inhalation characteristics crucially. The factors used in this study were chosen 
with respect to earlier studies, which dealt with the spray drying of mannitol and the influence 
of drying conditions on the appearance of the mannitol carriers [11,16,82]. 
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Morphology was distinguished between particle shape and surface roughness to focus on 
the drying of bi-component mannitol-water droplets as shape and roughness were believed 
to arise independently. Further, it was of interest to evaluate the influence of both on the 
aerodynamic performance of interactive powder blends to discuss the effects separately. 
4.1.4.1 Particle Shape 
The three factors varied in the framework of the DoE were tested for significant effects on the 
particle shape, but only Tax and Tswirl were found to affect the shape, which results in the 
following Equation (4.2): 
 
y = a0 + a1Tax + a2Tswirl + a4Tax
2 (4.2) 
 
which includes Tax and Tswirl as linear terms as well as a quadratic term of Tax. Scaled and 
centred values for the coefficients depicted in this equation revealed Tax to have the main 
impact on the particle shape as an alteration of the factor Tax for one level (Tax = 30 °C) 
changed the particle shape by 1.065 ± 0.10 categories. The effect of Tswirl was less 
pronounced with only 0.435 ± 0.10 categories per level (Tswirl = 20 °C). These differences can 
be attributed to the chosen air stream volumes since Vswirl only amounts to 40 % of Vax. 
Table 4.5 - Scaled and centred coefficients (± standard deviation) for carrier particle shape as a 
response. Values give the effect on the particle shape in categories (Category 1 – 5), when the 
factor is changed for one level (Tax = 30 °C; Tswirl = 20 °C) 
Coefficients 
Particle shape, Cat. 1-5 
scaled & centred 
a0 - 
Tax 1.065 ± 0.10 
Tswirl 0.435 ± 0.10 
Tax·Tax -0.494 ± 0.15  
 
Experiments resulted in a broad range of differently shaped particles starting from quite 
spherical particles as scored with an average shape of category 1.4 (Table 4.1, Run 1) up to 
deeply indented particles with an average shape of category 4.9 (Table 4.1, Run 4) as 
assessed by visual inspection of SEM images. The whole range of particle shapes with its 
dependencies in terms of axial or swirl air stream temperature is illustrated in Figure 4.7. 
Almost perfect spheres (category < 2) occurred, when drying temperatures of both Tax and 
  
 
Tswirl were kept low (Tax = 130 °C; Tswirl = 60 °C), which is further depicted by the appropriate 
SEM image shown in Figure 4.7. In turn, droplets dried at higher temperatures (Tax = 190 °C; 
Tswirl = 100 °C) lead to mannitol particles with deep indentions as displayed by the SEM 
image in Figure 4.7. 
 
Figure 4.7 – Contour plot of the carrier particle shape as a response of the DoE with the factor 
swirl air stream temperature (Tswirl) on the y-axis and axial air stream temperature (Tax) on the x-
axis. Results are given in categories from category 1 (spherical carrier particles, Run 5) to 
category 5 (deeply indented carrier particles, Run 4) and are visualised exemplarily by two SEM 
images (1,000 fold magnification) 
The evaluation of SEM images in form of a survey used several subjective perspectives to 
generate an objective view on the particle shape. Image analysis was applied to overcome 
subjectivity. The mean aspect ratios were measured for six mannitol batches as illustrated in 
Figure 4.8 for particles from 25 to 150 µm in diameter. Results gained here support the data 
gained by SEM image evaluation.  
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Figure 4.8 – Mean aspect ratios of the six mannitol batches chosen for interactive powder 
blends (n=3 ± standard deviation) 
Further, two representative mannitol batches were cut using a kryo microtome to complete 
the results gained by visual inspection of SEM results and image analysis since these cross 
sections offered the opportunity to examine the inside of the particles, when visualised by 
SEM analysis. 
The SEM images shown here represent the average cross sections of the batches of interest 
as it was necessary to find particles, which received a centered cut. In fact, cross sections 
exhibited the same (outer) particle shape as expected with respect to earlier SEM images 
and aspect ratios. Figure 4.9 – A shows a spherical carrier batch, which comprises an 
obvious cavity inside the particle, while Figure 4.9 – B reveals indentations in the outer core 
of the particle and a smaller inner cavity. The crystalline structure of the mannitol shell 
consisted of smaller and larger crystals involving several pores, which – in conjunction with 
the inner cavity – led to an appropriate porosity as discussed by Littringer et al. earlier [22]. 
Noticeably, spherical particles dried at lower drying temperatures consist of both smaller and 
larger crystals compared to those generated at higher temperatures, which are mostly built of 
smaller ones, which can be attributed to the increased number of crystal seeds when spray 
drying is conducted at higher temperatures. 
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Figure 4.9 – Cross sections of two mannitol carrier batches at 1,000 fold magnification; A: 
spherical carriers (Run 5); B: indented carriers (Run 4) 
The formation of the observed particle shapes can be assessed by the drying history of bi-
component mannitol-water droplets. Assumptions were based on earlier studies by Nesic & 
Vodnik [21] who had been discussing the general principle of solvent evaporation from 
droplets and its different stages but were not focussing on the drying of mannitol or the 
generation of different particle shapes. Figure 4.10 displays the different temperatures inside 
the droplet or early particle over time by proposing five different stages (stage I to V), which 
are closer depicted in Figure 4.11. 
 
Figure 4.10 – Inner temperature development of bi-component mannitol-water droplets over 
time as proposed by Nesic and Vodnik [21,142] 
 
Figure 4.11 – Drying history of bi-component mannitol-water droplets with the inner pressure p 
The drying of droplets emerging from the filaments, which left the LamRot atomiser during 
the process, started with the initial heating and evaporation of water from the droplet surface 
(stage I). Accordingly, the volume of the droplet decreased, while the temperature of the 
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droplet increased to reach a plateau at the wet bulb temperature (stage II). Droplet 
temperature and drying rate (Δ surface area / time) kept constant at quasi-equilibrium until 
the mannitol concentration exceeded the saturation solubility of the sugar alcohol at the 
droplet surface. Several crystallisation seeds initiated the formation of a solid layer around 
the droplet since diffusion of mannitol towards the surface proceeded slower than 
evaporation of the solvent. The temperature of the solvent inside the early particle started to 
increase as evaporation of water was hindered due to the shell already being formed 
(stage III). Consequently, this resulted in rising pressure inside the particle. Pressure 
differences reasoned both a stabilising effect on the spherical particle shell against external 
aerodynamic stress and mannitol-water solution being pressed through small pores in the 
shell to compensate the rising inner pressure. Concurrently, the temperature of the bi-
component solution inside the particle rose depending on the chosen drying temperature. 
Moderate drying conditions caused inner temperatures, which remained below the boiling 
point of the mannitol solution (Figure 4.10 – dotted line). Harsh conditions with higher drying 
temperatures could result in inner temperatures, which even exceeded the boiling point 
(Figure 4.10 – solid line). Accordingly, the weak shell was subjected to a considerably rising 
pressure inside the particle, which led to the expansion of the particle shell (stage IV). This 
effect was further observed in levitator experiments in the context of this project, where larger 
mannitol-water droplets were observed to ´explode´ due to the spontaneous increase in 
volume [142]. Single droplets were dried at two different drying temperatures (T = 80 / 
120 °C) in an ultrasonic field, which kept the droplets in place during the experiment. The 
corresponding droplet or particle size was tracked via shadowgraphy over drying time and 
exhibited a vast increase in size for those single droplets dried at higher temperatures 
(T = 120 °C, Figure 4.12) right after the initial shell was built. A stable shell was observed for 
lower drying temperatures (T = 80 °C), where particle size stayed constant after shell 
formation. These effects occurred similarly for droplets dried with the pilot scale spray drier, 
but did not lead to particle explosion as the particle volume appeared to be > 300 times 
smaller than for levitator experiments. Accordingly, the shell was stable enough to hold the 
inner pressure. 
In the last drying stage, particle temperature decreased due to cooling of the ambient air, 
which led to a slight loss of pressure for moderate drying conditions but a considerable 
pressure drop for particles with water vapour, which condensated upon cooling (stage V). 
The vacuum, which is applied to the shell, caused the particles to collapse and to build the 
observed deep indentions. The lower pressure gradient at moderate drying conditions got 
compensated by the small pores in the shell as mentioned earlier, which kept those particles 
spherical and stable against the occurring stress. 
  
 
 
Figure 4.12 – Droplet or particle diameter of bi-component mannitol water droplets dried with a 
levitator at two different drying temperatures (T = 80 / 120 °C) over time (1
st
 x –axis for T = 
120 °C; 2
nd
 x-axis for T = 80 °C) as measured by shadowgraphy – droplets were inserted at t ≈ 
10 s (t120) or t ≈ 60 s (t80) 
To sum up, spray drying can be applied to prepare carrier particles with controlled outer 
appearance as the particle shape is a function of the chosen drying temperatures. This can 
be of great interest in the context of inhalation as several earlier studies – mainly based on 
lactose monohydrate – mentioned the shape of carrier particles to influence the inhalable 
drug fraction significantly. Optimally, the FPF of any drug can be controlled by adjustment of 
drying conditions as this controls the occurrence of indentations. The effect of particle shape 
on the aerodynamic performance during inhalation will be discussed in Section 4.3.1.  
4.1.4.2 Surface Roughness 
The drying of bi-component mannitol-water droplets was performed with special focus on the 
microstructure or roughness of the surface. Several earlier studies dealing with the 
morphology of carrier particles did not distinguish between particle shape and surface 
roughness but were mainly focussing on a general measure of morphology, when discussing 
its effect on the aerodynamic performance of these particles. Assessment of roughness was 
challenging as surface asperities appeared to be quite small in size, which complicated the 
detection. Nevertheless, surface roughness was evaluated by categorisation of SEM images 
and 3D laser microscopy to understand why surface asperities occur and connect those 
irregularities with the drug detachment during impaction analysis (Section 4.3.2). 
All nineteen batches of the DoE were evaluated based on SEM images. Obtained results 
mention the drying temperatures Tax and Tswirl to significantly influence the surface 
roughness, which resulted in the following Equation (4.3): 
 
0 100 200 300
0
100
200
300
400
500
0 10 20 30 40
Drying Time, t80°C, s 
D
ro
p
le
t 
/ 
P
a
rt
ic
le
 D
ia
m
e
te
r,
 µ
m
 
Drying Time, t120 °C, s 
T = 120 °C T = 80 °C
Results & Discussion 
 
y = a0 + a1Tax + a2Tswirl (4.3) 
 
showing that both factors show a linear correlation (a1; a2) between drying temperature and 
resulting surface roughness. The scaled and centred values for the coefficients displaying 
the model exhibited the surface roughness categories to increase for 0.68 ± 0.11 categories, 
when Tax was raised for one level (Tax = 30 °C), but only for 0.24 ± 0.11 categories when Tswirl 
was raised for one level (Tswirl = 20 °C). Similarly to particle shape, effects of the axial drying 
air exceeded those of the swirl air stream since the drying air volumes are different. 
Table 4.6 - Scaled and centred coefficients (± standard deviation) for carrier surface roughness 
as a response. Values give the effect on the surface roughness in categories (Category 1 – 5), 
when the factor is changed for one level (Tax = 30 °C; Tswirl = 20 °C). 
Coefficients 
Surface roughness, Cat. 1-5 
scaled & centred 
a0 - 
Tax 0.68 ± 0.11 
Tswirl 0.24 ± 0.11 
 
The nineteen experiments cover a range from category 2.2 (Table 4.1, M70(S)) to category 
4.5 (Table 4.1, M97(L)), which is further displayed by the contour plot in Figure 4.13. This 
plot illustrates that high drying temperatures caused several surface asperities including 
granular accumulations on the surface (surface roughness category > 4.0), while moderate 
drying conditions led to smoother particles, which still showed some smaller surface 
irregularities (surface roughness category < 3.0). The SEM images (inserts of Figure 4.13) 
display the visualisation of the smoothest surface (M70(S)) gained by the DoE compared to 
the roughest surface (M97(L)). 
  
 
 
Figure 4.13 - Contour plot of the carrier surface roughness as a response of the DoE with the 
factor swirl air stream temperature (Tswirl) on the y-axis and axial air stream temperature (Tax) on 
the x-axis. Results are given in categories from category 1 (smooth carrier particles, M70(S)) to 
category 5 (rough carrier particles with granular accumulations, M97(L)) and are visualised 
exemplarily by two SEM images (2500 fold magnification) 
Further, a 3D laser scanning microscopy tool was applied to objectively evaluate the carrier 
surface as survey results are based on subjective decisions. Results shown in Figure 4.14 
depict both the line roughness Ra and the surface roughness Sa. Evaluation was performed 
with a special focus on the six mannitol carrier batches, which were used for further 
characterisation as carriers in interactive powder blends as discussed later. The according 
images of the carrier particles display exemplarily where surface roughness was measured 
(line or area roughness). Line roughness was determined with the same orientation for all 
spherical batches, but was adapted for particles dried at higher temperatures to exclude 
indentions. Similarly, distinct areas were chosen to avoid indentions for these 
measurements. 
Line roughness Ra was found to be < 0.11 µm for the batches dried at lower temperatures 
(M70(S); M71(L) and M74(M)) but appeared quite large with Ra > 0.20 µm for two batches 
dried at higher outlet temperatures (M80(S); M97(L)). Differences in roughness were 
significant between those two groups of particles, while batch M80(M) revealed a medium 
roughness, which was not significantly different to other batches except for M97(L). 
Similarly, surface roughness Sa was determined and evaluated on the same five particles to 
evaluate not only a line but an defined surface area. Tendencies found here met the results 
of Ra evaluations as M70(S); M71(L) and M74(M) appeared with the smoothest surface (Sa < 
1.0 µm) compared to M80(S) and M97(L) (Sa > 3.0 µm). 
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Figure 4.14 – Evaluation of carrier surfaces by 3D laser microscopy; A: images show the 
surface exemplarily for a particle of the roughest (M70(S)) and the smoothest (M97(L)) carrier 
batch with the line, for which the line roughness was calculated. The graph displays the line 
roughness Ra in µm for six mannitol carrier batches (n = 5 ± standard deviation); B: images 
show particles of the same batches as for the line roughness, but display the surface for which 
the surface roughness Sa was calculated. The graph shows the surface roughness Sa in µm for 
six mannitol carrier batches (n = 5 ± standard deviation). 
Obviously, mannitol carrier particles exhibited more surface asperities, when drying 
temperatures Tax and Tswirl were set to maximum values. This effect went along with the 
impact of drying temperature on the particle shape and can be explained based on the drying 
history mentioned in Section 4.1.4. Overlying crystals and granular accumulations originated 
in drying stage III (Figure 4.10 and Figure 4.11) when an initial shell was formed. The inner 
pressure rose due to increasing temperatures within the particle. Small pores occurred 
subsequently to compensate the pressure gradient. Mannitol solution was pressed through 
the early shell and crystallised on the outside of the particle since the hot surrounding air 
forced the water to evaporate. This effect was observed for all particles as the inner pressure 
  
 
is supposed to increase for all different drying temperatures. The probability that surface 
asperities appear was strongly depending on the drying temperature since this affected the 
pressure gradient. The higher the pressure gradient, the more pores were formed, the more 
overlying crystals occurred. 
Additionally, crystallisation behaviour during spray drying might affect the microstructure. 
Even though the final product was generally found to consist of the ß-modification as the 
most stable one, it cannot be precluded that other crystalline structures like the less stable α-
modification or amorphous transition states occur during and right after spray drying. 
Assumptions, that drying temperature might influence the crystallisation behaviour and the 
microstructure of the mannitol particle surface, are based on the drying velocity. Low drying 
velocities enable direct crystallisation to gain the β-modification, while fast drying might 
cause other intermediates, which recrystallise or transform subsequently. This would 
supplement the results found in this project but needs to be proved by onsite analytics like in-
line Raman analysis. Cornel et al. had shown that Raman analysis can be applied to 
distinguish between three different polymorphs of mannitol and mannitol in solution [143], 
which needs to be transferred to an in-line spray drying approach. 
In summary, spray drying can be used to adjust the surface roughness of mannitol carrier 
particles. The influence of different microstructures on the drug detachment will be discussed 
in Section 4.3.2. 
Despite of the quite prominent dependencies between drying temperature and particle shape 
or surface roughness, it was not possible to control those two parameters independently. 
Spherical particles always exhibited the smoother surfaces than the indented ones. 
4.1.5 Influence of Outlet Temperature 
All effects regarding particle morphology in terms of particle shape and surface roughness 
strongly depended on the chosen drying temperatures. Tax and Tswirl were found to affect the 
appearance of the particles with respect to temperature and air stream volumes Vax and Vswirl. 
The inlet temperatures were altered as factors within the scope of the DoE as the spray 
tower offers to directly control them via the heater batteries. Nevertheless, it was found that 
effects on the particle morphology can more easily be explained by Tout, which combines the 
impact of Tax, Tswirl, Vax and Vswirl in one parameter. 
Table 4.1 summarises the drying conditions of all spray drying experiments, while Figure 
4.15 exhibits the dependencies between Tout and the categorisation of carrier particles into 
particle shape or surface roughness categories. A general trend towards more indentions 
and rougher surface structures was observed for rising outlet temperatures as mentioned for 
the data gained for the DoE.  
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Figure 4.15 – Effect of Tout (2
nd
 y-axis in °C displayed by black bars) on particle shape and 
surface roughness (1
st
 y-axis in Categories 1 to 5 displayed by grey columns, n=30 ± relative 
standard deviation) for six spray dried mannitol batches  
Based on these correlations, six mannitol batches were chosen with respect to Tout and 
particle size to examine the effects of these properties on the aerodynamic performance 
during impaction analysis. These batches were labelled according to outlet temperature and 
particle size and further investigated regarding their properties. 
4.1.6 Flowability 
Particle size and morphology are particle properties, which are known to affect the flowability 
of a bulk. Particles designed for use in multi-dose inhalers for dry powder inhalation need to 
provide good flow properties as this is crucial for accurate dosing of the powder blends. 
Flowability was determined to ensure that spray dried mannitol carrier particles meet those 
requirements. Carr Index and BFE, measured with a powder rheometer, were taken into 
account for evaluation. 
Carr Index as a measure of compressibility, which is often linked to the flowability of a bulk, 
was determined for all mannitol batches. Results were first evaluated within the scope of the 
DoE, but did not show any significant dependencies regarding the chosen drying conditions 
(Table 4.1). This might be attributed to the accuracy of this method as determination of bulk 
and tapped densities, was not precise enough to detect differences between spray dried 
mannitol batches. Nevertheless, results enabled to estimate that all batches show good flow 
properties as Carr Indices were found to be < 16. Some batches (with larger particles) even 
revealed Carr Indices below 10, which indicates excellent flow properties (M71(L); M97(L)).  
Powder rheology was then performed as a more accurate method to link effects of particle 
properties like particle size or morphology to the resulting flow properties of the according 
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mannitol batches. Indeed, an excellent fitted model was gained from the DoE (Section 4.1.2) 
which resulted in dependencies based on the factors Tax and n as further depicted in 
Equation (4.4). 
 
y = a0 + a1Tax + a3n + a4Tax
2 + a8Taxn (4.4) 
 
Coefficients of both factors included linear correlations to the resulting BFE but also an 
interactive influence of Tax and n as well as a quadratic effect of Tax, which will be explained 
in the following.  
Table 4.7 - Scaled and centred coefficients (± standard deviation) for the Basic Flowability 
Energy (BFE) as a response. Values give the effect on the flowability of the mannitol carrier 
particles in mJ, when the factor is changed for one level (Tax = 30 °C; n = 3,000 rpm) 
Coefficients 
Flowability, Basic flowability energy 
(BFE), mJ 
scaled & centered 
a0 - 
Tax 14.25 ± 2.04 
n -14.93 ± 2.04 
Tax·Tax -14.70 ± 2.96 
Tax·n -9.10 ± 2.28 
 
Effects on the BFE arise from alteration of both Tax and n as depicted in Table 4.7. An 
increase of Tax reasons higher BFEs (Tax = 14.25 ± 2.04), whereas more centrifugal forces 
and smaller droplets decrease the resulting BFE (n = -14.93 ± 2.04). The negative quadratic 
effect of Tax (Tax
2 = -14.70 ± 2.96) becomes apparent in the flowability contour plot (Figure 
4.16), where particularly low inlet temperatures trigger an effect on the BFE, while the effect 
was negligible for high drying temperatures. The general decrease of the BFE as detected 
for a concurrent increase of Tax and n (Tax·n = -9.10 ± 2.28) cannot be gained from the 
appropriate contour plot. 
Mannitol batches generated within the scope of the DoE cover the BFE ranging from 90 mJ 
to 149 mJ (Table 4.1). Lowest values appear for high LamRot rotation speeds (resulting in 
small droplets and hence small particles) in accordance with low axial drying temperatures, 
whereas highest values were found for low rotation speeds and high axial drying 
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temperatures. Those effects can further be linked to particle properties like particle size and 
morphology as described in literature [131]. 
Thus, enhancement of Tax from 130 °C to 160 °C, which caused the appearance of 
indentions, showed the main effect on the flowability of the mannitol carriers. The twisted 
paddle of the powder rheometer required the lowest energy when moving through spherical 
particles dried at the lowest temperatures (Tax = 130 °C, BFE = 90 mJ). The resistance 
increased rapidly towards batches dried at Tax = 160 °C (BFE > 140 mJ), whereas the 
temperature effect was diminished for further increase to Tax = 190 °C. Hence, the 
occurrence of first indentions constituted particle-particle interlocking, which resulted in a first 
increase of the energy. Further deterioration of the shape (Tax > 160 °C) had no effect on the 
BFE. 
In contrast, the effect of n on the BFE was found to be more conspicuous for higher drying 
temperatures (Tax = 160 – 190 °C) than for lower ones. Particle size, as known to be affected 
by n, can be identified as the reason for differences in the resistance towards the turning 
powder rheometer paddle. Nevertheless, effects of particle size were only detected for 
indented particles, whereas the flowability of spherical mannitol carriers was found to not be 
dependent on particle size. This can easily be attributed to the indention depth, as smaller 
particles (BFE < 110 mJ) exhibited smaller indentions than larger ones (BFE > 140 mJ), 
which in turn affected particle-particle interlocking and so the BFE. Particles without 
indentions were without particle-particle interlocking. 
Additionally, a slight decrease of the BFE was detected from the maximum value between 
Tax = 165 °C and 180 °C towards higher axial drying temperatures. This effect can be 
attributed to a size effect observed for higher drying temperatures (Section 4.3.3). Increase 
of drying temperature caused earlier shell formation and larger carrier particles, which in turn 
showed slightly better flow properties compared to the ones dried at moderate conditions. 
  
 
 
Figure 4.16 - Contour plot of the Basic Flowability Energy (BFE) as a response of the DoE with 
the factor rotation speed (n) on the y-axis and axial air stream temperature (Tax) on the x-axis. 
Results are given in mJ 
To conclude, mannitol carrier flowability was found to correlate with both axial drying 
temperature and rotation speed. Small spherical carriers performed better than large 
indented ones, which is a measure of particle-particle interlocking. Results evaluated in the 
framework of the DoE revealed that spray drying of mannitol carrier particles enabled the 
formation of carrier particles with defined flow properties in terms of their primary particle 
properties particle size and morphology. With respect to the overall size range, all carrier 
batches gained from the DoE showed proper flow properties for a DPI use. Nevertheless, it 
needs to be mentioned, that flow properties might change crucially by the addition of fine 
drug particles or mannitol fines. 
4.1.7 BET Surface Area 
Determination of the BET surface area was applied as an analytical tool to support and 
confirm earlier findings as the surface area is able to reflect differences in particle size and 
morphology. Indeed, evaluation within the frame of the DoE revealed all factors mentioned 
for particle size (Section 4.1.3), particle shape (Section 4.1.4) and surface roughness 
(Section 4.1.4.2) to be relevant for the BET surface area (Equation (4.5) after neglecting 
insignificant terms in a backward regression). 
 
y = a0 + a1Tax + a2Tswirl + a3n + a4Tax
2 + a8Taxn (4.5) 
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BET areas from 0.26 m² g-1 for low rotation speeds (n) and drying temperatures (Tax / Tswirl) to 
0.61 m² g-1 for high rotation speeds (n) and drying temperatures (Tax / Tswirl) were observed 
for these experiments (Table 4.1). 
 
Figure 4.17 - Contour plot of the BET surface area as a response of the DoE with the factor 
axial air stream temperature (Tax) on the y-axis and axial air stream temperature (Tswirl) on the x-
axis. The three plots represent the BET surface area at 8,000, 11,000 and 14,000 rpm. Results 
are given in m² • g
-1
  
The contour plots (Figure 4.17) show a general trend towards larger surface areas for rising 
drying temperatures (Tax / Tswirl), which is more pronounced for Tax. This coincides with the 
findings gained from categorisation of SEM images, which observed more indentions and 
rougher surfaces for harsh drying conditions compared to moderate ones in accordance with 
stronger influence by Tax. Surface asperities as well as all deviations from a perfect sphere 
increased the surface area of the mannitol batch. 
The impact observed by n was mainly attributed to the droplet size, which was affected by 
the centrifugal forces during spray drying with the LamRot atomiser. BET surface area 
results agreed with particle size evaluations since higher rotation speeds caused smaller 
particles and, therefore, larger BET surface areas. 
In general, all surface areas determined with nitrogen as test gas were close to detection 
limit but were measured in triplicate and with respect to good DoE correlation coefficients, 
which allowed the evaluation of these results. 
  
 
4.1.8 Surface Energy 
Determinations of surface energies of mannitol carrier batches were performed to investigate 
the influence of drying temperature and droplet size on the surface characteristics. The slope 
of the straight line gained by plotting RT ln VR
0 versus √γL
d was used to calculate the 
dispersive surface energy. Fittings were excellent for all investigated mannitol carrier batches 
(R² > 0.99). 
Results summarised in Figure 4.18 exhibited most spray dried mannitol batches with free 
dispersive surface energies of γs
d = 60 – 65 mJ ● m-2. Only commercially available 
Pearlitol® 160C, which served as crystalline raw material for all experiments, and batch 
M71(L) resulted in lower dispersive surface energies of γs
d = 45.6 ± 1.3 mJ ● m-2 and γs
d = 
47.2 ± 0.4 mJ ● m-2, respectively. Results were measured at infinite dilution of the alkanes 
used (0.03 p/p0) and represent γs
d of spots with the highest free dispersive surface energy. 
 
Figure 4.18 – Free dispersive surface energy 𝛄𝐬
𝐝 of six spray dried mannitol qualities and 
Pearlitol
®
 160C as crystalline raw material (n=3 ± standard deviation) 
In order to investigate the whole surface of spray dried mannitol carrier particles, dispersive 
surface energy profiles were determined by injecting alkanes with rising injection volumes 
(p/p0 = 0.03 to 0.95). Figure 4.19, which shows the free dispersive surface energy γs
d plotted 
against the alkane surface coverage, displays the results of mannitol M71(L) and M80(M), for 
which M80(M) represents the dispersive surface energy profile of all further spray dried 
qualities as only M71(L) deviated from the general results. 
Surface coverage was plotted on two different x-axes due to differences in the maximum 
coverage of the mannitol batches evaluated here. M71(L) with a maximum alkane surface 
coverage of 0.15 n/nm exceeded the maximum coverage of M80(M), which covered 0.06 n/nm 
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when measured at p/p0 = 0.95. This effect can be related to the according BET surface areas 
as M71(L) revealed a lower BET surface area of 0.26 m² ● g-1 than M80(M) with a surface 
area of 0.55 m² ● g-1 (Table 4.1). The lower the surface the less alkanes were needed to 
reach full coverage, which explains the results found for larger particles (M71(L)) with lower 
BET surface areas compared to smaller particles. 
Dispersive surface energy profiles revealed mannitol M71(L) to have a homogeneous 
surface as surface energy was found to remain almost similar (Δγs
d < 5 mJ ● m-2) with rising 
partial pressures and surface coverages. The experiments performed at finite dilution agreed 
with results gained at infinite dilution as both calculated a maximum free dispersive energy of 
γs
d ~ 45 mJ ● m-² measured at 0.03 p/p0. In theory, alkane probe molecules adhere to high 
energy spots first and to areas of lower energy next, when applicable. Here, the whole 
particle surface was found to have the same energy. 
 
Figure 4.19 – Dispersive surface energy profiles of mannitol M71(L) (spray dried, homogenous 
surface energy profile) and M80(M) (spray dried, heterogeneous surface energy profile 
exemplarily for other spray dried qualities) with the surface coverage n/nm 
Contrarily, dispersive surface energy profiles of all other mannitol qualities, represented by 
mannitol M80(M) in Figure 4.19, occurred to be heterogeneous as illustrated by the negative 
slope of γs
d plotted against the surface coverage. The surface revealed spots of high energy 
with γs
d > 60 mJ ● m-² for p/p0 = 0.03 and the lowest surface coverage, but also spots of low 
energy with γs
d < 40 mJ ● m-2 for higher surface coverage at p/p0 = 0.95. Areas of higher or 
lower energy are evenly distributed for surface coverages from 0 % to approximately 20 % as 
depicted by the linear correlation of the plot.  
In general, spray drying of sugar alcohols such as lactose monohydrate or mannitol is known 
to increase surface energies in comparison to crystalline non-spray dried qualities. Most of 
these results agreed with results published earlier, as spray dried mannitol revealed 
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dispersive surface energies of γs
d > 60 mJ ● m-2 in contrast to the crystalline quality of 
Pearlitol® 160C investigated as raw material (γs
d = 45.6 mJ ● m-2). The surface of these 
samples was more energetic with respect to non-polar London forces [10]. 
Nevertheless, mannitol batch M71(L), which was one of the batches spray dried at the lowest 
outlet temperatures and a batch with quite large particles, showed a dispersive surface 
energy of comparable level to the raw material in accordance to a homogeneous surface 
energy distribution. These findings could be attributed to spray drying conditions as this 
batch was dried close to the limits of the spray tower. Large droplets in conjunction with low 
drying temperatures led to particles, whose drying process was not finally finished, when 
they were deposited in the collecting vessel. This resulted in small amounts of particles that 
dried subsequent to the usual drying process on the conical spray tower walls, while most 
particles were found clumped together in the collecting vessel due to their high residual 
moisture content. The slow drying and crystallisation process led to surface energies close to 
raw material level. 
In general, the large number of spray dried mannitol batches was found at higher surface 
energies than the raw material and with heterogeneous dispersive surface energy profiles. 
This indicates the mannitol carriers to have active sites on the carrier surface that might 
adhere particles tighter than other spots on the surface. The occurrence of active sites might 
influence the detachment of drug particles as mentioned by Grasmeijer et al. earlier [72]. 
Therefore, further experiments were performed with mannitol carrier particles, SBS drug 
particles and mannitol fines to cover high energy spots with focus on dependencies between 
drug detachment and added mannitol fines (Section 4.3.8).  
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4.2 Preparation of Model Drugs 
Model drugs were prepared in order to associate effects to either carrier particle properties or 
drug particle properties. With this target, four different drugs were spray dried to generate 
particles that were comparable in particle size and shape as this prevented the occurrence of 
effects that might be related to those drug properties. Observed effects on the aerodynamic 
performance could therefore directly be correlated to the carrier properties or intrinsic drug 
properties like hydrophilicity or surface energy. Shape control was provided by the process 
itself as drug-containing droplets trigger the generation of overall mostly spherical particles. 
Further, spray dried SBS was prepared in different sizes (and morphologies) in the scope of 
a DoE to examine the effects by drug size and morphology. The shape effect was further 
supplemented by the investigation of jet-milled SBS and BUD qualities which additionally 
included the examination of influences by crystallinity as spray dried material was used in 
amorphous state and micronised drugs in mostly crystalline state. 
Initially, the effect of spray drying parameters of a standard laboratory spray dryer on SBS 
particle properties was tested. Table 4.8 lists all experiments performed within the 
experimental design covering the two factors outlet temperature (Tout) and mass fraction (Ym) 
and the responses particle size, span and particle shape as will be evaluated in Section 
4.2.1. 
The spray drying parameters used for BUD, TIO and FOR as well as for SBS batches spray 
dried for interactive powder blends are coherently summarised in Table 4.8 and were mainly 
based on investigations performed within the priority program PICO, where spray drying of 
different drugs for inhalation was treated as part of the project. 
 
 
 
 
 
 
 
 
 
 
  
 
Table 4.8 – Summary of spray drying parameters (or factors within the DoE) and resulting 
particle properties (or responses within the DoE) for all drug batches (including two 
micronised qualities) investigated in this project. *SBS batches prepared for interactive powder 
blends were prepared with slightly elevated spraying gas (42 mm instead of 40 mm) to generate 
smaller drug particles than in die experimental design 
Drug 
Run / 
Drug 
Quality 
Factor Response 
Tout, °C Ym, % 
Particle 
Size, x50, 
µm 
Particle 
Span 
Particle 
Shape, 
Category 
1-5 
iGC, mJ 
m-2 
SBS in 
Experi-
mental 
Design 
N1 65 2.5 2.6 2.0 1.1   
N2 115 2.5 2.7 2.1 3.3   
N3 65 12.5 4.1 1.9 1.8   
N4 115 12.5 4.0 1.7 3.9   
N5 65 7.5 3.7 2.1 1.8   
N6 115 7.5 3.8 2.0 3.8   
N7 90 2.5 2.6 2.0 1.1   
N8 90 12.5 4.6 1.9 2.1   
N9 90 7.5 3.4 2.1 1.5   
N10 90 7.5 3.6 2.1 2.4   
N11 90 7.5 3.9 2.0 2.1   
N12 90 7.5 3.5 2.0 1.9   
N13 90 7.5 3.5 2.0 2.0   
Drug 
Batches 
for 
Interactive 
Powder 
Blends 
SBS 
SD(S)* 
90 2.5 2.4 1.8 
spherical, 
golf ball 
structure 
42.17 
SBS 
SD(M)* 
115 7.5 2.8 1.8 spherical, 
smooth 
  
SBS 
SD(L)* 
90 12.5 3.7 1.8 
spherical, 
golf ball 
structure 
  
SBS 
micro 
n.a. n.a. 2.5 2.8 needle 
like 
44.97 
TIO SD 100 4.8 2.2 2.2 spherical 48.08 
BUD 
SD 
100 4.0 1.8 2.1 spherical 50.53 
BUD 
micro 
n.a. n.a. 1.4 1.8 uneven 60.12 
FOR 
SD 
 100 4.8  2.1  1.9 spherical 34.04 
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4.2.1 Design of Experiments 
A DoE was employed for the preparation of spherical SBS particles but not for BUD, TIO or 
FOR since only SBS was chosen to be used in different qualities regarding drug size and 
morphology. The CCF design comprised thirteen experiments for two factors and three levels 
as summarised in Table 4.8. Each response was evaluated separately to calculate the best 
fitting models based on a backward regression of insignificant terms. 
Drug properties of batches used in interactive powder blends were then adjusted with 
respect to results presented and discussed in the following. However, drug particles for 
aerodynamic characterisation were desired to appear from 2.0 to 2.5 µm, which was not 
covered by the DoE. Those batches were therefore prepared with slightly increased spraying 
gas (42 mm instead of 40 mm) to match those requirements (Table 4.8). 
4.2.1.1 Power of the model 
Evaluation of spray dried SBS batches provided significant models with appropriate quality 
parameters for the control of particle size and particle morphology. The models of both 
particle properties are featured by well fitted data (R² adjusted ≥ 0.88), good predictive power 
(Q² ≥ 0.84), reliable model validity (p ≥ 0.79) and optimal reproducibility (RP ≥ 0.88). Another 
model calculated for the particle span did not meet the required limits in terms of predictive 
power and was not taken into account for evaluation. 
Table 4.9 - Quality parameters for SBS properties evaluated within the DoE. First column gives 
the evaluated quality parameter including the limits of acceptance. Further columns show the 
responses and the according quality results 
Quality Parameter Particle Size Particle Morphology 
R² adjusted (> 0.50) 0.88 0.90 
Q² (> 0.50) 0.84 0.87 
P (> 0.25) 0.79 0.89 
RP (> 0.50) 0.90 0.88 
 
The good quality parameters enable profound statements on the drying of bi-component 
SBS-water droplets that can be derived from dependencies between factors and responses 
as will be discussed in the following (Section 4.2.1.2 and Section 4.2.1.3). 
4.2.1.2 Particle Size (SBS) 
Preparation of SBS particles for inhalation was performed by spray drying as this technique 
enables the generation of mostly spherical particles with a dadyn < 5 µm that usually arise in 
the amorphous state indicating storage stability issues. The factors used here were mainly 
  
 
chosen with respect to already published effects on the according particle properties 
[20,63,89]. Particle size was controlled by different mass fractions (Ym) in this study as 
illustrated in Figure 4.20. Small mass fractions (Ym = 2.5 %) caused particles of d50.3 < 2.8 µm 
as measured by laser diffraction, while large mass fractions (Ym = 12.5 %) lead to particles of 
d50.3 > 4.2 µm. The model depicts a linear correlation between mass fraction and particle size 
without any effect detected for Tout.  
 
Figure 4.20 - Contour plot of the final SBS particle size as a response of the DoE with the factor 
outlet temperature (Tout) on the y-axis and the mass fraction (Ym) on the x-axis 
Higher mass concentrations trigger earlier crystallisation and, therefore, larger particles. The 
initial droplet size as another crucial factor for the resulting particle size was kept constant 
since the spraying gas air flow was not altered for the experimental design. The drying 
temperature (here Tout instead of Tin) which was found to affect the particle size of the carrier 
material did not significantly influence on the size of SBS during drying. Mass fraction as a 
well-known factor to control particle size defined the moment of shell formation and by this 
the final particle size. 
The preparation of three SBS batches of different sizes was based on these results and is 
described in Section 3.3.2.1. However, particles prepared within the experimental design 
were larger than the targeted drug size for the standard powder blends so that spraying gas 
was elevated from 40 mm to 42 mm for those batches to reduce droplet and by this the 
resulting particle size. 
4.2.1.3 Particle Morphology (SBS) 
The overall particle morphology of all SBS batches spray dried in the framework of this DoE 
was evaluated by categorisation of SEM images into five categories from 1 to 5 as described 
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earlier. SBS particles were found with a golf ball like structure (Figure 4.21, particle 
morphology > Category 2.5), when Tout was kept low (Figure 4.22 – A / C). Here, drug 
particles of all sizes appeared with small indentions. Smoother surfaces occurred first for 
smaller particles, when particles were prepared at higher Tout. Further, particles of medium 
size showed smooth surfaces for rising drying temperatures and only some single larger 
particles with golf ball like morphology were found for batches dried at Tout = 115 °C, which 
resulted in batches rated as smooth particles (Figure 4.21, Category < 2.5, Figure 4.22 - B). 
The main effect on the particle morphology arose from drying temperature, but was 
supplemented by an increase in mass fraction. 
 
Figure 4.21 – Contour plot of the SBS particle morphology in Categories from 1 (smooth 
surface, all particles without indentions) to 5 (golf ball like shape for particles of all sizes) as 
response for a DoE with the factors outlet temperature (Tout, y-axis) and mass fraction (Ym, x-
axis) 
In general, it was possible to control the particle morphology of spray dried SBS particles by 
the chosen drying temperature. Harsh conditions generated smoother particles, while lower 
temperatures caused golf ball like structures. 
These findings were taken into account for the preparation of spray dried SBS batches for 
interactive powder blends as drug shape is known as a factor, which might affect the 
aerodynamic behaviour of an API crucially. Results will be discussed in Section 4.3.1.2. 
4.2.2 Particle Size 
Several drug batches were prepared in spray dried and micronised qualities for interactive 
powder blends and with the intention to reach the respiratory zone of the lungs during 
inhalation. 
  
 
Inhalation of drug particles is limited by drug size since size is one of the relevant factors that 
determine the FPF. A combination of particles with an d50.3 < 2.5 µm and a PSDs with span 
values < 2.5 was chosen to be applicable for these experiments as these limits ensure that 
most particles have a size suitable to assess the fine airways of the lung or those stages of 
the NGI that are relevant for the respirable fraction. 
Mean particle sizes (d50.3) and span values are coherently summarised in Table 4.8. 
Micronised BUD was purchased and used with a size of d50.3 = 1.4 µm. The spray dried 
quality of BUD was applied with a d50.3 of 1.8 µm. This size serves as a compromise between 
the small micronised BUD purchased by the vendor and all other drug qualities (SBS, TIO, 
FOR) used (d50.3 = 2.0 – 2.5 µm). 
Spray dried TIO and FOR particles, which were prepared based on parameters investigated 
in earlier experiments, were applied to interactive powder blends with particle sizes of 
d50.3 = 2.2 µm (TIO) and d50.3 = 2.1 µm (FOR). The micronised quality of SBS was jet-milled 
again to reach a final particle size of d50.3 = 2.5 µm. 
Spray dried SBS was prepared in three qualities, which were different in size (and shape). 
SBS SD(S) as the standard batch used for all SBS investigations (including addition of fines 
and comparison of Novolizer® and Easyhaler® performance) represented the smallest SBS 
batch with an d50.3 of 2.4 µm. SBS SD(M) was slightly larger (d50.3 = 2.8 µm), while SBS 
SD(L) (d50.3 = 3.7 µm) was used as the largest drug batch within this project. 
All span values were appropriate indicating narrow PSDs for all batches used for 
aerodynamic characterisations. 
4.2.3 Drug Shape 
In this study micronised and spray dried drug qualities were used in interactive powder 
blends to investigate the influence of drug shape on the detachment and dispersion of these 
drug particles. Jet-milling caused needle-like SBS particles (Figure 4.22 – D), while 
micronised BUD particles were found with a more uneven shape (Figure 4.23 – B) as 
purchased from the vendor.  
Most spray dried qualities used in this study appeared with spherical character (SBS, Figure 
4.22 – A to C; TIO, Figure 4.24 – B; FOR, Figure 4.24 – A). Only spray dried BUD was found 
with slightly unevenly shaped particles (Figure 4.23 – A) as it was spray dried dissolved in 
methylene chloride. Surface tension of this solvent is lower than in aqueous solutions as 
used for SBS which makes droplets more accessible to turbulences and thus to other 
morphologies during drying. 
Apart from the comparison of needle-like or unevenly shaped micronised drug particles and 
spherical spray dried ones, this study applied two different qualities of spray dried SBS 
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particles. Two out of three SBS batches appeared with golf-ball like structure (SBS SD(S), 
Figure 4.22 – A and SBS SD(L), Figure 4.22 – C), while one was dried with a smoother 
surface (SBS SD(M), Figure 4.22 – B). 
All different drug qualities were blended with the six chosen mannitol qualities to further 
investigate the impact of particle properties on the drug detachment and FPF. 
 
Figure 4.22 – SEM images of spray dried SBS particles (A: SBS SD(S), B: SBS SD(M), C: SBS 
SD(L)) and micronised SBS particles (D: SBS micronised) at 5,000 fold magnification 
 
Figure 4.23 – SEM images of A: spray dried BUD and B: micronised BUD at 5,000 fold 
magnification 
  
 
 
Figure 4.24 – SEM images of A: spray dried FOR and B: spray dried TIO at 5,000 fold 
magnification 
4.2.4 Drug Storage Stability 
In general, drugs are known for its ability to modify in crystal lattice structures over time when 
not initially present in the most stable form. This goes along with a change in the overall 
particle properties, but can be prevented by the chosen storage conditions. The capability to 
absorb moisture or physical parameters like the melting point repose on the crystal 
modification and can be used to determine the moment of recrystallisation at different 
ambient conditions to draw conclusions regarding the storage stability.  
First of all, drug storage stability can be derived from the crystal lattice structure as measured 
with XRPDx. The inertness at different temperatures was tested by DSC analysis, while DVS 
was applied to approve stability of the products at higher relative humidity. All results 
together provide an overview over the suggested storage stability during handling and 
storage. 
Figure 4.25 gives the XRPD diffractograms of SBS and BUD in micronised and spray dried 
quality. Crystalline structures were found for the micronised qualities of both drugs, while 
amorphous material without crystal lattice was detected right after spray drying. 
The technique of XRPD allows to state that spray dried SBS and BUD batches appear 
almost completely amorphous as only a halo was detected, but prohibits statements about 
the ratio of crystalline and amorphous contents unless quantification with samples of known 
amount of crystalline and amorphous contents would be performed. Samples investigated 
here showed that crystalline structures appear. Nevertheless, it is known from literature that 
micronised materials most probably comprise amorphous spots after preparation. Similar 
results were published for FOR [88]. XRPD indicated spray dried FOR particles to be 
amorphous, while micronised FOR exhibited characteristic XRPD peaks [88].  
Appropriate storage conditions are necessary for all drugs to avoid recrystallisation as this 
might cause crystal growth or built solid bridges between drug particles resulting in reduced 
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respirable fractions during inhalation. Additionally, drug particles might stick to the carrier 
surface (in interactive powder blends) upon recrystallisation, which might affect drug 
detachment crucially. 
 
Figure 4.25 – XRPD diffractograms of SBS and BUD in spray dried amorphous quality and 
micronised quality with crystalline structures 
Moisture uptake at different relative humidity was discovered by DVS analysis for SBS SD 
and TIO SD (Figure 4.26 and Figure 4.27). The change in mass increased steadily for SBS 
SD, when humidity was raised to 40 % rH, but increased rapidly above 40 % rH (change in 
mass > 12 %) to spontaneously release large amounts of water at 70 % rH. This step 
indicates recrystallisation of the spray dried material. Almost no moisture uptake was 
observed for the second increase of surrounding relative moisture, which substantiates that 
the whole spray dried material recrystallised during the first DVS cycle. 
  
 
 
Figure 4.26 – DVS change in mass plot of spray dried SBS for relative humidities from 0 % rH to 
90 % rH (2
nd
 y-axis) and the according moisture uptake in % (1
st
 y-axis) 
 
Figure 4.27 – DVS change in mass plot of TIO SD for relative humidities from 0 % rH to 90 % rH 
(2
nd
 y-axis) and the according moisture uptake in % (1
st
 axis) 
Similarly, the uptake of moisture recorded for TIO SD exhibited slight uptake of moisture for 
the first steps of the analysis, but rapid increase, when moisture was set above 60 % rH to 
release larger amounts of water at an rH of 70 % rH. Again, this indicates recrystallisation of 
the spray dried material, which was again proved by a lower moisture uptake during the 
second cycle. 
DVS results need to be considered for storage conditions and experimental work as they 
assume both spray dried APIs to be unstable for higher relative humidity. Handling of SBS 
SD or TIO SD should be performed below 40 % rH to avoid severe moisture uptake or even 
recrystallisation. As a result, preparation of interactive powder blends and impaction analysis 
were performed under controlled conditions at 35 % rH. Dry powder formulations that are 
used in every-day life would require desiccants to ensure stability of the product. 
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Figure 4.28 – DSC analysis of different drug qualities; A: BUD SD; B: FOR SD; C: TIO SD. 
DSC analysis was further applied to BUD SD, FOR SD and TIO SD as not only humidity but 
also temperature might affect the stability of a product. Results obtained several thermic 
events that occurred at temperatures far away from standard laboratory conditions (Figure 
4.28). BUD SD showed an exothermic event at Tr = 130.3 °C representing the 
recrystallisation of the spray dried product and the melting point at Tm = 263.3 °C which 
agrees with findings in literature [88]. A glass transition was not observed, but has been 
mentioned for Tg = 89.5 °C by Tajber et al. earlier. FOR SD revealed a small endothermic 
event at Tp = 80.4 °C that was suggested as glass transition by Tajber et al. and another 
endothermic event displaying the melting point at Tm = 151.1 °C. Recrystallisation was not 
detected as a thermic event here, but by Tajber et al. at Tr = 126 °C [88]. TIO SD was found 
with a typical recrystallisation event at Tr = 154.2 °C followed by the melting point at 
Tm = 220.4 °C. DSC analysis of SBS SD (not shown here) obtained a glass transition at 
Tg = 113.1 °C, but no further thermic events up to 250 °C. 
  
 
All DSC results found that spray dried drug particles are stable at 20 °C as the chosen 
conditions for these experiments. Drug storage stability was proved for all drug particles used 
in these studies at the chosen conditions. 
4.2.5 Surface Energy 
Dispersive surface energy of all drug qualities used for interactive powder blends was 
determined to discover the potential to form non-polar particle-particle interactions. Results 
summarised in Table 4.8 and illustrated in Figure 4.29 exhibit that drug batches cover a 
range from γs
d = 30 mJ ● m-2 to γs
d = 60 mJ ● m-2. 
Spray dried qualities of SBS and BUD were found with lower dispersive surface energy than 
their micronised counterparts. Amorphous material exhibited reduced non-polar interactions 
between particle surface and eluent compared to crystalline structures that occur for jet-
milled materials resulting in lower dispersive surface energies as illustrated in Figure 4.29. 
 
Figure 4.29 – Dispersive surface energy of different drug qualities used in these studies 
The comparison of all spray dried drug particles revealed lipophilic FOR SD to have the 
lowest dispersive surface energy with γs
d = 34.0 mJ ● m-2 and lipophilic BUD SD to show the 
highest dispersive surface energy with γs
d = 50.5 mJ ● m-2. The hydrophilic drug batches SBS 
SD (γs
d = 42.2 mJ ● m-2) and TIO SD (γs
d = 48.1 mJ ● m-2) were found between those values, 
which leads to the conclusion, that dispersive surface energy does not appear to be a 
measure of hydrophilicity. 
Dispersive surface energy has earlier been used to correlate differences in surface 
characteristics and resulting FPFs, which will be discussed in Section 4.3.7. 
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4.3 Aerodynamic Characterisation – Investigation of Particle-
Particle Interactions 
Engineered mannitol particles as investigated in Section 4.1 and the drug particles described 
in Section 4.2 were blended to generate carrier-based interactive powder blends that were 
examined for their aerodynamic performance by impaction analysis as will be discussed in 
this section. The quality of a powder blend is determined by several parameters such as the 
ability to be dispersed by the inhaler device during inhalation or the facilitation of drug 
deagglomeration resulting in adequate fine particle fractions (FPFs). Impaction results can 
further be linked to carrier and drug properties since detachment and dispersion of single 
drug particles or agglomerates are known to be affected by those characteristics. This 
section will approach blend quality and impaction results first and discuss the findings in the 
scope of particle-particle interactions subsequently. 
 
Figure 4.30 – Recovery and blend homogeneity averaged for all drug qualities as blended with 
six different mannitol carrier qualities 
Initially, powder blends were tested for its drug recovery and homogeneity as those quality 
parameters build the basis for all further experiments (Figure 4.30). Most powder blends met 
the defined limits for recovery (> 90 %) and homogeneity (relative StD < 5 %). Only the spray 
dried qualities of TIO and BUD were found with decreased homogeneity as relative standard 
deviation was found above the 5 % limit, which was mainly due to tribo-charging effects that 
could not efficiently be reduced by deionisation prior and during the blending procedure. 
Charges were only observed for these two drug qualities where drug particles got stuck to 
the vessel wall after blending indicating that this affected the homogeneity of those blends. 
Further, powder blend homogeneity of blends prepared with the most spherical carrier 
particles (M71(L)) was reduced for TIO SD, BUD SD and FOR SD compared to those 
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batches with slight indentions which indicated SBS SD to adhere tighter as will be discussed 
later in this section. The recovery of all blends was evaluated with reasonable measures of > 
90 %. 
Impaction analysis was then performed with the NGI resulting in deposition profiles like 
exemplarily depicted for powder blends consisting of SBS SD(S) and the six chosen mannitol 
qualities in Figure 4.31. Results exhibited that most of the administered drug deposited in 
throat or preseparator, which indicates that large amounts of drug particles were not well 
dispersed during inhalation or stayed attached to the mannitol carrier, which most likely 
impacted in the preseparator. The following stages showed a maximum SBS deposition on 
Stage 2, which gradually decreased towards the following stages. 
 
Figure 4.31 – SBS in µg ± StD (y-axis) as deposited on the different stages of the NGI (x-axis) 
after administration of ten doses with the Novolizer
®
 for powder blends with six different 
mannitol batches and SBS SD(S) (n=3) 
Apart from this overall description, mannitol batches differ in the deposition on single stages. 
Significant differences were observed for the comparison of M70(S)/M71(L) and 
M80(M)/M97(L). Blends prepared with carriers dried at lower outlet temperatures 
(M(70S)/M71(L)/M74(M)) were found with less deposition in the preseparator, but with more 
SBS on the stages, while those batches prepared with carriers dried at higher outlet 
temperatures (M80(S)/M80(M)/M97(L)) revealed more SBS deposited in the preseparator 
and less on the stages. 
The cut-off diameter for particles with a dadyn < 5 µm was located between Stage 1 and 2 for 
a flow rate of 78.2 L min-1 (as illustrated in Figure 4.31) as necessary for the Novolizer®, so 
that the respective FPF is based on an extrapolation. The resulting FPFs are summarised in 
Table 4.10, which displays the FPFs of powder blends containing one of the four SBS 
qualities and the chosen mannitol carrier batches. The observed respirable fractions agree 
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with the respective deposition profiles since batches with more deposition on the stages 
resulted in higher FPFs than those with more deposition in preseparator and throat. 
Results shown here covered an overall range from 11.1 % to 35.0 % with the highest FPFs 
detected for the micronised SBS quality. Detachment and dispersion of spray dried SBS was 
generally lower than for micronised SBS since the according FPFs ranged from 11.1 % to 
27.3 %, while the micronised drug caused FPFs ranging from 27.3 % to 35.0 %. 
Table 4.10 – FPF ± StD in % of six mannitol batches blended with four different SBS qualities 
Mannitol batches Drug batches 
DoE: Labelling 
Results: 
Extra 
Labelling 
SBS 
Run 
Order 
Exp 
Name 
SBS micronised 
Spray Dried 
SBS SD(S) SBS SD(M) SBS SD(L) 
FPF StD FPF StD FPF StD FPF StD 
Run 9 N5 M70(S) 33.4 0.6 27.3 2.6 26.7 0.5 19.4 0.7 
Run 10 N1 M71(L) 35.0 3.2 25.7 3.1 22.4 0.9 15.9 0.3 
Run 14 N9 M74(M) 32.6 1.0 23.9 0.8 22.2 1.4 18.7 0.8 
Run 13 N14 M80(S) 33.2 1.4 20.9 0.7 21.3 0.8 14.3 0.6 
Run 2 N19 M80(M) 27.3 1.8 11.2 0.3 15.4 0.6 11.1 0.5 
Run 11 N4 M97(L) 29.4 0.7 12.9 0.7 11.5 1.8 11.7 0.3 
 
Experiments performed with hydrophilic SBS were supplemented by other drugs of different 
hydrophilicity to SBS. Table 4.11 summarises the FPFs of the aerodynamic characterisation 
of interactive powder blends with 1 % (w/w) TIO SD, BUD SD, BUD micronised and FOR SD 
and the six chosen mannitol batches as gained by impaction studies utilising the Novolizer®. 
Noticeably, results revealed quite different levels for the different drugs and drug qualities. 
SD TIO exhibited the highest FPFs of all drug batches investigated here with 
FPF = 32.0 ± 1.2 % to 41.8 ± 1.0 %. Interactive powder blends containing BUD showed quite 
divergent FPFs for spray dried and micronised drug particles. Contrary to SBS, BUD SD 
performed much better (FPF = 28.3 ± 1.4 % to 33.6 ± 1.6 %) than the micronised counterpart 
(FPF = 15.2 ± 2.0 % to 24.2 ± 1.1 %). FOR SD revealed FPFs between 26.6 % and 35.0 %. 
Contrary to blends consisting of mannitol and SBS SD(S/M/L), M70(S) and M74(M) 
containing blends with FOR SD resulted in the lowest FPF, while M80(S) and M97(L) caused 
higher FPFs. 
  
 
Table 4.11 – FPF ± StD in % of six mannitol batches blended with TIO SD, BUD SD / micronised 
and FOR SD. 
Mannitol batches Drug batches 
DoE: Naming 
Results: 
Extra 
Labelling 
TIO BUD FOR 
Run 
Order 
Exp 
Name 
TIO SD BUD SD BUD micronised FOR SD 
FPF StD FPF StD FPF StD FPF StD 
Run 9 N5 M70(S) 34.1 1.8 32.1 1.1 15.7 2.0 29.1 1.1 
Run 10 N1 M71(L) 35.6 0.2 28.3 1.4 24.2 1.1 35.0 0.5 
Run 14 N9 M74(M) 38.2 2.0 33.6 1.6 20.2 1.0 26.6 1.7 
Run 13 N14 M80(S) 41.8 1.0 37.2 1.0 15.6 2.0 34.3 1.5 
Run 2 N19 M80(M) 32.0 1.2 32.6 0.8 15.2 2.0 31.6 0.7 
Run 11 N4 M97(L) 33.4 2.7 33.0 0.9 15.3 1.0 33.7 0.2 
 
Carrier-containing interactive powder blends as applied here are based on particle-particle 
interactions that cause adhesion or cohesion between particles. Experiments performed in 
this project were designed to cover numerous particle properties of both carrier and drug 
particles and its effect on the dispersion during impaction analysis to examine effects on 
particle-particle interactions and respirable fraction and, therefore, on the quality of the 
product. The following subsections will deal with the correlation of respirable fractions and 
carrier or drug properties like particle shape (Section 4.3.1), surface roughness 
(Section 4.3.2), particle size (Section 4.3.3), flowability (Section 4.3.6), surface energy 
(Section 4.1.8) or also drug hydrophilicity (Section 4.3.4) and crystallinity (Section 4.3.5). 
Supplementary investigations will further focus on the influence arising from inhaler device 
(Section 4.3.9) and from the addition of mannitol fines (Section 4.3.8). 
4.3.1 Particle Shape 
During preparation, both carrier and drug particles were varied in terms of particle shape. 
Hence, evaluation of the aerodynamic performance was performed divided into carrier shape 
and drug shape to separate appropriate effects. 
4.3.1.1 Carrier Shape 
The carrier shape is known to influence the DPI performance of interactive powder blends as 
it has been reported for lactose monohydrate carriers, but also for mannitol carrier particles 
earlier in this project (Section 2.3.2). The results gained from impaction analysis with spray 
dried model drugs and six chosen mannitol carriers demand different descriptions for the 
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dispersion mechanisms of the applied drugs that are in turn based on different particle-
particle interactions.  
Evaluation of impaction results will start with results of powder blends containing spray dried 
SBS and will be followed by powder blends with spray dried BUD and TIO to end up with the 
evaluation of FOR SD containing blends.  
 
Figure 4.32 – FPF ± StD in % (y-axis) of powder blends consisting of six chosen mannitol 
batches (M70(S)/M71(L)/M74(M)/ M80(S)/M80(M)/M97(L)) and SBS SD(S/M/L) related to 
measurements describing the particle shape: A: particle shape by categorisation of SEM 
images into five categories from category 1 (spherical) to category 5 (indented); B: aspect ratio 
measured by image analysis (n=3). Results that do not fit the trend due to effects arising from 
carrier size are bracketed. 
Two different parameters were applied to discover the effect of particle shape. Figure 4.32 – 
A illustrates the correlation of FPF (y-axis) to particle shape categories (x-axis) as 
determined with the survey. It was observed that powder blends with more spherical 
character (shape category < 2.5) led to higher FPFs for all different spray dried SBS qualities 
(Table 4.10, 18.7 % - 27.3 %) compared to those with more indentions (Table 4.10, 11.1 % - 
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21.3 %). This effect was even more pronounced for powder blends with SBS SD(S) and SBS 
SD(M) compared to SBS SD(L) as will be discussed in Section 4.3.3.2. 
In more detail, the three mostly spherical carrier batches do not significantly impact on the 
FPF of SBS drug batches, when compared with each other, but show significantly higher 
FPFs compared to the three batches prepared with indented carriers (p < 0.05). However, 
blends with mannitol M80(S) (Shape Category 4.3) were found to deviate from the general 
trend towards lower FPFs for all SBS qualities when more indentions occur. Its respirable 
fraction was detected to be higher than the one for blends prepared with mannitol M80(M) 
(Category 3.7, bracketed in Figure 4.32 – A) which will further be explained by effects of 
carrier size in Section 4.3.3.1. 
Supplementary, Figure 4.32 – B gives the FPFs correlated to the aspect ratio of the carrier 
particles the powder blends were prepared with. Similar trends were found for all these 
batches as lower aspect ratios (Table 4.1, 0.8967 to 0.8547) generally caused worse DPI 
performances (FPF = 27.3 % to 11.1 %). Batches M80(S) and M80(M) were evaluated with 
almost equal aspect ratios, but reveal again significant differences for the respective FPF. As 
mentioned above, this effect can coherently be described as a factor of particle size in the 
following. 
Figure 4.33 gives the visualisation of four powder blends with mannitol carriers of spherical 
and indented character as prepared with SBS SD(S). The spray dried drug particles were 
well spread over the whole surface or build drug bridges between the carrier particles, when 
carriers are spherical. Drug bridges were mainly detected in powder blends prepared with 
M70(S) (Figure 4.33 – A) since smaller carrier particles facilitate accumulations due to the 
lower mass per particle, while the single carrier mass might have been too large for bridges 
in powder blends consisting of larger M71(L) (Figure 4.33 – B) and SBS SD(S). 
Nevertheless, performance of both powder blends led to FPFs above 25 %, which suggested 
that both kinds of drug distribution support adequate drug detachment and agglomerate 
dispersion. 
Particles presented in Figure 4.33 – C/D exhibited indentions that trapped drug particles 
during blending to enable the generation of drug accumulations. The resulting FPFs 
decreased with the occurrence of indentions. 
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Figure 4.33 - Visualisation of interactive powder blends with SBS SD(S) and different mannitol 
carrier batches; A: M70(S); B: M71(L); C: M80(S); D: M97(L) 
Figure 4.34 gives a more schematic view on the detachment and dispersion of SBS particles 
from carriers of different shape. Scheme A indicates that spherical carriers facilitate both the 
generation of drug bridges and drug particles being evenly distributed on the whole carrier 
surface, while Scheme B illustrates how drug particles get trapped by indented carrier 
particles. Most of the drug particles get entrained by the air flow and are dispersed by 
inhalative shear forces, when the carrier appears spherical, but only a few get detached from 
indented carriers, where several particles remain in the indentions as observed in the 
experiments discussed before. 
 
Figure 4.34 – Scheme of the detachment of SBS particles (black) from the carrier (light grey) 
during inhalation for A: spherical carrier particles and B: indented carrier particles 
  
 
Drug detachment of TIO SD and BUD SD as measured by impaction analysis resulted in 
contrary trends compared to SBS SD as illustrated in Figure 4.35. The plot shows the FPFs 
of both drugs correlated to the according shape categories as evaluated by a survey.  
 
Figure 4.35 - FPF ± StD in % (y-axis) of powder blends consisting of six chosen mannitol 
batches (M70(S)/M71(L)/M74(M)/ M80(S)/M80(M)/M97(L)) and TIO SD or BUD SD related to the 
particle shape as evaluated by categorisation of SEM images into five categories from category 
1 (spherical) to category 5 (indented) (n=3). Results that do not fit the trend due to effects 
arising from carrier size or indention depth are bracketed. 
Most powder blends with TIO SD triggered higher FPFs than with BUD SD (except for 
M80(M) and M97(L), which were found at the same range), which will be discussed later. 
With focus on the carrier particle shape, the efficiency of drug dispersion increases 
significantly with rising shape categories or the occurrence of indentations. Accordingly, the 
FPFs of powder blends with TIO SD rose from 34.1 ± 1.8 % (M70(S)) to 41.8 ± 1.0 % 
(M80(S)), while blends prepared with BUD lead to FPFs from 28.3 ± 1.4 % (M71(L)) for 
spherical carriers to 37.2 ± 1.0 % (M80(S)) for slightly indented ones. For both model drugs, 
an decrease of the FPF was observed for powder blends containing mannitol M80(M) or 
M97(L), which will be attributed to the carrier size in the following sections. SEM 
visualisations in Figure 4.36 give images of powder blends containing of spherical carriers 
with lower FPF (T1 / B1), of medium indented carriers performing best in impaction analysis 
(T2 / B2) and of deeply indented carriers with decreased FPF (T3 / B3). 
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Figure 4.36 – SEM visualisations of powder blends containing TIO SD (T1-3) and BUD SD (B1-3) 
and the following mannitol qualities: T1: M70(S); T2: M80(S); T3: M97(L); B1: M71(L); B2: 
M80(S); B3: M97(L). 
  
 
Again, drug bridges were found between small and spherical carrier particles (T1), while drug 
particles were evenly distributed on the surface for larger carriers (B1). The batches 
performing best during impaction analysis exhibited small indentions, which entrap drug 
particles (T2 / B2). Powder blends with mannitol M97(L) (T3 / B3) revealed several deep 
indentions that were filled with drug accumulates. 
 
Figure 4.37 – Scheme of the detachment of TIO SD / BUD SD (black) from carriers of different 
particle shapes (grey), A: spherical carrier; B: slightly indented carrier, C: carrier with deep 
indentions 
The trends observed for idealised spherical drug particles of TIO SD and BUD SD support 
the theory of press-on forces that occur during blending and handling. Drug particles blended 
with spherical carrier particles are pressed on the carrier surfaces during the blending 
procedure as there is no ability to hide in surface irregularities. These press-on forces 
increase the adhesion forces between drug particles and carrier surface, which decreases 
the FPF (Figure 4.37 – A). The occurrence of first slight indentations enables drug particles 
to hide from press-on forces by other carrier particles during blending. Less press-on forces 
and so less adhesion forces cause easier detachment of drug particles during inhalation, 
which results in rising respirable fractions for this group of model drugs (Figure 4.37 – B). 
Only particles with several deep indentions show decreased FPFs since drug particles are 
hindered to be entrained by the air flow (Figure 4.37 – C). 
That this effect is not prominent for the SBS particles as described above might be explained 
by the tendency to be detached by the air stream. SBS seems to be adhered tighter when 
caught in even slight indentions compared to BUD or TIO particles. In turn, SBS is not 
affected by press-on forces as observed for the other two drugs. However, this could not 
directly be measured in these experiments.  
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Figure 4.38 - FPF ± StD in % (y-axis) of powder blends consisting of six chosen mannitol 
batches (M70(S)/M71(L)/M74(M)/ M80(S)/M80(M)/M97(L)) and FOR SD related to the particle 
shape as evaluated by categorisation of SEM images into five categories from category 1 
(spherical) to category 5 (indented) (n=3) 
Experiments performed with lipophilic FOR SD revealed carrier particles with several deep 
indentions (M80(S)/M97(L)) to trigger the best FPFs, while two batches with more spherical 
character were found with reduced FPFs (M70(S)/M74(M)). M71(L) as a large and spherical 
carrier quality deviated from this trend since the FPF was found on the same level than 
indented carriers M80(S) and M97(L). 
Results can be linked to an interplay of carrier particle shape and agglomerate strength 
which is most likely linked to the drug size. FOR SD was suggested to appear as a quite 
cohesive drug with high tendency to build agglomerates of remarkable agglomerate strength 
due to its blending behaviour. The blending process was adapted to faster rotation of the 
blending vessel to enable homogeneity by destroying these agglomerates. Challenges based 
on the occurrence of agglomerates help to understand trends in correlation to carrier particle 
shape observed here.  
Carrier particles with a high number of indentions enable adequate drug distribution without 
the generation of large drug accumulates within these indentions as the sum of indentions 
provides a lot of space for the low number of drug particles (Figure 4.39 – B). The least 
indentions occur the higher is the tendency to build larger agglomerates, which hardly get 
dispersed during inhalation. This reduces the according FPF for M74(M) exemplarily. An 
additional negative effect can be assumed for batch M70(S) with respect to the small carrier 
size. As for the other model drugs, FOR SD exhibited a tendency to build drug bridges 
between those small carrier particles due to the absence or low numbers of indentions 
(Figure 4.39 – B). These bridges were formed by drug agglomerates that needed to be 
dispersed during inhalation, which caused a reduction in FPF. The mentioned agglomerates 
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were not adequately dispersed during impaction analysis, which could be attributed to the 
possibly more intense agglomerate strength compared to other drugs. 
 
Figure 4.39 – SEM visualisations of powder blends containing FOR SD and A: mannitol M70(S) 
or B: mannitol M97(L). 
Interactive powder blends containing M71(L) and FOR SD lead to significantly higher FPFs 
compared to blends with M70(S) even though both carriers were of spherical shape. The 
particle mass of the larger carrier quality avoids the development of drug agglomerates in 
form of drug bridges, so that the drug was evenly distributed over the whole carrier surface 
resulting in an easier dispersion during inhalation and appropriate FPFs. 
The fact that FOR SD was less entrapped by the deep indentions than e.g. SBS SD can be 
related to particle-particle interactions between carrier and drug particle as will be discussed 
in Section 4.3.4.  
In general, formulations for DPI use are desired to easily generate high FPFs with adequate 
reproducibility as this reduces the loss of drug as well as the risk of systemic side effects. 
Results claim the particle shape to affect the detachment of drug particles since indentions 
either enable the entrapment of small particles or help to hide from press-on forces. Spray 
dried carriers need to be spherical (SBS; FOR for large carrier particles), slightly indented 
(TIO, BUD) or deeply indented (FOR) to trigger the best aerodynamic performance when 
tested with spray dried drug particles. Mechanisms are based on how well the drug particles 
get detached from the carrier surface but also on the suggested agglomerate strength of the 
respective drugs. The development of new dry powder formulations requires new evaluations 
for every drug as the effect of carrier shape appears to be drug dependent. However, the 
examination of drug agglomerate strength and adhesion forces requires methods for direct 
investigations to enable predictions. 
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4.3.1.2 Drug Shape 
Drug shape was of further interest, as not only the carrier might influence particle-particle 
interactions. Investigations were performed using spray dried and micronised qualities of 
hydrophilic SBS and lipophilic BUD. 
The aerodynamic performance of powder blends containing these drug qualities is 
summarised in Figure 4.40, which displays the FPFs for six different mannitol batches. 
Starting with the comparison of both SBS qualities, inhalation of SBS micronised resulted in 
noticeably higher and mostly similar FPFs (Table 4.10, FPF = 32.6 ± 1.0 % – 
35.0 % ± 3.2 %) compared to all spray dried qualities. Only powder blends prepared with 
M80(M) and M97(L), where carriers exhibited the most indentions, showed slightly 
decreased values (Table 4.10, FPF = 27.3 ± 1.8 % – 29.4 ± 0.7 %), that might be explained 
by entrapped drug particles. 
Reduced FPFs for spray dried SBS can be attributed to drug shape, but also to crystal 
structure. Micronised SBS exhibited needle-like particles (Figure 4.22 – D), that align in the 
air flow after detachment from the carrier. This affects the impaction of drug particles since 
needles that are entrained by the airflow provide less surface area to be accelerated and 
impacted. Drug orientation within the airflow supplements this effect as needle-like particles 
pass the impactor nozzles easier [144]. 
In fact, SBS SD(S) showed decreasing FPFs, when first slight indentions occurred on the 
carrier surface, while micronised SBS kept similar FPFs. The needle-like shape prevents 
those particles from entrapment in small indentions, so that dispersion was not influenced 
here. 
 
Figure 4.40 - FPF ± StD in % (y-axis) of six chosen mannitol batches (x-axis) and appropriate 
powder blends with SBS SD(S), SBS micronised, BUD SD and BUD micronised (n=3) 
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The comparison of BUD SD and micronised BUD contrasted the findings described before. 
BUD micronised was found with lower FPFs (FPF = 15.2 ± 1.1 % - 24.2 ± 1.0 %) than the 
spray dried quality (FPF = 28.3 ± 1.4 % - 37.2 ± 1.0 %). Micronised BUD containing blends 
were initially investigated with Raman analysis to check for the drug distribution on the 
surface (Figure 4.41) as micronised drug particles cannot easily be distinguished from 
surface asperities by SEM. 
 
Figure 4.41 – Overlay images of Raman analysis with BUD micronised containing powder 
blends with A: spherical mannitol carrier particles (M71(L)) and B: indented mannitol carrier 
particles (M97(L)). 
Results revealed that BUD was spread over the surface for spherical carriers and 
accumulated in indentions, if present, which went along with findings described for SBS or 
BUD SD. Hence, differences between BUD SD and micronised BUD need to be assigned to 
further reasons. 
Observed effects can be dedicated to the tendency to build agglomerates as well as to the 
effective contact area of the different BUD drug qualities. Agglomerate strength decreases 
with larger drug sizes, so that the spray dried quality (d50.3 = 1.8 µm) was favoured for 
detachment compared to the micronised one (d50.3 = 1.4 µm). The contact area between 
single BUD particles of the same quality decreases and enables easier dispersion. Further, 
the effective contact area between BUD drug particles of different quality gets impacted by 
drug shape. Spherical particles have the lowest effective contact area between single 
particles and, therefore, the lowest particle-particle interactions, which reduces its 
agglomerate strength and triggers higher FPFs. 
The comparison of SBS and BUD qualities provides quite divergent results, which hardly 
offer overall conclusions for the influence of drug shape on the resulting FPF. Drug 
orientation in the airflow, agglomerate strength, effective contact area as well as the 
detachment ability can be taken into account to reason findings of these experiments. 
However, these characteristics were changed drug specifically and do not show overall 
dependencies.  
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4.3.2 Surface Roughness 
Carrier surface roughness – also known as the microstructure of the particle surface – was 
correlated to the impaction results with respect to carrier particle shape since both particle 
properties could not be adjusted separately. Figure 4.42 gives the FPF in % (y-axis) plotted 
against the surface roughness in roughness categories (x-axis) from category 1 (smooth) to 
5 (rough) for powder blends consisting of six different mannitol qualities and three spray 
dried SBS batches. 
 
Figure 4.42 - FPF ± StD in % (y-axis) of powder blends consisting of six chosen mannitol 
batches (M70(S)/M71(L)/M74(M)/ M80(S)/M80(M)/M97(L)) and three different drug qualities (SBS 
SD(S/M/L)) related to the surface roughness as evaluated by categorisation of SEM images into 
five categories from category 1 (smooth) to category 5 (rough) (n=3) 
The illustration suggests decreasing FPFs with rising surface roughness categories or 
rougher carrier surfaces, which needs to be scrutinised since particle shape revealed similar 
trends for the same powder blends. The main impact on the aerodynamic performance was 
most likely triggered by particle shape, but supplemented by an additional effect ensuing 
from the surface roughness. 
In more detail, it was found, that the roughest carrier surfaces provided by mannitol M97(L) 
caused similarly low FPFs for drug particles of all sizes (SBS SD(S/M/L)). Starting from here 
to smoother surfaces, smaller SBS drug particles performed better than the larger ones. This 
suggests the surface roughness to impact on powder blends containing SBS batches with a 
large number of small particles (SBS SD(S/M)) rather than those with larger drug particles 
(SBS SD(L)). 
In fact, SEM images of powder blends containing SBS SD(S) and smooth or rough mannitol 
carrier particles (Figure 4.43), that were visualised after impaction analysis, obtained fine 
spray dried SBS particles entrapped by the surface asperities on the mannitol carrier surface. 
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Images illustrate that remaining drug particles are of small size (below 1 µm). Apparently, 
rough structures enabled fine drug particles to stay attached during inhalation, so that 
differences between smooth (Figure 4.43 – A) and rough surface (Figure 4.43 – B) occurred. 
Only some single spherical drug particles were detected on the smooth surface of mannitol 
M71(L), while mannitol M97(L) retained several SBS drug particles during impaction 
analysis. This effect is a factor of the size and number of intermediate spaces between 
overlying crystalline structures on the carrier surface. 
 
Figure 4.43 – SEM images (5000 fold magnification) of SBS SD(S) attached to the surface of two 
different mannitol qualities after impaction analysis, A: M71(L); B: M97(L). 
Appropriate particle-particle interactions are schematically illustrated in Figure 4.44, which 
gives a simplified view of either a rough or a smooth surface structure with spherical drug 
particles of different size attached to the surface. It emphasizes, that smooth carrier surfaces 
provide the least contact area to spherical drug particles as only a single point of contact 
exists. Nevertheless, the effective contact area between carrier surface and drug particle 
needs to be discussed since it strongly depends on the drug size. Larger drug particles 
exhibit larger effective contact areas per particle than smaller drug particles. The number of 
contact points increases, when surface asperities occur. This establishes larger effective 
contact areas for smaller drug particles, but decreases these contact areas for larger drug 
particles simultaneously as depicted in Figure 4.44. 
Not only the effective contact area, but also the ratio of particle mass to effective contact 
area and with this adhesion forces is of importance to describe particle-particle interactions 
between drug and carrier. Preferably, smaller particles remain attached to the carrier surface 
as the ratio mass to effective contact area is low, while the ratio increases rapidly with rising 
drug particle sizes, which supplements detachment of these particles during inhalation. 
Nevertheless, the effect of surface roughness on the inhalation performance of an interactive 
powder blend is rather low and determined by the size and number of intermediate spaces 
between rough crystalline structures on the carrier surface.  
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Figure 4.44 – Scheme of contact areas for spherical spray dried API particles (e.g. SBS 
SD(S/M/L)) of different sizes attached to rough (e.g. M97(L)) or smooth carrier surfaces (e.g. 
M71(L)) and needle-like jet-milled qualities attached to the same surfaces 
Experiments performed here favour smooth surfaces for the hydrophilic model drug SBS 
since such surfaces reduce the number of contact points for spherical drug particles. 
Littringer et al. [20,23] proposed rough surfaces to be advantageous for micronised SBS as 
this decreases the number of contact points and the effective surface contact area for those 
needle-like particles, which agrees with the theory displayed here (Figure 4.44). The different 
drug shape plays an important role for the effective contact area, so that different surface 
appearances may be beneficial for different drug particles. 
To conclude, the connection of aerodynamic performance and surface roughness of a carrier 
needs to be discussed with respect to the overall shape of a drug particle, but also with focus 
on the drug shape as both properties influence each other. Surface asperities might hinder 
the smallest drug particles to be detached from the carrier, but are at the same time 
beneficial for materials with non-spherical appearance. 
4.3.3 Particle size 
The particle size was investigated as a parameter for dry powder formulations that has 
widely been described in literature. This project covered a broad set of different carrier and 
drug sizes to get a coherent overview about how particle size affects the dispersion of drug 
particles during inhalation. Necessarily, the observed effects were divided into carrier size 
and drug size based ones. 
4.3.3.1 Carrier Size 
Carrier size effects were observed for different model drugs as indicated earlier. Figure 4.45 
gives relations between FPF (1st y-axis), mannitol carrier batches (x-axis) and its carrier sizes 
(2nd y-axis) for four different SBS drug qualities. The four presented mannitol batches were 
grouped into spherical carriers and indented carriers as not only size, but size in connection 
to the apparent particle shape was found to affect the impaction results. 
  
 
 
Figure 4.45 - FPF ± StD in % (1
st
 y-axis, columns of different greyscales) of powder blends 
consisting of four chosen mannitol batches (M70(S)/M71(L)/M80(S)/M97(L)) and SBS SD(S/M/L) 
or SBS micronized related to the particle size (black marks) (n=3) 
Powder blends investigated here revealed that the FPF of spherical carrier particles was not 
affected by the carrier size, since the results of blends with SBS micronised, SBS SD(S) and 
SBS SD(M) do not significantly differ for smaller M70(S) and larger M71(L). In contrast to 
that, differences in the aerodynamic performance were found for the indented carrier batches 
M80(S) and M97(L), where the smaller carriers triggered significantly higher FPFs for all SBS 
qualities, when compared to the larger ones. 
The observed effects can be derived from an interplay between carrier size and shape. 
Obviously, particle size does not affect the dispersion of drug particles, when carriers occur 
spherical and without indentions, whereas for indented carriers particle size deals as a 
measure of indention depth since larger particles are supposed to obtain deeper indentions 
than smaller ones. In turn, this determines the space provided for drug accumulations in 
these cavities. Drug particles entrapped in the indentions of smaller particles get easier 
detached by the airflow than those accumulated in larger ones. This affects the detachment 
of SBS particles significantly as was observed for small spray dried SBS qualities (p < 0.01), 
but also for SBS SD(L) and SBS micronised (p < 0.05). 
Similarly, reduced respirable drug fractions of TIO SD or BUD SD were gained from powder 
blends with the indented carriers M97(L) and M80(M) compared to indented M80(S) as 
mentioned earlier (Figure 4.35). Slight indentions were suggested to be advantageous for 
these drugs as they prevent those drug particles from press-on forces. However, deep 
indentions hinder TIO and BUD particles from being detached during inhalation, which again 
reduces the FPF for these batches. No carrier size effect was found for lipophilic FOR 
particles. Results described here agree with findings of Steckel et al. earlier, who mentioned 
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smaller (lactose monohydrate) carriers to perform better during inhalation than with larger 
ones [81]. 
4.3.3.2 Drug Size 
Drug size is known to be a crucial parameter that affects the amount of drug, which is 
enabled to reach the deeper airways of the lung. The FPF as the fraction of particles with an 
aerodynamic equivalent diameter < 5 µm is strongly depending on the drug size. Three SBS 
qualities different in size (SBS SD (S/M/L)) were tested by impaction analysis to proof this 
concept. 
Results obtained the smaller SBS batches SBS SD(S) (d50.3 = 2.4 µm) and SBS SD(M) 
(d50.3 = 2.8 µm) to generate larger respirable fractions (FPF = 11.2 ± 0.3 % – 27.3 ± 2.6 %) 
compared to the larger SBS batch SBS SD(L) (d50.3 = 3.7 µm) with the FPF covering a range 
from 11.1 ±0.5 % to 19.4 ± 0.7 %.  
 
Figure 4.46 – MMAD in µm ± StD for four SBS qualities and six chosen mannitol batches 
The drugs applied for powder blends differed in size and so in the amount of particles that 
were below an d50.3 / dadyn of 5 µm. Laser diffraction analysis found 89.3 ± 0.5 % of the SBS 
SD(S) particles below 5 µm, while only 67.2 ± 0.2 % of SBS SD(L) remained under the 5 µm 
limit. This corresponds to the MMADs measured for all different SBS drug qualities by 
impaction analysis (Figure 4.46). SBS SD(S) revealed the lowest values since MMAD was 
found to range from 3.7 ± 0.1 µm to 4.1 ± 0.1 µm compared to SBS SD(L) that covered 
MMAD from 4.8 ± 0.1 µm to 5.7 ± 0.1 µm. 
MMADs were found with larger values compared to the drug sizes measured by laser 
diffraction. This could be attributed to the tendency to build drug agglomerates that were not 
dispersed adequately during inhalation. Consequently, those agglomerates impacted earlier 
mimicking larger particles. Dry dispersion with the dry dispersing unit of the laser 
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diffractometer is recognised to be more efficient than dispersion during inhalation, justifying 
smaller particle sizes measured with this technique. 
The smaller the particles the higher is the tendency to build agglomerates as adhesion forces 
exceed weight forces. All factors result in higher MMADs compared to the laser diffraction 
results, even though adequate allocation is not possible. 
Accordingly, the inhalable drug fraction can be derived from the initial drug size as larger 
particles or agglomerates of fine particles impact earlier with respect to their inertial forces as 
published by Biddiscombe et al. earlier [19]. 
4.3.4 Drug Hydrophilicity 
Four different model drugs that covered a broad range of different log P values (TIO = -1.8; 
SBS = 0.6; BUD = 1.9; FOR = 2.2) were compared regarding their aerodynamic performance 
when blended with the same mannitol carrier particles and investigated by impaction analysis 
to discover the effect of drug hydrophilicity on particle dispersion. 
Results coherently summarised in Section 4.3 revealed drug particles of all model drugs to 
reach maximum FPFs around 27 – 41 % without any correlation to the respective 
hydrophilicity. Dependencies were mostly found for drug size or shape or based on the 
carrier properties as discussed before. 
Nevertheless, findings can be related to drug hydrophilicity in terms of detachment 
behaviour. The chosen model drugs detached in different manners as described above. 
Hydrophilic SBS was found with strong dependence on the carrier shape with spherical 
carriers performing best, TIO and BUD were preferably applied with slightly indented carrier 
particles due to lower press-on forces and FOR particles with either large spherical carriers 
or indented carriers of every size. 
Differences between SBS and FOR detachment can easily be derived from drug 
hydrophilicity. Particle-particle interactions between carrier and drug are based on several 
different forces like e.g. polar forces in hydrogen bonds or non-polar van der Waals forces 
that – in most cases – cannot be quantified by a distinct value yet. Hydrogen bonds as 
typically observed for molecules with hydrophilic parts or van der Waals forces are of interest 
for the differentiation of materials with various hydrophilicities. The log P values of drug and 
carrier give an idea of the interactions that might occur. The hydrophilic sugar alcohol 
mannitol (log P = -3.1) can easily build hydrogen bonds but has no hydrophobic parts for 
appropriate van der Waals forces. TIO (log P = -1.8) or SBS (log P = 0.6) comprise 
hydrophilic functions that have the ability to build hydrogen bonds, while BUD (log P = 1.9) or 
FOR (log P = 2.2) are mostly lipophilic with the tendency to interact via weaker van der 
Waals forces. 
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Particle-particle interactions observed in these experiments do not provide direct correlations 
between log P value and detachment manner as not only hydrogen bridge bonds or van der 
Waals forces but also effects arising from agglomerate strength affect the detachment of 
drug particles from a carrier. Nevertheless, the values can be applied to make suggestions 
on the drug detachment. 
Figure 4.47 gives an overview over the initial distribution of drug particles on the surface of 
four different mannitol carriers and the optimal dispersion upon inhalation as most particles 
got detached in form of single particles. Impaction results suggest different drugs to be 
affected by different characteristics. SBS particles were easily dispersed even when 
agglomerates occurred in slight indentions or in form of drug bridges, but were not detached 
when entrapped in deep indentions. This suggests this drug to build weak drug-to-drug 
interactions, but to have stronger drug-to-carrier-interactions. Contrary, FOR particles were 
found to be dispersed best when the occurrence of drug agglomerates was prevented by the 
carrier choice. Large spherical or deeply indented carriers were beneficial for high FPFs, 
while agglomerates that occurred for small spherical or slightly indented carriers were not 
dispersed adequately during inhalation. This behaviour suggests FOR having strong drug-to-
drug interactions, but at the same time weak drug-to-carrier interactions as the drug was 
even detached from deep indentions. 
 
Figure 4.47 - Distribution of drug particles on the surface of differently shaped carriers upon 
blending and dispersion of those drug particles during inhalation (carrier size: S = small / L = 
large). (+) and (-) indicate how well particles get dispersed from the carriers of different particle 
shape and size. 
Hydrophilic SBS builds hydrogen bonds to the hydrophilic mannitol carrier surface, which 
results into drug particles that are stronger attached to the surface compared to e.g. lipophilic 
FOR, whose ability to build such bonds is rather low. Hence, drug entrapment in indentions is 
favoured for hydrophilic SBS particles, while even low shear or impaction forces during 
  
 
inhalation last to detach FOR particles even when entrapped in deeper indentions. This 
concurs with findings described earlier, where SBS detachment was strongly depending on 
the occurrence of indentions. Even slight indentions lowered the respirable fraction. BUD or 
TIO containing blends were favoured with those slight indentions as they were not attached 
as strong as SBS resulting in easier detachment. However, particle-particle interactions of 
SBS, BUD and TIO particles were strong enough to entrap those drugs in deeper indentions 
during inhalation. Contrary, lipophilic FOR particles appeared to have the weakest interactive 
potential, which resulted in adequate dispersion even from deeply indented carriers. 
However, as mentioned before, there was no effect on the overall FPF of those drugs, but 
only an effect that suggested the best carrier shape for the different drug particles. 
4.3.5 Crystallinity 
The influence of crystallinity on drug detachment was gained from experiments performed 
with micronised and spray dried drug qualities. All spray dried drugs were of fully amorphous 
quality, while micronised drugs contained crystalline structures. Different mannitol particles 
were assumed to not affect the drug detachment in terms of crystallinity since all mannitol 
batches were found to have the same crystalline modification. 
Hydrophilic SBS and lipophilic BUD particles were used for powder blends in spray dried and 
micronised quality as described above. Comparison of crystalline and amorphous particles 
cannot easily be performed since those different drug qualities are associated with different 
drug shapes, which are known to affect the aerodynamic performance. 
Some assumptions on the effect of crystalline structures can still be made based on the 
results illustrated here. The use of micronised SBS drug particles lead to increased FPFs 
compared to amorphous spray dried SBS particles (Figure 4.40). This effect was mainly 
attributed to different drug shapes as impaction analysis was performed more efficiently for 
needle-like particles. Nevertheless, amorphous material and its tendency to recrystallise 
might have an additional reducing effect on the FPF since those particles most likely stay 
attached to the carrier surface. Experiments in this study were conducted at controlled 
conditions (21 °C, 35 % rH) to avoid recrystallisation events, which was proved by SEM 
images (not shown here). Powder blends with spray dried amorphous SBS are more 
susceptible to recrystallisation than micronised materials that usually show some small 
amorphous spots at the breaking edges after micronisation even though most of the material 
appears to be crystalline. Hence, all powder blends, but especially the ones containing spray 
dried SBS, might be affected by higher relative humidity or uncontrolled conditions, as this 
allows moisture uptake and recrystallisation. 
The comparison of amorphous BUD SD (with higher FPFs) and mostly crystalline micronised 
BUD (with lower FPFs) cannot directly be correlated to the crystalline state as factors like 
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particle size or shape exceed effects that possibly arise from crystallinity. The spray dried 
quality was found with better results than the micronised one even though amorphous 
structures most likely were expected with lower FPFs due to storage issues. 
Conclusively, powder blends with micronised or spray dried SBS are not applicable for 
devices without desiccants and for the use in everyday life as only low moisture contents 
keep those products stable. BUD results did most likely not match assumptions for effects 
arising from crystallinity. 
4.3.6 Flowability 
SBS drug detachment was further compared to the flow characteristics of the pure mannitol 
particles as measured with a powder rheometer (Section 4.1.6). Figure 4.48 shows the 
correlation of powder blends consisting of six different mannitol batches and the three 
different SBS qualities SBS SD(S/M/L). A clear trend to lower FPFs was observed for rising 
BFEs or lower mannitol bulk flowability. 
These findings can easily be attributed to mannitol properties that were described before 
since flow characteristics are based on primary particle properties like particle size or shape. 
As evaluated earlier, the highest BFEs were caused by large indented carrier particles 
(M97(L)), which in turn provide the deepest indentions for SBS drug particles. The according 
FPFs are quite low for SBS particles of every size (SBS SD(S/M/L) with an FPF < 12 %). 
Lowest resistance was found for small spherical carriers (M70(S)) that triggered the best 
aerodynamic performance for this drug quality. SBS particles were evenly distributed over 
the whole surface or built drug bridges that were dispersed easily. 
 
Figure 4.48 - FPF ± StD in % (y-axis) of powder blends consisting of six chosen mannitol 
batches (M70(S)/M71(L)/M74(M)/ M80(S)/M80(M)/M97(L)) and SBS SD(S/M/L) related to the BFE 
in mJ (x-axis) (n=3) 
0
5
10
15
20
25
30
75 100 125 150
F
in
e
 P
a
rt
ic
le
 F
ra
c
ti
o
n
, 
F
P
F
, 
%
 
Basic Flowability Energy, BFE, mJ 
SBS SD(S) SBS SD(M) SBS SD(L)
  
 
In general, it is important to generate powder blends with appropriate flow properties. All bulk 
batches used here were of good overall flowability as evaluated with Carrs Index (CI < 15), 
but differed in the BFE due to different particle properties. The delivered mass per shot with 
the Novolizer® was reproducible with a relative standard deviation below 10 % for all powder 
blends, so that differences in the impaction results can be correlated to carrier properties like 
size or shape. 
4.3.7 Surface Energy 
Surface energy measurements were performed for both, mannitol carrier particles and 
various drug particles. Correlations between dispersive surface energies and according FPFs 
were hardly detected for any of the different powder blends. 
Most mannitol qualities were found with similar dispersive surface energies, where only 
mannitol quality M71(L) gave reduced values (Section 4.1.8). At the same time, this batch 
occurred as the most spherical one, so that appropriate findings are assigned to carrier 
shape rather than to the reduced dispersive surface energy. 
Similarly, surface energies of drug particles covered a wide range from 31 mJ m-2 for FOR 
SD to 60 mJ m-2 for BUD micronised, but did not enable correlations to FPF level or trends in 
the detachment of different APIs. Nevertheless, mannitol carrier particles were found to have 
heterogeneous surfaces in terms of dispersive surface energies, which gave rise to the 
assumption that some spots on the carrier surface might adhere particles (e.g. drug particles) 
tighter than other spots which in turn implemented the use of mannitol fines to increase the 
respirable fraction as discussed in the following section. 
4.3.8 Influence of Fines 
Based on results that indicated mannitol carrier surfaces to be heterogeneous in dispersive 
surface energy, mannitol fines were prepared and added prior to the addition of drug 
particles to generate ternary interactive powder blends consisting of mannitol carrier, 
mannitol fines and SBS SD(S). Several studies based on lactose monohydrate deal with the 
addition of fines targeting an increase of the FPF [27,145,146]. One mentions active sites as 
high energy spots on the surface to bind particles stronger than the rest of the surface 
[7,72,138]. This theory was used as basis for a row of powder blends containing different 
concentrations of mannitol fines (cfines = 0 – 10 % [w/w]). Results are summarised in Table 
4.12, which gives the FPFs in % ± StD, and are further illustrated in Figure 4.49. 
Table 4.12 – FPF ± StD in % of mannitol M80(S) as carrier, SBS SD and different amounts of 
mannitol fines (n=3) 
SBS plus Mannitol Fines 
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cFines, % [w/w] FPF, % StD 
0 19.8 1.1 
2 22.9 1.7 
4 25.2 0.7 
6 26.6 1.4 
8 29.5 0.4 
10 31.5 0.2 
 
The aerodynamic performances of all powder blends were compared to a blend containing 
only mannitol M74(M) and SBS SD as a control. Experiments with rising cfines generated 
constantly rising FPFs starting from 19.8 ± 1.1 % for blends without fines and resulting in 
blends containing 10 % fines with an FPF of 31.5 ± 0.2 %. The obtained correlation was 
found to be linear (R² = 0.992). 
 
Figure 4.49 – FPF in % ± StD (y-axis) for powder blends with mannitol M74(M), SBS SD and 
different concentrations of mannitol fines (x-axis) (n=3) 
SEM visualisations revealed blends containing 2 % [w/w] mannitol fines (Figure 4.50 – A) to 
build small bridges consisting of spherical SBS SD and fines. The same bridges were also 
observed for blends containing 10 % [w/w] mannitol fines, but were supplemented by 
agglomerates attached to the carrier surface (Figure 4.50 – B). 
R² = 0,9921 
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Figure 4.50 – SEM images (1,000-fold magnification) of interactive powder blends consisting of 
A: 97 % mannitol M74(M), 1 % SBS SD and 2 % mannitol fines; B: 89 % mannitol M74(M), 1 % 
SBS SD and 10 % mannitol fines 
Experiments were performed with a maximum concentration of 10 % [w/w] since powder flow 
and accurate dosing was not adequate for higher concentrations. The positive effect on drug 
dispersion increased up to cfines = 10 %, while further addition of fines rendered dosing 
impossible. Following this, the best aerodynamic performance was achieved for interactive 
powder blends containing the highest fines concentration possible. 
Mechanisms behind this improvement can be correlated to theories postulated for blends 
containing lactose monohydrate [27]. It can be assumed that a small amount of mannitol 
fines lasts to cover high energy spots with respect to the active sites theory. SBS particles 
bind at spots of lower energy and detach easier from the surface during inhalation, which in 
turn results in higher FPFs [27,71].  
This theory concurs with the buffer hypothesis, which describes that lactose fines of larger 
size than the drug particles preserve those drug particles from press-on forces, which in turn 
results in higher FPFs [24,27]. Mannitol fines were used with a d50.3 of 4.1 µm compared to 
drug particles of d50.3 = 2.4 µm in this study to protect SBS drug particles from press-on 
forces according to the proposed buffer effect. 
Further improvement can be gained, when more fines are added to build agglomerates on 
the carrier surface. This so-called agglomeration theory indicates that agglomerates of 
mannitol fines and drug get dispersed easier than formulations consisting of drug and carrier 
only [7,71]. Mannitol fines were chosen with a size that was small enough to build 
agglomerates, but large enough to trigger easy dispersion of the drug. These agglomerates 
supplement the buffer hypothesis as described above [24]. 
To conclude, the addition of fines to powder blends containing spray dried mannitol particles 
and drug particles enables reasonable improvements during inhalation. The maximum 
concentration of fines is restricted by flow properties and with this accurate dosing of the 
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powder blend when administered with a DPI. Capsule based inhaler devices might be 
advantageous for such formulations as free powder flow is not necessary during inhalation. 
4.3.9 Impact of the device 
All powder blends were investigated using the Novolizer® as device despite the low apparent 
density of the mannitol batches used [20,23]. The Novolizer® with its impaction walls was 
mainly constructed for larger carrier particles with higher densities to use appropriate 
impaction forces for dispersion of the drug [75]. 
This part of the study dealt with the Easyhaler® as an alternative device without cyclone or 
impaction walls to simplify drug dispersion. Unsurprisingly, experiments resulted in 
comparably low FPFs as summarised in Table 4.13. 
A maximum FPF of 4.2 ± 0.4 % was measured for blends containing mannitol M70(S), which 
was at the same time the batch performing best with the Novolizer® (FPF = 27.3 ± 2.6 %), 
while the minimum of 1.8 ± 0.0 % for powder blends containing M80(M) matched with the 
same batch performing worst with the Novolizer® (FPF = 11.2 ± 0.3 %). 
 
 
 
Table 4.13 – FPF ± StD in % of six different mannitol batches and SBS SD(S) administered with 
Novolizer and Easyhaler (n=3) 
Mannitol batches SBS SD(S) 
DoE: Naming Results: 
Extra 
Label-
ling 
Novolizer
®
 Easyhaler
®
 
Run 
Order 
Exp 
Name FPF, % StD FPF, % StD 
Run 9 N5 M70(S) 27.3 2.6 4.2 0.4 
Run 10 N1 M71(L) 25.7 3.1 3.4 0.1 
Run 14 N9 M74(M) 23.9 0.8 3.7 0.2 
Run 13 N14 M80(S) 20.9 0.7 2.2 0.2 
Run 2 N19 M80(M) 11.2 0.3 1.8 0.0 
Run 11 N4 M97(L) 12.9 0.7 3.2 0.3 
 
Trends observed for both inhaler devices were similar but on different levels as illustrated in 
Figure 4.51. Both revealed mannitol particles dried at higher outlet temperatures (and with 
more indentions) to perform worse than those with spherical character. Only mannitol M97(L) 
  
 
did not follow this trend when dispersed with the Easyhaler® in accordance to results gained 
for experiments with the Novolizer®. 
The Easyhaler® led to remarkably lower respirable fractions than the Novolizer® which can 
mainly be attributed to the design of the device but also to carrier particle properties. 
Dispersion with the Easyhaler® is mainly based on the laminar air stream during inhalation 
without any further dispersion mechanisms. Drug particles are preferably detached from 
large carriers with respective inertia. Low density carrier particles like used in these 
experiments are disadvantageous as they can easily follow the inspiratory air stream 
resulting in a low velocity gradient between inhaled air and carrier particle and thus low 
forces for particle detachment and reduced FPFs. Similarly, low carrier particle densities 
negatively affect dispersion with the Novolizer®. However, the device design compensates 
the negative effect as cyclone and impaction walls provide adequate dispersion of the 
interactive powder blends. Larger respirable fractions simplify the correlation of particle 
properties and arising FPF, which finally reasons the Novolizer® to be the first choice device 
for the experiments described here. 
 
Figure 4.51 – FPF ± StD in % (y-axis) for powder blends consisting of six different mannitol 
batches (M70(S)/M71(L)/M74(M)/M80(S)/M80(M)/M97(L) and SBS SD. A: results for application 
with Novolizer
®
 and Easyhaler
®
; B: results for application with Easyhaler
®
 only (n=3) 
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5 Overall Findings and Future Perspectives 
This work highlights the relevance of process control with respect to the impact on particle-
particle interactions in a dry powder formulation for inhalation purposes. The carrier-based 
dry powder formulations consisted of engineered drug and carrier particles as mostly 
prepared by spray drying in the scope of this priority program. It could be shown that drug 
dispersion was crucially influenced by particle properties like size or morphology of both 
carrier and drug particles. Thus, control over the spray drying process was of tremendous 
importance to control drug and carrier characteristics. 
Engineered mannitol carrier particles were successfully generated with a special spray drying 
approach that was particularly aiming at narrow particle size distributions to maximise the 
size control during the process. The laminar rotary atomiser (LamRot) was operated at 
various rotation speeds to control the droplet size based on according acceleration forces, 
where the smallest droplets were gained in experiments with the highest rotation speed. 
Effects on the carrier size were supplementary detected for alternating drying temperatures 
as these determine the drying rate and therefore the moment of shell formation in association 
to the surface concentration of the solute mannitol. The drying temperature was further 
varied to affect the carrier morphology as separately examined for particle shape and surface 
roughness. Spray drying experiments in collaboration to levitation based single droplet trials 
performed by Grosshans et al. were successfully conducted to improve knowledge about the 
drying history of differently shaped spray dried mannitol particles [142].  
It was found that indentions that occurred for higher outlet temperatures could be associated 
to the temperature inside the early particle as this determines the physical condition of the 
solvent. The appearance of water vapour triggered an expansion of the shell that further 
resulted into collapsing particle shells during cooling and condensation of the water vapour. 
Likewise, surface roughness could be correlated to the drying temperature as mannitol 
solution was pressed through pores in the shell temperature-dependently to finally build 
rough structures of recrystallised mannitol on the carrier surface. 
Profound knowledge about all parameters that influence the product properties enables the 
preparation of tailor-made carrier particles for inhalation. Particle-particle interactions 
between drugs and carriers are well-known to be affected by size and morphology so that 
maximum control over the engineering approach helps to govern these interactions. 
In fact, differently shaped and sized mannitol batches were chosen to be blended with four 
different drugs. Salbutamol sulphate, tiotropium bromide, budesonide and formoterol 
fumarate were successfully spray dried to gain inhalable particles ranging from 1.8 to 2.5 µm 
in size. The spray drying approach was chosen to generate spherical particles as controlled 
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by the shape of the spray dried droplet to idealise the setup for particle-particle interactions 
during an aerodynamic characterisation of spray dried carrier and drug particles. 
Impaction analysis as required by the European Pharmacopoeia to assess the fraction of fine 
particles indicated that the dispersion of different drug particles during inhalation is based on 
different drug-depending mechanisms. The carrier shape was found as the main factor of 
influence on the fine particle fraction. Salbutamol sulphate was the only drug exhibiting a 
direct correlation between particle shape and respirable drug fraction as indented carriers 
performed the worst and spherical ones enabled the largest amount of drug to penetrate the 
stages of interest in the impactor. Tiotropium bromide and budesonide dispersion were 
influenced with reference to press-on forces, as slight indentions that provide shelter from 
those forces during blending are preferred to mostly spherical carriers. Budesonide or 
tiotropium bromide particles were adhered tighter to the surface when no indentions occurred 
or got trapped when indention depth was appropriate as observed for large carriers prepared 
at higher outlet temperatures. An interplay of carrier shape and agglomerate strength was 
suggested to govern formoterol fumarate dispersion. Deeply indented carriers or large 
spherical carriers performed best, while slightly indented ones or small spherical ones 
resulted in reduced fine particle fractions. 
Several further carrier or drug properties were examined in this thesis and described with 
significant effects on the respirable fraction. Carrier size was found to worsen the 
aerodynamic performance shape dependency as larger carriers comprise deeper indentions 
for the entrapment of drug particles. Drug size and shape was of importance as it determines 
where drug particles impact and how well they orientate in the inspiratory air stream to 
penetrate the deeper airways of the lung. It further affects the tendency to build 
agglomerates since cohesion proceeds depending on size and contact area.  
Coherently, this work concludes that a broad range of particle-particle interactions need to be 
considered for the development of innovative dry powder formulations. Spray drying was 
proved as an excellent engineering approach to control particle properties in the preparation 
of carrier and drug particles and therefore to affect inter-particle forces. However, an overall 
correlation between drug dispersion and related particle properties that enables prediction for 
further drugs cannot be drawn since dispersion mechanisms could not be linked to 
respective properties.  
  
 
6 Summary 
Drug delivery to the lungs for the treatment of respiratory diseases was proved to exceed all 
other therapeutic strategies and is routinely used in pulmonary therapies today. The lung has 
further been recognised as a potential target for systemic drug uptake that prevents 
administered drugs from first-pass metabolisms. Particles for lung penetration require 
aerodynamic particles sizes between 0.5 µm and 5.0 µm to reach the respiratory zone of the 
lungs. The European Pharmacopoeia lists nebulisers, pressurised metered-dose inhalers, 
non-pressurised metered dose inhalers and dry powder inhalers as suitable devices for 
inhalation. Dry powder formulations as focussed on in this thesis are suggested to be 
beneficial in terms of long term stability of drugs and administration efficacy due to the 
absence of a solvent. Most marketed products apply the well-known system of fine drug 
particles attached to the surface of coarse carrier particles to overcome the cohesiveness of 
drugs with sizes applicable for lung penetration. The adhered particles are meant to detach 
from the carrier surface by inspiratory forces during inhalation to follow the air into the lungs. 
Adhesion of carrier and drug as well as cohesion between several drug particles is known to 
be affected by a broad range of different particle-particle interactions. 
However, only little is known about the mechanistic understanding of those interactions in 
interactive powder blends and its magnitude of force despite several years of intensive 
research. This work was therefore designed to particularly focus on adhesion and cohesion 
as suggested for carrier and various drug particles and to discover how they got affected. 
Particle preparation was mostly performed by spray drying as an approach that provides 
maximum control over the targeted particle properties. 
Mannitol was chosen as a sugar alcohol for carrier particles instead of the commonly used 
lactose monohydrate with regards to storage stability since lactose might be incompatible for 
all formulations containing primary amines and is known to comprise amorphous contents 
upon spray drying. A laminar rotary atomiser particularly designed to generate very narrow 
particle size distributions was implemented for the preparation of carrier particles. Spray 
drying was conducted in the framework of a design of experiments to investigate the drying 
kinetics of bi-component mannitol water droplets as this provides knowledge about the 
appearance of the carriers in terms of size and morphology. The carrier size was mainly 
observed as a function of the rotation speed and, therefore, based on the emerging droplet 
size with a small supplementary effect by the drying temperature that affected the drying rate 
resulting in a faster onset of shell formation for higher temperatures. The process 
temperature was further varied to affect the carrier shape as different particle shapes were 
described earlier to affect drug dispersion during inhalation. Improved knowledge about how 
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indentions and surface asperities occur temperature-dependently was investigated by single 
droplet drying experiments with a levitator at the University of Hamburg as this is of 
importance for the engineering of tailor-made carrier particles. Higher drying temperatures 
triggered an expansion of the early shell based on the appearance of water vapour that 
further condensated during cooling and caused the shell to collapse while lower 
temperatures enable the preparation of spherical carriers since less water vapour occurs. 
Further characterisations enabled good correlations for the bulk flowability of these mannitol 
carriers, where spherical particles performed better than indented ones with regards to 
mechanical interlocking. Appropriate BET surface areas were successfully linked to particle 
properties like size and morphology since small, rough, and indented carriers were found 
with the larger BET surface areas than those of large size and with smooth and spherical 
character.  
A controlled engineering process is of importance not only for carriers but also for drug 
particles as both might crucially affect the aerodynamic behaviour. Salbutamol sulphate, 
tiotropium bromide, budesonide and formoterol fumarate were prepared with a commercially 
available laboratory spray dryer resulting in spherical particles at a size range from 1.8 to 
2.4 µm. The drugs were chosen with respect to different intrinsic properties like hydrophilicity, 
hygroscopicity and surface energies to possibly detect influences by those. 
Various mannitol carriers different in size and shape were blended with those drug batches 
to generate interactive powder blends for aerodynamic characterisations. Investigations on 
the outer particle properties found the carrier shape to have the main influence on drug 
dispersion and respirable fraction. The occurrence of indentions influenced the impaction 
analysis drug-dependently. Different mechanisms were described for salbutamol sulphate 
that was dispersed best from spherical carriers, tiotropium bromide and budesonide that 
were preferably detached from slightly indented carriers, and formoterol fumarate that 
performed best when blended with deeply indented or large and spherical carriers. Different 
drugs demand different carriers for the best performance based on the mechanisms of 
dispersion. Tiotropium bromide and budesonide need to be sheltered from press-on forces 
during blending as those forces reduced the respirable fraction. Formoterol fumarate was 
generally detached easily, but exhibited tremendous agglomerate strength, so that carriers 
need to prevent the occurrence of agglomerates. Therefore, large spherical carriers or those 
with several deep indentions were preferred. A direct correlation between particle shape and 
drug dispersion was observed for salbutamol sulphate, which performed best when spherical 
carriers were used. Supplementary, carrier size was of importance for indented carriers as 
larger carriers provide deeper indentions than smaller ones to finally entrap more drug 
particles. 
  
 
The work was extended to further drug properties like size and shape, but also to the 
influence of properties like crystallinity, hydrophilicity, hygroscopicity or surface energy. Drug 
particle size was of importance since larger drug batches comprise higher amounts of 
particles that are larger than 5 µm, which reduced the respirable fraction. The effect of drug 
shape was tested by comparison to micronised qualities of salbutamol sulphate and 
budesonide to spray dried batches, resulting in quite divergent but significant results that 
suggest the shape to have major impact on the fine particle fraction during inhalation. 
Unfortunately, intrinsic properties like hydrophilicity, crystallinity, hygroscopicity or surface 
energy could not particularly be correlated to impaction results. 
Further, different concentrations of mannitol fines were added to the powder blends to 
discover whether theorems summarised by Grasmeijer et al. on the basis of lactose 
monohydrate are applicable for powder blends containing mannitol as a carrier [27]. In fact, 
rising concentrations were found to steadily increase the respirable drug fraction. Powder 
blends performed best with 10 % fines since further addition of fines decreased dosing 
reproducibility.  
Supplementary trials with the Easyhaler® as another inhaler device found vastly decreased 
fine particle fractions that however exhibited similar trends in terms of carrier particle shape 
and respirable fraction. Nevertheless, the Novolizer® was acknowledged as the preferred 
device to detect particle-particle interactions since even low density carrier particles like used 
here got dispersed adequately due to cyclone and impaction walls of the device. 
Overall, results presented in this work allow insight into the accurate preparation of 
engineered carrier and drug particles and the particle-particle interactions that arise from 
respective particle properties. However, the effects of intrinsic particle properties on the 
aerodynamic performance will need further investigations in the future. 
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7 Summary (German) 
Die pulmonale Verabreichung von Arzneistoffen mittels Inhalation ist heutzutage als Routine-
Therapie in den Leitfäden zur Behandlung von Asthma oder der chronisch obstruktiven 
Lungenerkrankung verankert. Zusätzlich ist die Lunge vor allem auf Grund einer möglichen 
Umgehung des First-Pass-Effektes im Fokus für die systemische Aufnahme von 
Arzneistoffen und der daraus resultierenden Behandlung weiterer Krankheiten. Eine 
aerodynamische Partikelgröße von 0.5 – 5.0 µm – die so genannte Feinpartikelfraktion – ist 
die Grundvoraussetzung, um das Erreichen der Lunge und damit die Aufnahme über das 
respiratorische Epithel zu ermöglichen. Das Europäische Arzneibuch nennt mit Verneblern, 
Druckgas-Dosieraerosolen, Normaldruck-Dosieraerosolen und Trockenpulver-Inhalatoren 
vier verschiedene Devices, die für die Inhalations-Therapie geeignet sind. Formulierungen 
zur Trockenpulver-Inhalation, wie in dieser Arbeit verwendet, zeigen hierbei ausgeprägte 
Vorteile in Bezug auf die resultierende Dispergiereffektivität sowie hinsichtlich der 
Lagerstabilität. Trägerbasierte Systeme, bei denen mikronisierter Arzneistoff an der 
Oberfläche eines groben Trägerpartikels adhäriert, stellen die größte Anzahl der derzeit 
zugelassenen Produkte, wobei die Arzneistoffpartikel durch Scherkräfte während der 
Inhalation abgelöst werden, um dem Luftstrom in die Lunge zu folgen. Die hierbei 
herrschenden Adhäsionskräfte zwischen Träger und Arzneistoff sowie die Kohäsionskräfte 
zwischen den Arzneistoffpartikeln werden durch viele verschiedene Faktoren beeinflusst. 
Die Hintergründe dieser Interaktionen sowie die Intensität der hierbei auftretenden Kräfte 
sind trotz langjähriger intensiver Forschung nur oberflächlich bekannt. Diese Arbeit zielt 
daher insbesondere auf Adhäsions- und Kohäsionskräfte zwischen verschiedenen 
Arzneistoffpartikeln und Trägerpartikeln sowie auf die Mechanismen, die diese Kräfte 
beeinflussen. Um die resultierenden Partikeleigenschaften zu kontrollieren, wurden die 
meisten Träger- und Arzneistoffchargen mittels Sprühtrocknung hergestellt. 
Die Trägerpartikel wurden aus Mannitol hergestellt, da sich die amorphen Anteile eines 
sprühgetrockneten Laktose-Produktes nachteilig auf die Lagerstabilität auswirken können 
sowie die chemische Stabilität von Arzneistoffen durch den reduzierenden Charakter der 
Laktose beeinflusst werden kann. Die Sprühtrocknung der Trägerpartikel wurde im Rahmen 
eines Versuchsplanes durchgeführt, wobei ein spezieller laminarer Rotationszerstäuber 
angewendet wurde, um enge Partikelgrößenverteilungen zu erzeugen. Hierbei wurde 
zunächst der Einfluss der Trocknungskinetik auf Partikelgröße und –morphologie studiert. 
Die Trägergröße variierte hierbei vor allem in Abhängigkeit von der Zerstäuber-
Rotationsgeschwindigkeit, da diese die Tropfengröße beeinflusst. Ein geringerer zusätzlicher 
Einfluss wurde für die Prozesstemperatur detektiert, da diese über die Trocknungsrate den 
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Moment der Hüllbildung bestimmt. Zusätzliches Prozessverständnis hinsichtlich der 
temperaturabhängig auftretenden Trägermorphologie wurde in Trocknungsexperimenten an 
levitierenden Einzeltropfen an der Universität Hamburg erlangt, da dies für die Herstellung 
von Partikeln mit kontrollierten Eigenschaften von großem Interesse ist. Höhere 
Prozesstemperaturen waren hier ursächlich für eine wasserdampfbasierte Expansion der 
initialen Hülle, die im Folgenden während des Abkühlens, einhergehend mit der 
Kondensation des Wasserdampfes, wieder kollabiert und die beobachteten Vertiefungen 
aufweist. Für niedrigere Prozesstemperaturen wird angenommen, dass kein Wasserdampf 
entsteht, weshalb sowohl die Partikelexpansion als auch die Eindellungen auf der Oberfläche 
des Partikels ausbleiben. Im Weiteren wurden Abhängigkeiten für die Fließfähigkeit der 
hergestellten Trägermaterialien untersucht. Hierbei wurden sphärische Partikel auf Grund 
des geringeren Potentials zu mechanischer Verzahnung besser bewertet als die eingedellten 
Pendants. Gleichzeitig wurde die BET Oberfläche sämtlicher Chargen ermittelt, wobei die 
Oberfläche basierend auf der Partikelgröße, Partikelform und Oberflächenrauheit variierte. 
Kontrollierte Prozesstechnik ist in der Trockenpulver-Formulierung nicht nur für die 
Trägerpartikel von großem Interesse, sondern auch für sämtliche Arzneistoffpartikel, da die 
Partikel-Partikel-Interaktionen auf einem Zusammenspiel zwischen beiden Komponenten 
beruhen. Salbutamolsulfat, Tiotropiumbromid, Budesonid und Formoterolfumarat wurden 
mittels eines kommerziell erhältlichen Sprühtrockners im Größenbereich von d50.3 = 1.8 bis 
2.4 µm getrocknet, wobei sie auf ihren intrinsischen Eigenschaften beruhend ausgewählt 
wurden. Einflüsse seitens Hydrophilie, Hygroskopizität, Kristallinität oder der jeweiligen 
Oberflächenenergie sollten so untersucht werden. 
Ausgewählte Mannitol-Trägerpartikel mit unterschiedlichen Partikelgrößen und –formen 
wurden im Folgenden mit sämtlichen Arzneistoffchargen gemischt, um interaktive 
Mischungen für die aerodynamische Charakterisierung zu erzeugen. Einflüsse auf die 
Feinpartikelfraktion nach erfolgter Impaktionsanalyse wurden vor allem der Form der 
Trägerpartikel zugeordnet, wobei die Mechanismen der Arzneistoffdispergierung vor allem 
arzneistoffspezifisch auftraten und keine generellen Schlüsse zuließen. Sphärische 
Trägerpartikel erzielten die besten Ergebnisse für sprühgetrocknetes Salbutamolsulfat, 
während Tiotropiumbromid und Budesonid nach Mischung mit leicht eingedellten 
Mannitolträgern besser dispergiert werden konnten. Die Dispergierung von 
Formoterolfumarat erfolgte wiederum bevorzugt von tief eingedellten oder großen 
sphärischen Trägerpartikeln. Verschiedene Arzneistoffpartikel zeigten unterschiedliche 
Anforderungen an die perfekten Trägerpartikel. Leichte Dellen erwiesen sich als nützlicher 
Schutz vor Aufpresskräften für Tiotropiumbromid und Budesonid während des Misch-
Vorgangs, was wiederum die Dispergierfähigkeit erhöhte. Die Ablösung von 
Formoterolfumarat erwies sich als generell vereinfacht, da selbst größere Vertiefungen eine 
  
 
Ablösung nicht behinderten. Nachteilig erwiesen sich lediglich Trägerpartikel, die eine 
Agglomeratbildung förderten, so dass große sphärische oder tief eingedellte Träger 
bevorzugt eingesetzt werden sollten. Salbutamolsulfat zeigte als einziger Arzneistoff eine 
direkte Korrelation zwischen Feinpartikelfraktion und Partikelform. Die Trägerpartikelgröße 
war vor allem für eingedellte Partikel von Interesse, da die Tiefe der entsprechenden Dellen 
und damit die Wahrscheinlichkeit Arzneistoffpartikel festzuhalten von der Trägergröße 
abhängt. 
Im Weiteren wurden Arzneistoffgröße und –form, aber auch Arzneistoffeigenschaften wie die 
Kristallinität, Hydrophilie, Hygroskopizität und Oberflächenenergie untersucht. Hierbei wurde 
die Partikelgröße des Arzneistoffs als wichtiger Faktor ausgemacht, da hierüber die Fraktion 
an Partikeln mit einer Größe < 5 µm bestimmt wird. Die Arzneistoffform, getestet mittels 
Vergleich von sphärischem und luftstrahl-gemahlenem Salbutamolsulfat und Budesonid, 
zeigte signifikante Unterschiede in der Feinpartikelfraktion, die einen eindeutigen Einfluss der 
Partikelform suggerieren. Allgemeingültige Aussagen hinsichtlich eines Einflusses basierend 
auf den intrinsischen Arzneistoffeigenschaften ließen sich anhand der aerodynamischen 
Charakterisierung nicht treffen. 
Weiterführende Untersuchungen zielten auf die seitens Grasmeijer et al. 
zusammengefassten Theorien, die feine Laktose zur Unterstützung der Dispergierung 
während der Inhalation verwendet haben [27]. Die Zugabe von feinem Mannitol zu den 
Mischungen zeigte eine sich kontinuierlich verbessernde Dispergierung mit steigendem 
Feinanteil analog zu Ergebnissen für Mischungen mit Laktose-Monohydrat. Ein Feinanteil 
von 10 % erwies sich als optimal, da die Dosiergenauigkeit bei höherem Feinanteil nicht 
mehr gegeben war.  
Zusätzliche Untersuchungen mit dem Easyhaler® als Inhalations-Device zeigten ebenfalls 
trägerformabhängige Ergebnisse, die jedoch auf weitaus geringerem Feinpartikelfraktions-
Niveau beobachtet wurden. Die Verwendung des Novolizers® wurde entsprechend 
bevorzugt, da selbst Partikel mit geringer Dichte – wie in diesem Projekt verwendet – leicht 
dispergiert wurden, um so auf interpartikuläre Wechselwirkungen zu schließen. 
Diese Arbeit bietet einen breit aufgestellten Gesamtüberblick hinsichtlich der 
reproduzierbaren Herstellung von Träger- und Arzneistoffpartikeln mit maßgeschneiderten 
Partikeleigenschaften sowie der Partikel-Partikel-Interaktionen zwischen diesen Partikeln 
basierend auf den jeweiligen Partikeleigenschaften. 
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8 Appendix 
8.1 HPLC Methods 
8.1.1 Salbutamol Sulphate 
Equipment: Waters HPLC System, Waters Corp., Milford, USA), 
evaluated with Empower® Pro 2 software, Waters Corp., 
Milford, USA 
 
Stationary phase: LiChroCART® 125-4  
 LiChrospher® 100 RP-18 (5 µm) 
 with pre-column 
 
Mobile phase: 78 % buffer (2.87 g • L-1 sodium heptansulfonate + 
2.5 g • L-1 KH2PO4 (0.2 mmol), pH adjusted to 3.65 with 
ortho-phosphoric acid 85 %) 
 22 % acetonitrile 
 
Flow rate: 0.8 mL • min-1 
 
Detection wavelength: 225 nm 
 
Injection volume: 100 µL 
 
Calibrated range: 0.2 – 120 µg • mL-1 
 
Samples were dissolved in 100 % bi-distilled H2O. 
 
8.1.2 Tiotropium Bromide 
Equipment: Agilent G1316A Colcom 1100 Series (Agilent 
Technologies, Santa Clara, USA) 
 
Stationary phase: LiChroCART® 125-4  
 LiChrospher® 100 RP-18 (5 µm) 
 with pre-column 
 
Mobile phase: 71 % buffer (1.42 g • L-1 sodium heptanesulphonate, pH 
adjusted to 3.2 with ortho-phosphoric acid 85 %) 
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 29 % acetonitrile  
 
Flow rate: 2.0 mL • min-1 
 
Detection wavelength: 239 nm 
 
Injection volume: 100 µL 
 
Oven temperature 40 °C 
 
Calibrated range: 0.2 – 120 µg • mL-1 
 
Samples were dissolved in 100 % bi-distilled H2O. 
 
8.1.3 Budesonide 
Equipment: Waters HPLC System, Waters Corp., Milford, USA), 
evaluated with Empower® Pro 2 software, Waters Corp., 
Milford, USA 
 
Stationary phase: LiChroCART® 125-4  
 LiChrospher® 100 RP-18 (5 µm) 
 with pre-column 
 
Mobile phase: 75 % methanol 
 
 25 % bi-distilled H2O 
 
Flow rate: 1.0 mL • min-1 
 
Detection wavelength: 248 nm 
 
Injection volume: 100 µL 
 
Calibrated range: 0.2 – 100 µg • mL-1 
 
Samples were dissolved in a mixture of 75 % methanol and 25 % bi-distilled H2O. 
 
  
 
8.1.4 Formoterol Fumarate 
Equipment: Agilent G1316A Colcom 1100 Series (Agilent 
Technologies, Santa Clara, USA),  
 
Stationary phase: LiChroCART® 125-4  
 LiChrospher® 100 RP-18 (5 µm) 
 with pre-column 
 
Mobile phase: 45 % buffer (2.34 g • L-1 sodium octanesulphonate + 
1.38 g • L-1 NaH2PO4 • H2O, pH adjusted to 3.2 with ortho-
phosphoric acid 85 %) 
 
 40 % methanol 
 
 15 % acetonitrile 
 
Flow rate: 1.0 mL • min-1 
 
Detection wavelength: 214 nm 
 
Injection volume: 100 µL 
 
Oven temperature 25 °C 
 
Calibrated range: 0.2 – 75 µg • mL-1 
 
Samples were dissolved in bi-distilled H2O (45 %), methanol (40 %) and acetonitrile (15 %). 
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8.2 Materials 
Acetonitrile (HPLC) Sigma-Aldrich, Inc., St. Louis, USA 
Brij® 35 Carl Roth GmbH & Co. KG,  
 Karlsruhe, Germany 
Budesonide Minakem SAS, Dunkerque, France 
Decane, GC grade Sigma-Aldrich, Inc., St. Louis, USA 
Dichloromethane Merck KGaA, Darmstadt, Germany 
Bi-distilled H20  freshly produced with in-house Finn Aqua 75, San-
Asalo-Sohlberg Corp., Helsinki, Finland 
Ethanol, 96 % Merck KGaA, Darmstadt, Germany 
Formoterol fumarate  Vamsi Labs Ltd., Maharashtra, India 
 (Batch: FF0041009)  
Helium 5.0  Linda AG, Munich, Germany 
Heptane, GC grade Merck KGaA, Darmstadt, Germany 
Hexane, GC grade AppliChem, Darmstadt, Germany 
Hydrogen 5.0 Linde AG, Munich, Germany 
Mannitol (Pearlitol® 160C) Roquette Frères Corp., Lestrem, France 
Methanol, HPLC grade Merck KGaA, Darmstadt, Germany 
Nitrogen 5.0  Linde AG, Munich, Germany 
Nonane, GC grade Sigma-Aldrich, Inc., St. Louis, USA 
Octane, GC grade Sigma-Aldrich, Inc., St. Louis, USA 
o-Phosphoric acid 85 % Merck KGaA, Darmstadt, Germany 
Potassium dihydrogen phosphate  
Purified H2O BWT Rondomat Duo 2 DVGW, BWT 
Wassertechnik, Germany 
Salbutamol sulphate SelectchemieAG, Zurich, Switzerland 
Sodium heptanesulphonate Sigma-Aldrich, Inc., St. Louis, USA 
Sodium octanesulphonate Sigma-Aldrich, Inc., St. Louis, USA 
Tiotropium bromide  Hangzhou Hyper Chemicals Ltd., 
 (Batch: 150122)  Zhejiang, China  
  
  
 
8.3 Abbreviations 
API active pharmaceutical ingredient 
BUD budesonide 
CCF central composite face-centred design  
CFC chlorofluorocarbon 
COPD chronic obstructive pulmonary disease 
DoE design of experiments 
DPI dry powder inhalation 
DSC differential scanning calorimetry 
DVS dynamic vapour sorption 
ED emitted dose 
EMA European Medicines Agency 
FDA Food and Drug Agency 
FPD fine particle dose 
FPF fine particle fraction 
FOR formoterol fumarate 
GC gas chromatography 
GINA Global Initiative for Asthma 
GOLD Global Initiative for Chronic Obstructive Lung Diseases 
HFA hydrofluoroalkanes  
RP-HPLC reversed phase high performance liquid chromatography 
ICS inhaled corticosteroids 
iGC inverse gas chromatography 
LABA long-acting ß2 agonist 
m million 
M70(S) mannitol quality dried at Tout = 70 °C consisting of small particles 
M71(L) mannitol quality dried at Tout = 71 °C consisting of large particles 
M74(M) mannitol quality dried at Tout = 74 °C consisting of medium particles 
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M80(S) mannitol quality dried at Tout = 80 °C and consisting of small particles 
M80(M) mannitol quality dried at Tout = 80 °C consisting of medium particles 
M97(L) mannitol quality dried at Tout = 97 °C and consisting of large particles 
MMAD mass median aerodynamic diameter 
rH relative humidity 
PSD particle size distribution 
RP reproducibility 
SABA short-acting ß2 agonist 
SBS salbutamol sulphate 
SD spray dried 
SEM scanning electron microscope 
StD standard deviation 
TIO tiotropium bromide 
WHO World Health Organisation 
XRPD X-ray powder diffraction 
 
  
  
 
8.4 Variables 
ai coefficient (displaying the statistical significance of the term) 
BFE basic flowability energy, mJ g-1 
cfeed feed concentration, % [w/w] 
cFines concentration of mannitol fines 
cp centre point 
D diameter of the spray tower, m 
d10.3 10 % quantile of the PSD 
d50.3 median of the PSD 
d90.3 90 % quantile of the PSD 
dadyn aerodynamic diameter, µm 
dcs cross-sectional diameter, µm 
f number of factor levels 
fx factor level 
γs
d dispersive surface energy, mJ m-2 
H height of the spray tower 
l sampling length, µm 
N number of factors 
n rotation speed 
n/nm surface occupancy  
p/p0 partial pressure  
Q volumetric flow rate, L min-1 
Q² prediction quality 
R² variation coefficient 
rpm rounds per minute, s-1 
rH relative humidity, % rH 
T temperature, °C 
t time, s 
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Tax axial air stream temperature, °C 
Tfeed feed temperature, °C 
Tin inlet temperature, °C 
tinh valve opening time, s 
Tm melting point, °C 
Tout outlet temperature, °C 
Tg glass transition temperature, °C 
Tr recrystallisation temperature, °C 
Tswirl swirl air stream temperature, °C 
Vax axial air stream volume, m³ h
-1 
Vfeed feed rate, L h
-1 
Vinh absolute inhaled volume, 4 L 
Vswirl swirl air stream volume, m³ h
-1 
Y response to the chosen factors 
Ym feed concentration, % [w/w] 
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